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ABSTRACT 
Musculoskeletal disorders are among the most important health problem affecting the quality 
of life and contributing to a high burden on healthcare systems worldwide. Understanding the 
molecular mechanisms underlying these disorders is crucial for the development of efficient 
treatments.  
In this thesis, musculoskeletal disorders including muscle wasting, bone loss and cartilage 
deformation have been studied using systems biology approaches. Muscle wasting occurring 
as a systemic effect in COPD patients has been investigated with an integrative network 
inference approach. This work has lead to a model describing the relationship between 
muscle molecular and physiological response to training and systemic inflammatory 
mediators. This model has shown for the first time that oxygen dependent changes in the 
expression of epigenetic modifiers and not chronic inflammation may be causally linked to 
muscle dysfunction. 
Bone and cartilage deformation observed in ageing, arthritis and multiple myeloma (MM) 
patients have also been investigated by using a novel modularization approach developed 
within this thesis. This methodology allows integration of multi-level dataset with large 
interaction networks. It aims to identify sub-networks with genes differentially expressed 
between experimental conditions that are co-regulated across samples in different biological 
systems. This study has identified several potential key players such as Myc, DUSP6 and 
components of Notch that could enhance osteogenic differentiation in MM patients. 
In conclusion, this thesis present the effectiveness of systems biology approaches in 
understanding complex diseases and these approaches could be applied for studying other 
systems and datasets.  
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 CHAPTER 1: INTRODUCTION AND 
BACKGROUND 
 
1.1 Human musculoskeletal system 
The functional role of the musculoskeletal system is to allow support, protection and 
movement of the body [1].  All these are achieved via a complex organisation of muscles, 
bones, joints, tendons, cartilage, and ligaments [2]. With the contraction of a muscle, the 
force generated is transmitted via tendons to bones allowing them to move (Figure 1.1) [3]. 
Bones are connected to each other via ligaments and protected from rubbing each other via 
cartilage that functions as cushion in the joints [1]. They are also a source of mineral 
homeostasis such as calcium, magnesium and phosphorus. Bone marrow, which fills the 
internal cavity of the bones, is responsible for the production of blood cells.  
In the next sections, the components of the musculoskeletal system that are affected during 
the ageing process and in various diseases including COPD, multiple myeloma and arthritis 
will be reviewed in detail. In section 1.1.1, skeletal muscle structure is described and known 
molecular mechanisms for muscle homeostasis are reviewed. In section 1.1.2 bone and 
cartilage formation and maintenance are described.  
1.1.1 Skeletal muscle  
Skeletal muscles are composed of numerous bundles of fibres (Figure 1.1), which are 
responsible for force and movement production. Muscle fibres are multinucleated cells 
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formed via the fusion of myotubes. Muscle fibres are surrounded by basal lamina. Beneath 
the muscle fibre basal lamina, there are satellite cells that play a crucial role for muscle repair 
as these have the ability to differentiate into myoblasts to form new muscle fibres [4, 5]¸ [6, 
2]. 
Proportions of muscle fibre types determine the physiological, metabolic and functional 
properties of the muscle [6, 2]. Individual fibre phenotypes are well conserved among 
mammals. However, the composition of a muscle can differ between mammals [7]. For 
instance, soleus muscle consists of 100% of slow muscle fibre types in guinea pig [7], 
whereas human soleus fibre composition can contain between 60% and 100% slow fibres [8]. 
Depending on the fibre type composition, muscles have different contractile speed, strength 
and resistance to fatigue. However, the muscle properties can change to adapt to various 
conditions such as disuse and exercise training.  
 
Figure 1-1. Structure of skeletal muscle published in [4] 
This figure shows the structure of the skeletal muscle, which is connected via tendons to 
bones. Skeletal muscles are composed of numerous bundles of fibres, called fascicle. The 
diameter and length of the fibres determine the strength of the muscle and contraction 
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velocity. The basal lamina surrounds the fibres and it plays a crucial role in fibre recovery 
from injuries.  
 
Muscle fibre types and properties 
Classification of muscle fibres is achieved using various techniques including histochemical, 
biochemical, morphological and physiological characteristics [6]. Histochemical ATPase 
assay classification can differentiate between slow (Type I) and fast fibres (Type IIa and IIb). 
The characteristics of the fibres are summarized in Table 1.1. Type I fibres, also called slow 
oxidative, are characterized by high density of mitochondria, which are responsible for the 
generation of energy aerobically (oxidative phosphorylation). As oxidative phosphorylation is 
very effective for ATP generation, type I muscles are resistant to fatigue. Hence, the muscle 
fibres’ endurance property is dependent on the mitochondria density; for instance in highly 
oxidative muscle 20% of the total cell volume consists of mitochondria [2]. Type IIa fibres 
(fast oxidative) are rich in michochondria and generate ATP mainly through oxidative 
phosphorylation. This type of muscle has faster contractile speed than type I and is less 
resistant to fatigue. Both of these types require adequate supply of oxygen for energy 
generation, these fibres are rich with capillaries and with high myoglobin content. On the 
other hand, Type IIb fibres (fast glycolytic) are low in mitochondrial density; therefore 
energy generation is mainly achieved in the cytoplasm in anaerobic conditions. The low 
oxidative capacity of type IIb fibres leads to increased susceptibility to fatigue. These fibres 
have very fast contractile speed as the tension activation system occupy a large volume, 
almost two to three times more than slow fibres [2]. 
 Type I (slow 
oxidative)
Type IIa (fast 
oxidative) 
Type IIb (fast 
glycolytic) 
Contractile speed  Slow  Intermediate Fast  
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Mitochondrial  
density  
High  High Low  
Capillaries Many Many Few 
Enzymes for 
anaerobic glycolysis 
Low Intermediate High 
Resistance to fatigue Resistant to fatigue  Intermediate 
resistance to fatigue
Fatigue easily  
Table 1.1. Properties of muscle fibre type I and II, selected from the book of Richard 
L.Lieber [2].  
 
Skeletal muscle tissue remodeling 
The maintenance of muscle homeostasis and adaptation to various conditions occurs via a 
remodeling process. Several studies have been carried out for the identification of molecular 
mechanisms underlying the signaling pathways regulating muscle remodeling, for a recent 
review see [9]. The key players include growth factors, cytokines, receptors, extracellular 
proteins that control protein synthesis and degradation via various mechanisms. For instance, 
it has been reported that insulin-like growth factor 1 (IGF1) activation induces muscle 
hypertrophy in vitro and in vivo through the activation of the mammalian target of rapamycin 
(Akt/mTOR) pathway [10, 11]. The role of pro-inflammatory cytokines such as tumor 
necrosis factor alpha (TNFa) and interleukin 1 (IL1) in skeletal muscle remodeling is more 
contradictory in the literature.  It has been reported that high level of TNFa regulates 
myogenesis and muscle regeneration [12], but it has also been reported to induce muscle 
atrophy [13]. Over-expression of IL1B has been reported to reduce protein synthesis, muscle 
weight and protein content in rats gastrocnemius and soleus musles [14] and impair 
myogenesis [15,  16]. On the other hand, in response to exercise training IL1 activity is 
increased in skeletal muscle [17]. The opposite role of TNFa and IL1 in skeletal muscle is 
thought to be a result of duration and magnitude of the inflammatory signals [18].   
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Regulation of skeletal muscle metabolism 
A number of regulators of skeletal muscle energy metabolism that is crucial for the 
maintenance and growth of skeletal muscle have been reported. One of the most studied 
metabolic regulators is peroxisome proliferator-activated receptor c coactivator 1 alpha 
(PGC-1a), which induces mitochondrial biogenesis and oxidative metabolism and controls 
muscle growth [19]. PGC-1a over-expression in skeletal muscle of mice increases type I 
fibres, muscle performance and resistance to muscle fatigue [20]. Regulation of PGC-1a and 
its targets has been reported to be mediated by chromatin modifier the silent information 
regulator T1 (SIRT1) in myoblasts [21]. Several other chromatin modifiers such as the silent 
information regulator T3 (SIRT3), histone deacetylase 4 (HDAC4) and histone deacetylase 5 
(HDAC5) have also been shown to be important regulators of skeletal muscle bioenergetics 
expression [22].  For instance, in human myotubes, HDAC5 was shown to regulate GLUT4, a 
glucose transporter [23].  
1.1.2 Bone and cartilage 
Bone remodeling is controlled by bone forming cells osteoblasts and bone-resorbing 
osteoclasts [24]. The tight balance between osteoclasts and osteoblasts allows the degradation 
of old bone and synthesis of new bone. The osteoblasts are derived from human 
mesenchymal stem cells (hMSCs) differentiation. 
Defining hMSCs 
hMSCs are adherent stromal cells, which were first identified in the bone marrow [25]. Later, 
they were also extracted from other tissues such as fat [26], skin [27], blood [28], umbilical 
cord blood [29], teeth [30], and pancreas [31]. These cells are self-renewal and have the 
ability to differentiate into various lineages including bone, cartilage and fat cells (Figure 
1.2) [32]. It should be noted that the usage of the definition MSC has been criticised lately 
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and three criteria have been proposed to define MSC by the Mesenchymal and Tissue Stem 
Cell Committee [33]. These criteria are derived from the data currently available. The first 
one is their adherence property to plastic when maintained in standard culture conditions. 
They should express specific surface antigen CD105, CD73 and CD90 and lack the 
expression of CD45, CD34, CD14, CD11b or CD19 and HLA-DR. The last criterion is based 
on their differentiation capacity in vitro towards the three lineages. In this thesis, hMSCs was 
used for referring to the stromal cells that are derived from bone marrow. It should be noted 
that with this current definition, it is not possible to distinguish MSCs from other stromal 
cells such as fibroblasts [34]. Although some efforts have been made to distinguish 
differences between those cells, more studies are required for redefining the complex family 
of stromal cells [34]. 
 
Figure 1-2. hMSC differentiation towards bone, fat, and cartilage cells.  
This figure is a selection from [35], which was adapted from [36]. 
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Known molecular mechanisms during the differentiation of hMSCs towards bone forming cells  
Understanding molecular mechanisms underlying normal osteogenic and chondrogenic 
differentiation from hMSCs is crucial for the identification of potential regulators that are 
abnormal in conditions leading to bone loss and cartilage deformation.  
hMSCs differentiation towards osteoblasts can be triggered in vitro with dexamethasone 
treatment, which is a glucocorticoid class of steroid drugs. Moreover, addition of other 
factors such as bone morphogenetic protein 2 (BMP2) and cholecalciferol (Vitamin D3) to 
dexamethasone treatment has been shown to enhance the differentiation capacity of hMSCs 
towards bone as compared to only dexamethasone treatment [37, 38]. A number of factors 
including cytokines, growth factors, and transcription factors have been shown to be involved 
during osteogenesis differentiation. Wnt signaling, Notch signaling, and BMP signaling 
pathways play a role in activating runt-related transcription factor 2 (RUNX2), which has 
been shown to regulate early stages of osteogenesis and RUNX2 null mice exhibits 
endochondral ossification (for recent reviews [39, 40]). However, the role of Wnt signaling 
pathway in osteogenesis is conflicting in the literature. Several components of Wnt activation 
have been shown to enhance the osteogenesis differentiation in vitro [41, 42] and mice 
lacking the Wnt antagonist sFRP1 display a phenotype with increased trabecular bone 
mineral density and volume [43]. On the other hand, it has been shown that Wnt3 activation 
suppresses dexamethasone-induced osteogenesis in hMSCs [44]. Other osteogenic enhancer 
factors such as dual specificity phosphatase 6 (DUSP6), guanine nucleotide-binding protein 
(GNAS) and purinergic receptor P2Y, G-protein coupled, 11 (P2RY11) were identified in a 
recent study by performing a siRNA library screening [45]. 
Description of key players during chondrocytes differentiation from hMSCs 
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The differentiation of hMSCs towards chondrocytes can be achieved via simultaneous 
treatment with dexamethasone and TGFB. Furthermore, addition of BMP6 or IGF1 to this 
treatment has been shown to enhance chondrocytes differentiation [46, 47]. The previous 
studies from hMSCs differentiation towards chondrocytes allowed the identification of 
several key players of this process. These include the transcription factor SOX9 [48], growth 
factors such as fibroblast growth factor 2 (FGF2) [49], BMPs [50], IGF1 [47], and 
transforming growth factor (TGF) [51], components of SMAD signaling [52], Notch 
signaling [53] and the Wnt signaling pathway [54]. Activation of SOX9 has been shown to be 
essential for chondrocytes differentiation and cartilage formation [48]. Inducing 
chondrogenic differentiation from hMSCs leads to activation of SOX9 that in turn activates 
the chondrocyte markers collagen type II alpha 1 (COL2A1), cartilage oligomeric matrix 
protein (COMP) and Aggrecan (ACAN) [48, 55]. For the activation of SOX9, suppression of 
Notch signaling pathway is required in TGFB induced chondrogenesis from hMSCs [56]. 
The importance of notch inhibition has also been reported in mice, which lead to induced 
chondrocyte activity [57].  
1.1.3 Diseases affecting the musculoskeletal system 
In this thesis, a number of diseases affecting various components of the musculoskeletal 
system including muscle, bone and cartilage have been studied. In the context of muscle 
wasting, muscle transcriptomics and physiological differences between COPD patients and 
aged-matched healthy individuals before and after exercise training have been studied. In the 
next section (section 1.2), the background and state of the art in muscle wasting in COPD 
patients are described. Then, the second biological system related to bone loss and cartilage 
deformation observed in ageing, in arthritis, and in MM will be introduced (section 1.3). The 
abnormal bone marrow microenvironment in these patients might be partially responsible for 
the aberrant hMSCs differentiation towards fat, bone and cartilage cells. In this thesis, the 
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aim has been to study the osteogenesis, adipogenesis and chondrogenesis differentiation 
process in ageing, in arthritis and in MM patients, as the defective differentiation process 
might result in bone and cartilage deformation.  
1.2 Muscle wasting in Chronic Obstructive Pulmonary disease (COPD) 
patients 
COPD is a progressive disease leading to accelerated decline in lung function. COPD patients 
suffer from limited airflow, which is induced by closure of small airways and loss of lung 
elasticity. The disease is the result of the interaction between genetic predisposition factors, 
smoking and exposure to fine particulates. A significant percentage of COPD patients suffer 
from severe extra-pulmonary effects such as weight loss, muscle wasting, osteoporosis, and 
cardiovascular diseases [58]. These contribute to poor quality of life and mortality in COPD 
patients. The World Health Organization has predicted COPD to be the third cause of death 
by 2030 [59]. 
1.2.1 Muscle wasting in COPD 
COPD patients suffer from shortness of breath caused by impaired lung function that leads to 
a decrease in exercise tolerance and physical activity. Skeletal muscle is a very plastic tissue 
with the ability to adapt in response to various levels of activity and disuse [2]. The loss of 
physical activity of COPD patients contributes to progressive muscle wasting, which is 
estimated to be observed in 40% of the patients [60]. Muscle wasting determines the course 
of the COPD [61] and predicts survival [62]. As the exercise training in COPD patients has 
limited recovery on skeletal muscle mass and strength compare to healthy individuals, other 
factors are likely to contribute to muscle wasting. Indeed, chronic hypoxia, inflammation, 
ROS imbalance has been shown to be key factors driving skeletal muscle dysfunction in 
COPD patients and these would be discussed in great details in the subsequent sections.  
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1.2.2 Muscle characteristics of COPD patients 
COPD muscle is characterized by muscle mass loss, reduced muscle strength, fibre type shift, 
reduced oxidative metabolic capacity and loss of capillary density. Loss of muscle bulk 
occurs early in COPD patients even in the absence of severe airflow limitation [63]. Reduced 
thigh muscle cross-sectional area has been observed in COPD patients compared to normal 
individuals [64].  Muscle biopsy samples taken from vastus lateralis muscles of COPD 
patients at rest have shown atrophy of type I fibres and an increase in type IIb fibres 
compared with healthy controls [65, 66, 67]. This shift from fibre type I to fibre type IIb has a 
major consequence in increasing susceptibility to fatigue and contributing to exercise 
limitation in COPD, as type IIb fibres are characterised by fast contraction velocity and low 
oxidative capacity (Table 1.1).   
1.2.3 Skeletal muscle energy metabolism in COPD 
In accordance with the shift of fibre type composition observed in COPD patients, skeletal 
muscle energy metabolism is altered towards glycolytic metabolism and reduced oxidative 
capacity. Reduced concentrations of mitochondrial oxidative enzyme in COPD skeletal 
muscle was reported compared to aged-matched healthy muscle [68]. The loss of 
mitochondrial density in COPD skeletal muscle has been recently reported, which contributes 
to the impaired oxidative capacity [69]. The impaired oxidative capacity and increase in 
glycolytic metabolism in COPD can cause reduced ATP synthesis due to the inefficient 
mechanism of ATP generation in anaerobic conditions. In support, several studies have 
reported a reduction in resting ATP concentration, in the quadriceps muscle of COPD 
patients [70, 71]. It has been also shown that required ATP demand during low exercise 
workload is not generated in COPD patients [71].  
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1.2.4  Potential players in skeletal muscle dysfunction and wasting in COPD 
patients 
The cause of the skeletal muscle disorder observed in COPD may be due to a number of 
factors including an imbalance between protein degradation and synthesis, systemic and local 
inflammation, oxidative stress and hypoxia. In the next paragraphs, these factors and the 
possible molecular mechanisms underlying the muscle degeneration in COPD patients will be 
elaborated. 
1.2.4.1 The role of systemic inflammation in muscle wasting 
High level inflammation in the lung of COPD patients leads to systemic inflammation, 
refered also as ‘overspill’ in the community [72]. COPD is associated with evidence of 
increased plasma levels of proinflammatory cytokines. A systematic review and meta-
analysis supported this and concluded that individuals with COPD had significantly raised 
levels of several markers of inflammation including C-reactive protein (CRP), IL-6, 
fibrinogen, and TNFa, confirming the presence of systemic inflammation [73]. Until recently, 
the systemic inflammation was thought to be a major driver of muscle wasting in COPD 
patients by inducing local inflammation and causing higher protein degradation.   
1.2.4.2 The role of local inflammation in muscle wasting 
The earlier common view was that local inflammation caused via systemic inflammation in 
COPD patients contributes to decline in muscle function. Although this hypothesis is 
supported by animal models linking systemic inflammation with local inflammation and 
muscle atrophy [74], it is still unclear whether this mechanism may play a role in COPD. For 
example, the analysis of cytokine profiles in the quadriceps of patients with COPD shows 
that the level of TNFα in COPD individuals is lower than in control subjects [67].  Moreover, 
in this case TNFα protein levels correlated positively with muscle function, implying higher 
levels were associated with increased quadriceps strength. Other pro-inflammatory cytokines 
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(e.g. TNFα receptors) as well as the pro-angiogenic factor VEGF showed similar trends [67]. 
These observations are consistent with the role of local inflammatory signals, induced by 
muscle contraction and required for the activation of tissue remodeling pathways. 
1.2.4.3 Molecular mechanisms underlying the imbalance between muscle protein synthesis 
and degradation 
As the tight balance between the protein synthesis and degradation controls the muscle mass, 
higher protein degradation and/or reduced protein synthesis is responsible for muscle loss. 
However, molecular mechanisms responsible for an imbalance between protein synthesis and 
degradation in COPD are still unclear. There are several pathways that are hypothesized to 
induce muscle protein degradation or inhibit protein synthesis (Figure 1.3). These include 
inhibition of AKT/MT pathway via catabolic signals and activation of NF-KB pathway 
MAPK signaling pathway via inflammatory signals (Figure 1.3). Activation of AKT/MTOR 
pathway has been shown to induce muscle hypertrophy in vivo [11]. Inhibition of Akt has 
been shown to dephosphorylate FOXOs causing localization of the FOXOs in the nucleus, 
which then induces activity of muscle specific target genes ubiquitin ligases MURF1 and 
MAFBX leading to protein degradation [75, 11, 76]. Similarly activation of MAPK pathway 
through phosphorylation of p38MAPK activates MURF1 and MAFBX in the muscle atrophy 
in cell culture experiments in response to cytokine stimulation [77] and in animal models of 
immobilization induced atrophy [78]. The activation of the transcription factor NF-KB leads 
to inhibition of MyoD expression, which is essential for skeletal muscle differentiation and 
the repair of the damaged tissue [79]. However, the molecular mechanisms derived from the 
animal studies cannot be verified in COPD patients. Recent studies have reported that 
activation of MAPK and NF-KB pathways in COPD patients are lacking. In a large clinical 
study, consisting of 105 COPD patients, samples from quadriceps muscle showed no 
differences in p38 MAPK protein or p38 MAPK mRNA levels compared with healthy 
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muscle [80]. Similarly lack of activation of NF-KB pathway was shown by Mercken et al. 
[81].  On the other hand, the consequence of Akt/mTOR pathway inhibition in animal models 
appears to be consistent with COPD muscle [82]. In a recent study, Akt/mTOR pathway has 
been shown to be inhibited in hyoxemic COPD patient compared with nonhypoxemic COPD 
patients, but the study consists of only 8 patients in total [82]. Therefore larger studies are 
needed to elucidate this pathway.  
 
Figure 1-3. Schema of the molecular mechanisms leading to increased activity of protein 
degradation and decreased protein synthesis.  
This figure represents the role of AKT signaling pathway, MAPK signaling pathway and 
NFKB in skeletal muscle atrophy. This figure has been summarized and adapted from [83, 
75, 11, 76, 79] 
 
1.2.4.4 Is muscle hypoxia a factor determining muscle wasting in COPD? 
As COPD patients have difficulties breathing and suffer from impaired oxygen uptake, they 
have a deficient oxygenation of the blood, which results in muscle tissue hypoxia [60].  There 
are several pieces of evidence supporting the view that this may be an important trigger for 
muscle dysfunction in COPD. Chronic hypoxia has been proposed to explain skeletal muscle 
loss in COPD patients as well as in healthy individuals at high altitudes [84, 85, 86]. It has 
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been reported that individuals at high altitudes suffer from reduced muscle mass and peak 
power [84, 85, 86]. A recent small study based on four hypoxemic and four nonhypoxemic 
COPD patients has reported that hypoxia is responsible for inhibition of Akt/mTOR signaling 
pathway [82], which was previously shown in animal models to be a crucial regulator of 
skeletal muscle hypertrophy [11]. In this study, they have also shown that inhibition of 
Akt/mTOR pathway is due to the activation of REDD1 (Regulated in Development and 
DNA Damage Responses) [82]. This was also validated in an animal study exposed to severe 
hypoxia for 3 weeks and REDD1 overexpression in vivo caused skeletal muscle fibre atrophy 
[82].  
1.2.4.5 Oxidative stress in COPD muscle 
Oxidative stress has also been shown to contribute to muscle structural and functional 
damage [87]. It occurs as a result of an imbalance between Reactive Oxygen Species (ROS) 
and antioxidant systems. Inflammation, hypoxia and mitochondrial dysfunction have been 
linked with increased muscle ROS levels [88, 89].  In line with this, oxidative stress in 
muscle measured by protein carbonylation has been shown to be higher in COPD patients as 
compared to healthy individuals and negatively correlated with quadriceps muscle strength, 
which was measured by muscle voluntary contraction [67, 90]. Koehlin and collegues have 
reported that COPD patients with chronic hypoxemia have increased muscle oxidative stress 
at rest and after exercise as compared to non-hypoxemic COPD patients [91]. 
1.2.5 Current therapies for muscle wasting in COPD 
Current treatments are still inefficient for increasing and preserving the muscle mass [92]. 
The known treatments are exercise training, oxygen therapy, nutritional interventions, steroid 
supplements and anti-inflammatory drugs [92]. The oxygen therapy has been shown to be 
beneficial in short term by enhancing exercise capacity [93]. Although exercise training 
represents one of the most effective treatments, the selection of the training regime is very 
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important as it has been shown that high intensity exercise training is causing oxidative stress 
[94].  
Steroid supplementation combined with exercise training has been shown to be beneficial in 
COPD patients. A recent study has reported that COPD patients with low serum testosterone 
levels who were subjected to resistance training and testosterone supplementation for 10 
weeks increased leg muscle strength as compared with patients subjected to resistance 
training and placebo [95]. However, dose optimization, establishing the safety and the 
benefits of long term anabolic steroids treatments are required [95]. 
Nutritional intervention did not lead to improvements to muscle function in COPD patients in 
several studies [96, 97, 98].  For example, creatine supplements have not yield to significant 
improvements on muscle strength and fatigue in COPD patients compared with exercise 
training [97]. Similarly, a recent study has reported no effect of glutamine ingestion of 
oxidative metabolism in stable COPD patients [98]. 
As the current treatments are still inefficient for restoring the muscle mass and strength in the 
COPD patients, it is crucial to understand molecular mechanisms underlying muscle wasting.  
1.3  Bone and cartilage degradation in ageing, myeloma and arthritis patients 
Having described various aspects of the muscle wasting in COPD patients, in this section the 
second biological system related to bone loss and cartilage deformation observed in ageing, 
in arthritis, and in MM will be introduced. Although this study represents a very 
heterogeneous scenario, all these conditions are associated with bone and cartilage 
deformation. In this thesis, the aim is to understand possible abnormalities that are deriving 
such deformation. First a background on the diseases will be provided. Then the role of 
abnormal microenvironment contributing to the abnormal bone and cartilage differentiation 
in ageing and in these conditions will be described.  
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1.3.1 Background on diseases associated with bone and cartilage degradation 
Multiple Myeloma (MM) is a cancer that is initiated by proliferation of malignant plasma B-
cells in the bone marrow. This disease has a median survival rate of 62 months for stage 1, 44 
months for stage 2, and 29 months for stage 3 patients [99]. The categorization of patients in 
various stages is based on the degree of bone lesions, anaemia, hypercalcemia, levels of M 
protein in the serum and urine [100]. During the course of the disease, most of the patients 
develop bone fractures and bone pain. Severity of bone lesions is a predictor of survival 
duration [101].  
Arthritis patients suffer from bone and cartilage deformation in the joints causing pain and 
mobility restriction. There are numerous types of arthritis but the most frequently observed 
type is osteoarthritis [102]. Osteoarthritis (OA) is progressive degenerative disease affecting 
the articular cartilage such as knees, hips, fingers and spine, causing bone deformation and 
mild synovial inflammation [102].  It is estimated to affect 9.6% of men and 18.0% of 
women aged over 60 years worldwide [102]. A less frequently observed type of arthritis is 
rheumatoid arthritis (RA), which is a systemic inflammatory disease affecting synovium in 
joints, leading to joint and bone destruction [102]. 
1.3.2 Bone and cartilage degradation as a result of abnormal hMSCs differentiation in 
ageing and in diseases 
Changes in the bone marrow microenvironment that occurs as a result of ageing and disease 
can potentially influence hMSCs differentiation capacity to bone, cartilage and fat cells. 
 In ageing, it has been shown that there is an increase in the number of adipocytes, which 
results in a fatty bone marrow microenvironment [103]. The changes in the bone marrow 
microenvironment are favouring adipogenic and osteoclastic differentiation over osteogenic 
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differentiation [104], [105]. The increase activity of osteoclastogenesis and decreased 
osteoblast activity result in sustained bone loss in ageing.  
Similarly, in MM patients a decreased osteoblast activity [106, 107] and an increased 
osteoclast activity [108] have been shown. Moreover, malignant plasma cells from MM 
patients cultured with human osteoblastic cells enhances osteoblast apoptosis [109]. Corre et 
al has reported that the osteogenesis differentiation from the MM patients is two-fold less 
effective than normal patients [106]. A novel study has confirmed the impaired osteogenic 
differentiation of hMSCs from Myeloma patients compare to normal patients [107]. They 
have also shown that the osteogenesis process is less effective in patients with bone lesions 
compared with the patients without bone lesions [107]. 
 In arthritis patients, the inflammatory bone marrow microenvironment leads to joint and 
bone destruction that can occur via interfering with osteoclast, osteoblast and chondrocyte 
activities and differentiation of hMSCs towards these lineages. Several in-vitro [110, 111, 
112] and animal models [112, 113] have shown that osteoclast activity is induced via 
cytokine activity, which is supporting that the abnormal bone remodeling in RA patients can 
be due to enhanced osteoclast activity. Indeed, a recent study has shown an increased 
osteoclast functional activity in RA patients [114]. The number of bone forming cells has also 
been shown to be decreased in inflammatory conditions. Osteoblasts collected from bone 
biopsies of RA patients treated with IL-1B and TNFa has been shown to induce apoptosis of 
osteoblasts via induction of FAS [115]. 
Only a small number of studies have investigated the hMSCs and their efficiency of 
differentiation from RA and OA patients. A particularly interesting result shows that in vitro 
chondrogenic and adipogenic differentiation of bone marrow derived hMSCs from OA 
patients is significantly reduced compared with healthy individuals, whereas osteogenic 
18 
 
differentiation was comparable [116]. Osteogenic differentiation of hMSCs from OA and RA 
patients has also been shown to be similar [117]. In another study, in vitro differentiation of 
hMSCs from RA patients towards the three lineages have been shown to be as efficient as 
from healthy donors [118]. Further studies are required to confirm the properties of hMSCs, 
differentiation efficiency in RA, OA and healthy individuals. Microarrays capturing the 
mRNA response during differentiation would be also very valuable for understanding key 
players in this process. 
1.3.3 Potential role of hMSCs for treatments 
Development of clinical applications for hMSCs is crucial for the treatment of degenerative 
diseases and many preclinical studies were reported, for recent reviews [119, 120, 121]. The 
potential clinical applications include autologous or allogeneic local implantation and 
systemic infusion of hMSCs, which might be also combined with gene therapy. Two clinical 
trials have been reported to be successful for bone regeneration. An autologous hMSCs 
treatment in three patients with defective fracture healing [122] and allogenic hMSCs 
treatment in three patients with osteogenesis imperfecta [123] has lead to bone formation. 
Autologous hMSCs treatment has also been demonstrated to contribute to cartilage repair in 
OA patients [124].  
Although the reported encouraging outcomes of the clinical trials in the literature, larger 
randomized studies are required before hMSCs treatments can be routinely available.  Better 
understanding of normal osteogenesis and chondrogenesis process and identification of 
potential players in disease states is crucial for enhanced bone formation combining hMSCs 
treatments with gene therapy.  
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1.4 Functional genomics and systems biology approaches 
In this thesis, muscle wasting in COPD patients, deformation of bones and cartilage in 
ageing, arthritis patients and multiple myeloma patients was studied using transcriptomics 
and systems biology approaches. In the following sub-sections, the state of the art in systems 
biology will be provided. 
1.4.1 Omics technology and challenges 
Technology advances in the last 10-15 years have made possible measuring the expression of 
genes, proteins and metabolites at genome level in single experiments. This has contributed 
to generate an unprecedented amount of data. Integrating, analyzing and interpreting these 
data using advanced computational methodologies is one of the objectives of the emerging 
discipline of systems biology.  Noisy data, technical variations between samples due to 
generation of data from different people or laboratories, patient heterogeneity, small number 
of samples and large number of variables to study makes this task very challenging. 
Furthermore, biological interpretation of this data is also difficult due to the large amount of 
data. In the section below, an overview of the computational approaches are described for the 
analysis of microarray based expression profiling, which is one of the most widespread 
functional genomics technology. Moreover, some of the methodologies described below 
allow also integration of multi-level datasets with classical physiology. 
1.4.2 Microarrays and various types of technologies 
DNA microarrays allow measuring expression levels of thousand of genes simultaneously. 
Microarrays are made of thousands of DNA probes immobilized into specific locations 
(spots) on a solid small support such as glass or silicon chips. There are two major types of 
platform to generate microarrays. In one platform, cDNA or long oligonucleotides (70-
80mers probes) have been spotted on a glass slide. The second technique has been pioneered 
20 
 
by Affymetrix technology and it is produced by synthesizing short oligonucleotides (20-
25mer probes) on silicon chips using photolithography. Another major provider is Agilent, 
which uses the first type of platform by printing long oligonucletodies on glass slides using 
an ink-jet based technology. In this thesis, microarrays generated with Affymetrix and 
Agilent technologies have been studied. Although the protocols of the two techniques differ, 
the principle behind microarray generation can be summarized in three major steps including 
sample preparation and labelling, array hybridization and scanning. Firstly mRNA extracted 
from a sample is reverse transcribed into complementary DNA strand (cDNA) by using an 
enzyme reverse transcriptase. The labelling protocol differs between the two technologies. 
For the Agilent arrays, the cDNA is labelled with fluorescent dye Cy3 for single colour arrays 
or Cy3 and Cy5 for two-channel arrays. The cDNA in the labelled samples hybridizes to 
specific spots on the microarray containing its complementary sequence. For the Affymetrix 
arrays, the cDNA is not labelled but it is used as a template in an in vitro transcription 
reaction to generate biotinylated cRNA stand. The cRNA is then hybridized to microarrays.  
Finally the hybridized arrays can be scanned with a laser. The binding between the 
fluorescently target sequence and probes on the spot generate a signal, which is directly 
proportional to the initial number of RNA molecules present for that gene in the sample.  
 
1.4.3 Typical steps in microarray data analysis 
There are a number of steps involved in microarray data analysis including data processing, 
quality control of data, identification of differential expression analysis, functional 
annotation, building networks and modularization approaches (Figure 1.4), which are 
described in the next paragraphs.  
21 
 
 
Figure 1-4. The major steps in microarray data analysis.  
This figure shows the major steps for the analysis of microarray data. The normalization and filtering 
of the lowest values is essential for data processing. Quality control of the processed data could be 
achieved by checking for outliers and batch effects by performing exploratory data analysis. To 
identify gene expression differences between experimental conditions, there are numerous statistical 
tool. These genes could be then used for building gene regulatory networks, identifying modules, 
annotating their functional role, and identify similar expression patterns.   
 
1.4.4 Microarray data processing and normalization 
The first step in microarray data analysis is the normalization and quality control of the data. 
The aim of the normalization is to correct the systematic technical variation without losing 
the biological variation. The systematic technical variation might be caused by labelling, 
scanning, different labs, and different scientists generating the data. To correct these, several 
normalization methodologies have been developed in the field, for reviews [125, 126]. The 
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choices of normalization methods depend on the array type (single or two channel arrays) and 
the manufacturer. For single channel arrays produced with Affymetrix, the most popular 
methods are Robust Multi-array Analysis (RMA) [127], Guanine Cytosine Multi-array 
Analysis (GCRMA) [128] and Affymetrix Microarray Suite (MAS5) [129].  The RMA 
method provides background correction for the probes, quantile normalization and 
summarization into expression measurements. GCRMA is an improved version of RMA that 
is able to incorporate the sequence-specific probe affinities [128]. These methods are 
implemented in R in the package affy [130] and also several GUI interfaces exist such as 
babelomics [131] and Genespring GX.  For the normalization of the Agilent arrays, limma 
package provides functions to perform loess normalization (Locally weighted polynomial 
regression), simple scaling or quantile.  
It should be noted that before performing the normalization methods, a log2 transformation is 
applied to the data in order to reduce variation among measures with high magnitude, thus 
adjust the variance to be the same for all intensities [126]. Once the data is normalized, it is 
important to check for batch effects and outliers using exploratory analysis techniques. 
1.4.5 Exploring the data 
The exploratory data analysis techniques are crucial in many scenarios including for outlier 
detection, identification of sample and gene similarity/dissimilarity and dimension reduction. 
The commonly used techniques in the field are clustering algorithms and ordination analysis 
such as principal component analysis (PCA), independent component analysis (ICA). There 
have been numerous clustering algorithms proposed including self organizing tree algorithm 
(SOTA) or Hierarchical Ordered Partitioning and Collapsing Hybrid (HOPACH) [132]. In 
each of these algorithms, it is possible to choose the distance measure and the linkage type.  
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To choose between various clustering algorithms, it is possible to perform a close analysis of 
clusters via a visual inspection. There are also tools that allow assessing the quality of the 
clusters generated and comparing the results of various algorithms [133]. 
1.4.6 Identification of differentially expressed genes 
An important question to address from microarray dataset is to identify genes that are 
differentially expressed between experimental conditions such as disease and healthy. To 
achieve this task several statistical analyses have been published and implemented. The 
appropriate methods can be chosen depending on the experimental setting, which might 
require comparison of two groups (t-test, SAM, ANOVA), more than two groups (SAM, 
ANOVA), or consideration of several factors such as treatment and disease types (2 Factor 
ANOVA), or time course data (SAM, ANOVA, BETR). These methodologies are 
summarized in Table 1.3. These tests can be performed in R on the command line [134] or in 
TMEV which provides a GUI [135]. For performance accuracy, a more recent review 
reporting the results of an extensive analysis comparing a wide range of these methodologies 
has recently been published using simulated and real datasets [136]. The authors have 
concluded that the selection of the significant genes heavily depends on the choice of the 
testing methods [136]. Another important factor in selection of significant genes relies on the 
threshold. Most of the statistical tests return a p-value for each gene representing the 
probability of observing the difference between experimental conditions by random chance. 
However, as the number of genes to test in a microarray dataset tends to be in the region of 
tens of thousands, the p-values should be corrected for the multiple testing.  One of the most 
widely accepted approach to control false positive rate and false negative rate is False 
Discovery Rate (FDR) [137]. It is acceptable to choose any threshold that is lower than 10% 
FDR, which is equivalent to expecting 10% false positives and 90% true positive. However, 
the final cut off should be selected by studying the results of various thresholds. In doing so 
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the number of genes is important but also sample separation, reproducibility, functional 
annotation of these genes should be performed before deciding the threshold.   
Test  Tests for comparing  Variance 
assumption 
between 
groups  
Description and examples  
t-test  One class 
Two class paired  
Two class unpaired  
Unequal  Genes with low variance, which are not 
affected by heterogeneity, can be 
statistically significant despite very low 
fold change (called stability problem). 
   
One way 
ANOVA  
Two or more classes  Equal  Generalization of t-test 
Example of use: different treatments  
Two way 
ANOVA  
Two factors  
Two or more classes 
for each factor  
Equal  Example of use: factor patient type and 
factor treatment  
Three way 
ANOVA  
Three factors  
Two or more classes 
for each factor  
Equal  Example of use: factor patient type, factor 
treatment, factor training  
BETR  Time-course   empirical bayes approach  
SAM  One class 
Two class paired  
Two class unpaired 
Multiclass 
Time-course 
Equal  Modification of t-test that removes the 
problem of stability encountered with t-test  
Table 1.2. Summary of the most used statistical tests. 
1.4.7 Functional annotation 
The advantage of microarray technologies is to measure gene expression of the whole 
genome. However, interpreting the results from a large amount of genes selected for instance 
from differential expression analysis is challenging.  It can also be biased as one would be 
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inclined to concentrate on the genes that one is familiar with. Functional annotation tools 
overcome this issue by performing statistical enrichment in databases such as KEGG 
pathways curated by experts in the fields, and GO terms. One of the most popular tools is 
DAVID (The Database for Annotation, Visualization and Integrated Discovery) and it 
provides a web interface and an R package (DAVIDQuery) to identify gene ontology terms 
and curated pathways that are significantly enriched in a list of genes [138, 139]. This is 
achieved by using a modified fisher test, called the EASE score. For only a few sets of genes 
the web interface is very practical, however the R package becomes the only option to avoid 
manual work for annotating large number of gene sets, which might be derived from 
clustering analysis for instance.  
1.4.8 Methodologies for building networks from datasets 
The aim of network inference methodologies is to capture interactions between entities such 
as genes, metabolites, proteins, and clinical measurements. Therefore, the network inference 
approaches allow data integration of various dataset and provide a framework to capture 
dependencies between entities. Constructing these interaction networks is crucial for the 
identification of disease responsible genes that can alter other entities and hence the function 
of important biological functions. These networks can enhance understanding of the 
mechanisms underlying diseases, which could lead to identification of biomarkers and 
development of potential drug targets.  
Numerous methods have been developed for building networks (for recent reviews [140, 141, 
142]). The choice of methods depends on the type of the data (time-course or static), number 
of samples, and number of genes.  There are methodologies based on pairwise association of 
genes (correlation, mutual information), on probabilistic methods (Bayesian networks), and 
differential equations. The methods based on a pairwise score can be applied by using the 
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whole dataset as an input, whereas methods based on Bayesian networks and differential 
equations can only be applied to a small number of entities.   
In the case of a study concentrating on a specific question with small number of genes to 
infer, the Bayesian networks and differential equations have the advantage of revealing the 
direction of the connection, unlike the methods based on pairwise association. There are 
several methodologies that have been published to infer networks using a Bayesian approach 
[143] and ordinary differential equations [144, 145, 146]. Systematic comparisons of these 
methodologies were performed in several reviews [140, 142].  
To infer large networks involving more than hundred genes, several metrics can be computed 
between all gene pairs in the data, including correlation and mutual information. It is 
important to note that these relations are statistical dependencies and not causal relationship. 
With smaller number of samples, correlation such as Spearman and Pearson with the latest 
being more sensitive to nonlinear relationships can be used. ARACNE computes the mutual 
information between all pairs of genes and eliminates potentially indirect connections using 
the Data processing Inequality (DPI) principal [147].  Mutual information can capture linear 
and non-linear relationships but a large amount of samples (>40 samples) is required.  
1.4.9 Constructing networks from the literature 
Inferring accurate networks from datasets of small number of samples is not possible. 
Constructing networks using knowledge in the literature provides an approach to achieve this 
task. Cytoscape provides plugins with a user interface (BionetBuilder [148] and MIMI [149]) 
that allows integration of databases including  DIP, BIND, Prolinks, KEGG, HPRD, The 
BioGrid and GO and construct networks for a given gene list [150].  
Construction of networks from the literature is also very useful to define a priori knowledge 
in network inference approaches such as Bayesian networks to enhance the accuracy of these 
methodologies or for validation of the networks that are inferred from the dataset.   
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1.4.10 Modularization approaches 
An immediate challenge rises after the inference of large networks for their interpretation and 
visualisation. To tackle this problem, several modularization approaches have been proposed 
to group entities based on certain properties including functional role, topology of the 
network, high co-regulation of nodes or nodes with high prediction of the phenotype. The 
first modularization approach was proposed by Ideker and colleagues with the aim of 
identifying sub-networks that consist of genes differentially expressed between experimental 
conditions in large protein-protein interaction networks [151]. The approaches based only on 
the network topology aims to identify sub-networks that are highly interconnected in a large 
network [152], for a recent review [153]. Other approaches include scoring of the edges using 
metrics such as correlation coefficient or mutual information with the aim to identify sub-
networks consisting of genes that are highly co-regulated [154, 155].  
1.5 Aims and outline of the thesis 
The overarching goal of this thesis is to identify molecular networks linked to 
musculoskeletal disorders. With the development of genomics and functional genomics 
technologies, the ability to measure and characterise the molecular state of cells and tissues 
have reached an unprecedented level of sophistication. Unfortunately, this has not resulted in 
a comparable increase in knowledge. The main rate limiting step has been 
the difficulty in analysing and interpreting this large amount of data. This thesis directly 
address this important challenge by illustrating in several relevant biological and clinical 
scenarios the usefulness of advanced statistics and systems biology  approaches 
in understanding musculoskeletal disorders. 
More precisely, muscle wasting occurring in COPD patients has been studied using an 
integrative approach and a pathway level approach. In Chapter 2, the aim has been to identify 
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pathways that are co-ordinatly modulated in response to exercise training in muscle of COPD 
patients and aged matched healthy individuals. This work has identified a number of 
pathways that are modulated between COPD and healthy individuals after training 
(inflammatory pathways) or specifically modulated in healthy individuals in response to 
training (metabolism and tissue remodeling pathways). In Chapter 3, the abnormal energy 
metabolism, tissue remodeling pathways in relation to physiological outcome and systemic 
inflammation have been studied by constructing gene regulatory networks. This approach 
addressed the hypothesis that systemic inflammation might be a key player driving muscle 
wasting in these patients. This approach has outlined no link between systemic inflammation 
and muscle dysfunction. Instead it shows that oxygen dependent changes in the expression of 
epigenetic modifiers may be controlling bioenergetics imbalance in COPD.  
The second aim of this thesis has been the identification of regulatory networks underlying 
bone and cartilage differentiation in healthy and diseased tissues (Chapter 5). First, high-level 
dynamical gene regulatory networks have been inferred describing the normal hMSCs 
differentiation to bone and cartilage cells. Then, I have aimed to identify molecular networks 
representing an alteration of the normal hMSCs differentiation in ageing, multiple myeloma 
and arthritis, a series of conditions that are associated to loss of bone and cartilage formation. 
For this, a novel modularization approach developed and described in Chapter 4 has been 
used. This methodology has been developed for integrating multi-level dataset. It allowed 
integration of biological knowledge, gene co-expression during normal hMSCs 
differentiation and differential expression analysis in disease patients. This work has lead to 
the identification of gene regulatory networks that consist of genes highly co-regulated in the 
hMSCs differentiation and at the same time differentially expressed in ageing or disease. 
Ultimately, the hypothesis generated using these models represent plausible targets, which 
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could enhance the differentiation in ageing and in disease and could be experimentally 
validated. 
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 CHAPTER 2: PATHWAY ANALYSIS OF 
TRAINING-INDUCED EFFECTS ON 
SKELETAL MUSCLE TRANSCRIPTOME IN 
COPD PATIENTS 
 
2.1 INTRODUCTION 
In a significant percentage of patients, COPD is characterized by a number of systemic 
effects, such as skeletal muscle dysfunction and wasting. This leads to a disease phenotype 
associated with poor prognosis [156]. The precise mechanisms underlying muscle wasting in 
this COPD are still largely unknown.  
Active life-style and skeletal muscle training are important factors improving the prognosis of 
COPD patients, including reduced systemic effects of the disease such as skeletal muscle 
dysfunction [157, 158, 159]. There is evidence suggesting that physical activity at early 
disease stages might have a beneficial impact on nitroso-redox balance and muscle 
remodeling [160], but the interplay between training and inflammatory phenomena at the 
systemic level is also still controversial.   
Recently, mRNA expression profile in quadriceps of patients with COPD provided the first 
evidence for impaired gene expression in the muscle of COPD patients compared to healthy 
subjects [161].  These genes represented a wide spectrum of biological processes such as 
protein turnover, energy production, muscle regeneration, and transcription factors. Radom-
Aizik and colleagues [162] performed a gene expression profiling analysis of the effects of 
31 
 
training on skeletal muscle biopsies of healthy and COPD individuals. The authors reported 
that training in healthy individuals induced modulation of a larger number of genes than in 
COPD [162]. However, even in healthy subjects, the reported fold changes in individual 
genes generated by training were too small to explain the prominent training-induced 
physiological effects. Hence, training-induced physiological effects are likely to be a 
consequence of a combination of small genomic changes within functional pathways. 
Consequently, in the current study, a pathway level analysis was applied using advanced 
bioinformatics methods that allow identification of multi-gene pathway, based molecular 
signatures associated with training-induced physiological changes. Differentially modulated 
functional pathways were identified between healthy subjects and COPD patients before and 
after training using the Radom-Aizik’s dataset (12 weeks training) [162] and a new 
expression profiling study generated by our collaborators in the group of Roca (3 weeks 
training) [160]. Because of the differences among the endurance training programs, the two 
datasets were analyzed independently. 
The pathway level analysis is consistent with the view that COPD muscles lose the ability to 
modulate key metabolic and tissue-remodeling pathways in response to training. Moreover, 
the results show that endurance training can induce opposite responses in inflammatory 
pathways, in healthy and diseased muscles.   
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2.2 METHODS 
2.2.1 Analysis strategy 
This study is based on a pathway-level analysis strategy developed to identifying molecular 
networks underlying a given biological response (see Figure 2.1 for a schematic 
representation). In this specific project this has been applied to study muscle dysfunction in 
COPD. The initial step in the analysis consists of mapping genes represented in the 
expression profiling datasets to KEGG pathways (Figure 2.1A). Once genes have been 
mapped into pathways, each pathway activity can be represented by performing a principal 
component analysis (Figure 2.1B). The overall activity of a given pathway characterized by 
the expression of several genes is summarized by two variables (the first two principal 
components, PCs, of the PCA analysis), (Figure 2.1C). This approach has been previously 
demonstrated to be very effective [154]. Then, each pathway can be assessed for differential 
transcriptional activity (for example in respect to training or disease factors) as a whole 
(Figure 2.1D). The pathways can be further analyzed using the knowledge management 
system Ingenuity Pathway Analysis (IPA) (Palo Alto, http://www.ingenuity.com), which can 
help with the biological interpretation (Figure 2.1E).  
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Figure 2-1. Analysis Strategy.   
This figure shows in a diagrammatic format the analysis strategy employed in this study.  
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2.2.2 Study groups 
The Radom-Aizik dataset [162]  - These authors developed a gene expression profiling 
dataset based on Affymetrix microarray technology representing muscle biopsies derived 
from 6 healthy and 6 COPD individuals before and after 13 weeks endurance exercise. 
Details of this study and of the training protocol are available in the original publication 
[162].  
The new dataset (3-weeks training study) – An additional transcriptional dataset with skeletal 
muscle biopsies of 5 COPD patients (aged 63  2 year) and 3 age-matched healthy 
individuals studied before and after a much shorter (3-weeks) supervised endurance training 
program was generated in the group of Josep Roca. Details of the selection procedure, 
clinical assessment and measurements performed before and after training are described in 
[160]. This study was carried out in accordance with the ethical standards on human 
experimentation , which were approved by ethical committees at IMIM-Hospital del Mar 
(Barcelona, Catalonia, Spain), Maastricht University Hospital (Maastricht, The Netherlands), 
Royal Brompton Hospital (London, UK) and Cruces Hospital (Barakaldo, Basque Country, 
Spain). Open muscle biopsies of the “vastus lateralis” were obtained at rest, and after the 
training period. Muscle samples (~0.1 g) were placed in RNA stabilization reagent 
(RNAlater®, Ambion, Inc., 2130, Woodward street, Austin TX-USA) and stored at -20oC for 
RNA extraction, which was performed by using the TRIzol Reagent (Invitrogen Life 
Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. Gene 
expression profiling was performed using oligonucleotide Affymetrix Human Genome Focus 
arrays following the manufacturer’s instructions (Focus 2 arrays).  
2.2.3 Mapping genes to pathways 
Individual genes represented in the datasets have been mapped to the Kyoto Encyclopaedia of 
Genes and Genomes (KEGG) pathway database using the web software package Database for 
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Annotation, Visualization and Integrated Discovery (DAVID) [163]. KEGG associates genes 
to a collection of expert defined pathways, representing the molecular interaction and 
reaction networks for metabolism, genetic information processing, environmental information 
processing, cellular processes, human diseases and drugs [164]. In this chapter, two 
independent analyses using two datasets published in [162] and [160] were analyzed. 
2.2.4 Summarizing pathway activity 
The analysis performed in this study is based on identifying KEGG pathways, which are 
differentially modulated between two groups, as described below. This strategy has great 
advantages compared to the analysis of individual genes because it simplifies the complexity 
of data analysis reducing the input data from tens of thousands of genes to a few hundreds of 
well characterized functional modules. It generally produces an increase in statistical power 
and improves biological interpretability [140]. 
One possible technique to summarize pathway activities is to use principal component 
analysis (PCA), which allows the representation of complex multi-dimensional datasets in a 
lower dimensional space by retaining the majority of the information [165]. Therefore, by 
using this technique the overall activity of a given pathway characterized by the expression of 
several genes is summarized by two variables (the first two principal components, PCs, of the 
PCA analysis), which describe up to 70% of the information present in the original data. 
These two indexes of pathway activity are then tested for their ability to separate the two 
sample groups. The procedure has been implemented in the statistical environment R [134]. 
The code is available for download on our group web site 
(http://biptemp.bham.ac.uk/software.html). 
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2.2.5 Pathway and gene level statistical analysis 
Differential modulations of a pathway activity represented by the corresponding PCs have 
been tested by performing Student t-tests between groups (unpaired analysis) and within 
groups (paired analysis). First, the differences between COPD patients and healthy sedentary 
controls before training were compared. To assess training-induced effects, muscle biopsies 
before and after training within each group were compared. Finally, post-training data were 
also compared between the two groups. 
A threshold for significance (FDR<10%) has been defined after correction for multiple 
testing using Benjamini-Hochberg false discovery rate (FDR) procedure [166]. Accordingly, 
functional pathway components associated with an FDR of 10% were considered 
differentially modulated and selected for further analysis and biological interpretation. For 
further analysis, heatmaps from standardized values of the PCs representing the pathway 
activity have been generated. 
2.2.6 Ingenuity Pathway Analysis 
Using the Ingenuity Pathway Analysis (IPA) software (Palo Alto, 
http://www.ingenuity.com,) biological networks linked to transcriptionally modulated 
pathways were identified. Once the gene lists were uploaded into the application, each gene 
identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge 
Base. These genes, called focus genes, were overlaid onto a global molecular network 
developed from information contained in the Ingenuity Pathways Knowledge Base. Networks 
of these focus genes were then algorithmically generated based on their connectivity 
according to the following procedure implemented in the IPA software application. The 
specificity of connection for each focus gene was calculated by the percentage of its 
connection to other focus genes. The initiation and the growth of pathways proceed from the 
gene with the highest specificity of connections. Each network had a maximum of 35 genes 
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for easier interpretation and visual inspection. Pathways of highly interconnected genes were 
identified by statistical likelihood. Networks with a Score greater than 20 and containing 
more than 60% of focus genes were selected for biological interpretation.  
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2.3 RESULTS 
2.3.1 Mapping genes to pathways 
Mapping individual genes to KEGG pathways lead to 166 pathways associated to the Radom-
Aizik dataset [162] and 157 pathways associated to the dataset published in [160]. The two 
pathway sets are completely overlapping. These represent respectively 77% and 73% of the 
annotated pathways in the KEGG database and 33% and 38% of the annotated probes in the 
two datasets respectively [162, 160]. The high coverage both at functional and gene level in 
the derive datasets give us the confidence that the derived datasets are representative of the 
transcriptional state of muscle biopsies.  
 
2.3.2 A comparison between Healthy subjects and COPD patients before 
endurance training   
Functional module analysis of the data generated by Radom-Aizik and colleagues [162] did 
not reveal any significant difference between healthy subjects and COPD patients in overall 
activity of the pathways. However, the analysis of the new dataset revealed differences in the 
activity of 4 pathways (Table 2.1). Two of these are metabolic pathways (polyunsaturated 
fatty acid biosynthesis and glutathione pathways). The other two are (bladder cancer and 
colorectal cancer pathways) related to processes involved in angiogenesis (VEGF signaling 
component) and tissue remodeling (MAPK and TGFß signaling component). 
 
PCs KEGG  pathways  Group 
PC1 Glutathione metabolism  metabolism 
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PC1 Polyunsaturated fatty acid biosynthesis  Metabolism 
PC2 Bladder cancer  Signaling 
PC2 Colorectal cancer  Signaling 
Table 2.1 This table shows all pathways which have a difference of >=1 between 
sedentary healthy and sedentary COPD patients (FDR<10%) using the new dataset. 
 
2.3.3 Training effects on healthy subjects and COPD patients  
In healthy subjects, training induced a massive response at pathway level in both datasets. Up 
to 79 differentially expressed pathways were seen in the dataset published in [162] and 52 
pathways were detected in the new dataset [160], see appendix Table A2.1 and Table A2.2 
respectively. These pathways belong to inflammation, metabolism and tissue remodeling. 
In COPD patients, training had a smaller effect on the muscle transcriptome than in healthy 
individuals, confirming the results previously reported by [162]. Only 12 differentially active 
pathways were identified using the data published in [162] and 3 pathways in the new dataset 
(3), see appendix Table A2.3 and Table A2.4 respectively. 
In the 12 weeks training study published by Radom-Aizik [162], healthy and COPD patients 
modulate the same inflammatory pathways in opposite directions (Figures 2.2A and 2.2D 
and Figure 2.4). In the shorter 3 weeks training study, only healthy individuals modulate 
inflammatory pathways (Figure 2.3).  
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Figure 2-2. Pathway components modulated in response to training (RA study) 
This figure shows the heatmaps generated from the standardized values of the PCs representing 
pathway activity. It shows significantly activated inflammatory related pathways between sedentary 
vs. trained healthy people (panel A) and sedentary vs. trained COPD patients (panel D) using Radom-
Azik’s dataset. The panel B and C show the heatmap of significantly activated  (respectively) 
metabolism  and tissue remodeling pathways between sedentary vs. trained healthy people. These 
pathways are not significantly activated between sedentary vs. trained COPD patients (panel E, panel 
F). However, the heatmaps shows that this is because of 3 patients which are not able to respond to 
training. Panel D shows the significantly activated metabolism pathways after training in COPD 
patients.  
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Figure 2-3. Pathway components modulated in response to training (new study) 
This figure shows the heatmaps the standardized values of the PCs representing pathway activity. The 
heatmaps are generated from the significantly activated inflammatory and metabolism related 
pathways (represented in red) between sedentary vs. trained healthy people (panel A, panel B, panel C 
respectively) using the new dataset. The panel D, E, F shows the pathways between sedentary vs. 
trained COPD of the previously identified as significant between sedentary vs. trained healthy people. 
These pathways are not significantly different between sedentary disease and trained COPD patients 
(represented in blue). 
My analysis also revealed that components of tissue remodeling pathways are activated in 
response to training in healthy individuals, but these pathways fail to be modulated in COPD 
individuals (Figure 2.2 panels C and H, Figure 2.3 panels C and F, and Figure 2.4). Training 
only effectively modulates the activity of tissue remodeling pathways such as gap junction 
and focal adhesion in healthy individuals. In contrast, COPD patients show either a very 
heterogeneous response or no response at all. Similarly, COPD patients fail to activate the 
42 
 
metabolic pathways and show a very heterogeneous response. Specifically, pathways 
belonging to lipid metabolism are activated in response to training in healthy and COPD 
patients whereas those belonging to carbohydrate metabolism, amino acid metabolism, and 
metabolism of cofactors and vitamins are only activated in response to training in healthy 
people. Analysis at the gene level for these pathways shows that the genes, which are 
significantly different in response to training in healthy patients are mostly up-regulated, 
whereas there are no significant changes in COPD patients (fold >1.5). 
 
Figure 2-4.Tissue remodeling pathways and Glutamate metabolism pathway 
This figure shows the response of training in Healthy (represented in black) and in COPD 
(represented in red) individuals tissue remodeling and glutamate metabolism pathways using 
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Radom-Aizik dataset. These pathways are all modulated in response to training in healthy 
people. However, in gap junction and glutamate metabolism only 3 out of 6 patients respond 
to training.  
 
 
Figure 2-5. Tissue remodeling pathways  
This figure shows the response of training in Healthy (represented in black) and in COPD 
(represented in red) individuals tissue remodeling and glutamate metabolism pathways using 
the new dataset.  
 
2.3.4 Direct comparisons between healthy and diseased samples after training 
There were 23 differentially active pathways between the two groups using the dataset 
published in [162], (Tables 2.2). These pathways represent metabolism and tissue remodeling 
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functions confirming the effects of exercise training separately in each group. Of these 
pathways obtained using Radom-Aizik dataset [162],  6 belong to metabolism (riboflavin 
metabolism, nicotinate and nicotinamide metabolism, nitrogen metabolism, fructose and 
mannose metabolism, pyrimidine metabolism), 2 belong to tissue remodeling (gap junction, 
focal adhesion) and 3 belong to inflammation (cytokine-cytokine receptor interaction, mTOR 
signaling pathway , ErbB signaling)  (Table 2.2). The significantly differentially active 
pathways identified using the new dataset belong to metabolism (nicotinate and nicotinamide 
metabolism, glutamate metabolism, Ala13 and aspartate metabolism) and cell-to-cell 
communication (focal adhesion, cell communication, ECM-receptor interaction), (Table 2.3). 
 
PC Kegg pathway Functional group 
PC1 Melanoma signaling pathway 
PC1 ErbB signaling pathway tissue remodeling 
PC1 Cytokine-cytokine receptor interaction inflammation 
PC1 Nicotinate and nicotinamide metabolism metabolism 
PC1 mTOR signaling pathway inflammation 
PC1 Phosphatidylinositol signaling system signaling pathway 
PC1 Complement and coagulation cascades signaling pathway 
PC1 Neurodegenerative Diseases signaling pathway 
PC1 Nitrogen metabolism metabolism 
PC1 Riboflavin metabolism metabolism 
PC2 Focal adhesion tissue remodeling 
PC2 Adipocytokine signaling pathway signaling pathway 
PC2 Gap junction tissue remodeling 
PC2 Pancreatic cancer signaling pathway 
PC2 Pyrimidine metabolism metabolism 
PC2 Fructose and mannose metabolism metabolism 
PC2 Hedgehog signaling pathway signaling pathway 
Table 2.2. This table shows all pathways which has a difference of >=1 between trained 
healthy and trained COPD patients (FDR<10%) using the dataset generated by Radom-
Aizik. 
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PCs Kegg Groups 
PC1 Cell Communication  tissue remodeling 
PC1 ECM-receptor interaction  tissue remodeling 
PC2 Glutamate metabolism  metabolism 
PC2 Alanine and aspartate metabolism  metabolism 
PC2 
Nicotinate and nicotinamide 
metabolism  metabolism 
PC2 Alkaloid biosynthesis II  metabolism 
PC2 Focal adhesion  tissue remodeling 
PC2 Hematopoietic cell lineage  Metabolism 
Table 2.3. This table shows all pathways which has a difference of >=1 between trained 
healthy and trained COPD individuals (FDR<10%) using the new dataset. 
 
2.3.4 Analysis of the genes that are not mapped to the pathways 
The analysis performed in this chapter focuses on detecting differences in the coordinate 
regulation of genes in a given pathway as opposed to identify individual gene expression. 
However, many genes could not be mapped into KEGG pathways. In order to not lose 
information from the discarded genes, it is important to carry out an analysis at the gene 
level. Here, the genes that are identified as significantly differentially expressed between 
COPD and healthy before and after exercise have been functionally annotated in DAVID. 
This analysis gives consistent results with the pathway analysis, especially for metabolic and 
tissue remodeling pathways (Table 2.5). The analysis derived from the new dataset shows 
only a few significantly enriched functions, but tissue remodeling functions are also enriched 
in response to training in healthy individuals but not in COPD individuals (Table 2.5). 
Results obtained from Radom-Aizik dataset show that the functional representation of the 
genes differentially expressed in response to training in healthy belong to bioenergetic 
pathways (mitochondrion, oxidative phosphorylation and mRNA metabolic process) and 
tissue remodeling (cell adhesion and ECM), (Table 2.4). The lack of response to training in 
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COPD patients is also observed in this analysis. The genes that did not map to KEGG 
pathways follow a similar functional trend. One major difference between this analysis and 
the pathway based analysis is the inflammatory pathways. Here, functional groups related to 
inflammation were not identified. 
 
 All the genes  Genes that are not mapped into 
KEGG pathways  
SH vs. TH  GOCC ribonucleoprotein complex [52] 
GOCC mitochondrion [45] 
GOBP mRNA metabolic process [21] 
GOBP oxidative phosphorylation [8] 
GOBP cell adhesion [5] 
GOCC ECM [4] 
GOCC ribosomal protein complex [22] 
GO mitochondrion [21] 
mRNA metabolic process [19] 
GOBP oxidative phosphorylation  [0]  
SD vs. TD  GOCC Sarcomere [4] 
GOBP Oxidation reduction [7]  
GOCC Sarcomere [2] 
GOBP Oxidation reduction [1]  
TH vs. TD  GOBP regulation of translation [12] 
GOCC ribonucleoprotein complex [14] 
GOCC Sarcomere[5] 
GOBP mRNA metabolic process [12]  
GOBP Translation [4] 
GOCC ribonucleoprotein complex [7] 
GOCC Sarcomere[3] 
GOBP mRNA metabolic process [5] 
Table 2.4. Functional annotation of the genes significantly different between COPD and 
healthy before and after exercise (Radom-Aizik dataset).  
This first column of this table shows the comparison between the experimental groups (SH: 
sedentary healthy, TH: trained healthy, SD: sedentary disease, TD: trained disease). The 
second column is the functional annotation of the genes that are significantly different 
between the groups indicated in column 1. The third column represents the functional 
annotation of the genes that were not mapped to the KEGG pathways. The functions in grey 
are not significantly enriched.  
 
 All the genes  Genes that are not mapped into KEGG 
pathways  
SH vs. TH  GOCC ECM-rec interaction[4]  
GOCC collagen [3] 
GOCC ECM-rec interaction[0]  
GOCC collagen [0] 
SD vs. TD  GOBP DNA metabolic process [10]  GOBP DNA metabolic process [7] 
TH vs. TD  GOBP translation [4] 
GOCC ECM [4] 
GOBP translation [4] 
GOCC ECM [3] 
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Table 2.5. Functional annotation of the genes significantly different between COPD and 
healthy before and after exercise (new dataset).  
This first column of this table shows the comparison between the experimental groups (SH: 
sedentary healthy, TH: trained healthy, SD: sedentary disease, TD: trained disease). The 
second column is the functional annotation of the genes that are significantly different 
between the groups indicated in column 1. The third column represents the functional 
annotation of the genes that were not mapped to the KEGG pathways. The functions in grey 
are not significantly enriched.  
 
2.3.5 Network Analysis  
In order to further elucidate the detailed structure of molecular networks underlying 
differences in training response between healthy and COPD muscles, genes represented in the 
three groups of functionally related KEGG pathways (metabolism, inflammation and tissue 
remodeling) were used as input to the knowledge management system IPA. 
The highest scoring network representing response to training in healthy individuals for genes 
linked to KEGG tissue remodeling pathways represent the interaction between components 
of the extracellular matrix (COL3A1, COL4A1, COL6A3, COL5A2), which are potentially 
induced by TGFa and components of the MAP Kinase signaling pathway (MAP3K3, 
MAP2K7, MAPK14, MAPKAPK3). The network also represents components of Notch 
signaling (the direct targets of notch MAPK14, ID2 and the transcription factor HES1) 
(Figure 2.6A).   
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Figure 2-6. Networks derived from Ingenuity pathway analysis representing response to 
training in healthy patients.  
This figure shows the top scored networks derived from the list of genes that are significantly 
different in response to training in healthy patients that are linked to tissue remodeling (Panel 
A and B). Genes that are upregulated are in response to training are represented in red, 
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whereas downregulated genes are represented in green. The genes marked with a green star 
(Fibrin and TGF-B) are not belonging to the tissue remodelling pathways but these are 
significantly downregulated in response to training in healthy patients. However, these genes 
fail to be modulated in COPD muscles. 
 
 
Figure 2-7. Networks derived from Ingenuity pathway analysis of genes involved in 
metabolism. 
This figure shows the top scored networks derived from the list of genes that are significantly 
different in response to training in healthy patients that are linked to metabolism. The genes 
marked with a red star (Pdha1 and PPARGC1A) are not belonging to the metabolic pathways 
(the input to ingenuity analysis) but these are significantly upregulated in response to training 
in healthy patients However, these genes fail to be modulated in COPD muscles.  
 
The second statistically significant network linked to KEGG tissue remodeling pathways 
represents a network linking the transcription regulators SMAD3, TCFL2, TCF7, ATF4, 
SNW1, and CREBBP to the epigenetic modifier HDAC2 and the angiogenesis factor VEGFA. 
Both networks show that effector molecules such as the angiogenesis factor VEGFA and 
collagen components are up-regulated in response to training. Both Notch signaling 
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components, which could potentially function as negative regulators of myogenesis [167] in 
sedentary state and effector genes fail to be modulated in COPD muscles.  
The highest scoring network representing response to training in healthy individuals for genes 
linked to KEGG metabolism pathways shows the interaction between components of the 
bioenergetics pathways (PDHA1, PDHB, DLAT, DLD and DLST) and amino acid metabolism 
(GOT1 and GOT2) (Figure 2.7). All these enzymes are up regulated in response to training in 
healthy but fail to do so in COPD muscles. Interestingly, the IPA software also identifies 
insulin as a key upstream regulator of this metabolic regulatory network. 
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2.4 DISCUSSION  
By reducing the complexity of the transcriptomics data, a set of pathways that are modulated 
between COPD and healthy individuals after training (inflammatory pathways) or specifically 
modulated in healthy individuals in response to training (metabolism and tissue remodeling 
pathways) were identified. The separate analyses carried out in the two data sets showed 
consistent results, particularly in respect to tissue remodeling and metabolic pathways, 
supporting the hypothesis that diseased muscles are unable to mount an effective response to 
training, and in turn validating the approach. This is particularly important since the two 
datasets [162, 160] presented different training strategies both in terms of intensity and 
duration.  
2.4.1 Tissue remodeling pathways are only modulated in response to training in 
healthy patients 
The results derived from this study suggest that only healthy individuals are able to co-
ordinately modulate tissue-remodeling pathways in response to training. The tissue-
remodeling pathway derived from ingenuity has shown that VEGF is only up-regulated in 
response to training in healthy patients. Exercise induced angiogenesis in healthy patients is 
an adaptive response to training resulting in an increase capillaries number per muscle fibre. 
In the same pathway, HDAC2 is up-regulated in response to training only in healthy muscles, 
which is known to be a critical player during the myogenic program for modulation and 
deacytylation of MyoD [168].  The current model for muscle wasting involves the 
inactivation of the myogenesis pathway driven by the expression of the MyoD gene.  
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2.4.2 Differential modulation of metabolic pathways between healthy and COPD 
muscles 
The significantly modulated pathways suggest that oxidative stress and cell hypoxia are 
possible factors contributing to differentiate normal and diseased muscle in the pre-training 
state. For example, the glutathione pathway is differentially modulated between healthy and 
diseased muscles before training (the new dataset). The glutathione pathway is involved in 
protecting cells from oxidant-induced lung injury and inflammation [169]. In this pathway, 
the expression level of glutathione transferase is reduced in COPD patients compared to 
healthy subjects, which is inversely associated to glutamate-cysteine ligase level. Glutathione 
is quantitatively the most important intracellular antioxidant and serves multiple cellular and 
metabolic functions [170]. Even a relatively moderate depletion of intracellular GSH causes 
oxidative damage and impairs the structural and functional integrity of mitochondria [171].  
Several studies have demonstrated that increased protein oxidation in the muscle of COPD 
patients plays a major role in the muscle dysfunction of these patients.  However, normal [94] 
or increased level [172] of glutathione has been reported in COPD compared to controls. My 
analysis supports an alteration on the glutathione metabolism, which might explain the 
activation of the oxidative stress.   The IPA analysis has revealed additional information on 
the transcriptional response of enzymes involved in bioenergetics and amino acid 
metabolism. These results reinforce the concept that diseased muscles are unable to activate 
the expression of enzymes involved in bioenergetics and on interconnected amino acid 
metabolism pathways (Figure 6B). It is reasonable to hypothesize that failure to 
transcriptionally activate these genes may contribute to muscle wasting in COPD. 
2.4.3 Study limitations 
The pathway analysis has shown that the lack of response to exercise training in metabolic 
and tissue remodelling pathways in COPD patients is due to patient heterogeneity. Hence, a 
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larger of number of samples is needed to better understand this lack of response to training in 
these patients. Merging the two datasets presented in this Chapter represent a potential way to 
increase the number of samples to study. However, this is not possible because of the 
different training intensity and duration carried out in the two datasets. 
2.5 Conclusions 
From a more methodological prospective, it is worth noticing that the analysis approach 
adopted in this study was integrated into the knowledge management system BioXM and 
published in [173]. The availability of such tools would indeed make available this analytical 
approach to a broader set of users.  
This study has contributed to characterize at the pathway level the transcriptional programs in 
response to training, in healthy and COPD individuals. The picture that emerges from this 
analysis is consistent with the view that diseased muscles are unable to activate metabolism 
and tissue remodeling pathways in the two training regimes.  
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 CHAPTER 3: A SYSTEMS BIOLOGY 
APPROACH IDENTIFIES MOLECULAR 
NETWORKS DEFINING SKELETAL MUSCLE 
ABNORMALITIES IN COPD 
 
 
3.1 INTRODUCTION 
The previous chapter describes the pathway level response to training in skeletal of COPD patients 
with muscle wasting and healthy aged matched individuals. This approach has shown that 
COPD muscles are unable to activate metabolism and tissue remodeling pathways in the two 
training regimes. Moreover, inflammatory pathways are either modulated in the opposite 
direction or lack the response to training. An interesting observation that emerged from the 
pathway analysis is that there is considerable molecular heterogeneity in the response of 
COPD muscles to training. Although the idea that COPD is a highly heterogeneous disease is 
well accepted, a molecular characterization of such diversity is going to require profiling a 
much larger population of individuals than the current studies. In this chapter, a larger multi-
level clinical dataset is studied in order to address the molecular mechanisms underlying the 
abnormal energy metabolism, tissue remodeling pathway and the role of systemic 
inflammation (as published in [174]). The complex interplay of molecular pathways that are 
potentially involved in regulating muscle functionality makes systems biology approaches a 
desirable option. Such an approach aims to model the relationship between key molecular and 
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physiological variables in healthy and diseased individuals to derive a testable hypothesis on 
the disease mechanism.    
In this study, skeletal muscle abnormalities in COPD were hypothesized to be the result of an 
imbalance in the physiological regulation of normal muscle homeostasis induced by systemic 
inflammatory mediators and chronic tissue hypoxia. To test this, a reverse engineering 
approach capturing relations between variables defining whole body physiology, systemic 
inflammation and muscle transcriptional state, with particular reference to cell bioenergetics 
and tissue remodeling functions. This analysis is based on a clinical study representing 12 
healthy subjects and 18 age and sex-matched COPD patients, before and after undergoing an 
8 weeks training program. In the latter category, patients with preserved muscle mass 
(COPDN) and patients showing muscle wasting (COPDL) were included. 
In this study, COPD muscles are characterized by a lack of correlation in expression of 
bioenergetic and tissue remodeling pathways, which included genes specifically involved in 
myogenesis. My analysis suggests that failure to activate and coordinate these functions in 
response to training is associated with a general lack of activation of NF-kB targets, including 
many pro-inflammatory signals (e.g. IL-1β). This study lead to discovery that expression of 
chromatin modification enzymes, known to control muscle differentiation and energy balance 
in other biological systems, is abnormal in COPD muscles and correlated with oxygen 
availability. This finding raises the possibility that an epigenetic mechanism triggered by 
tissue hypoxia may be the basis of skeletal muscle wasting in COPD.  
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3.2 METHODS 
3.2.1 Ethics Statement 
All animal work has been conducted according to relevant national and international 
guidelines and approved by the University of Birmingham, Medical School ethics committee. 
3.2.2 Study groups and design  
The 8 weeks training project (TP) was a clinical investigation in which eighteen COPD 
patients (687 yrs, 17 men, FEV1 4612% predicted and PaO2 750.7 mmHg) with a wide 
spectrum of body mass composition and twelve age-matched healthy sedentary controls (65 
yrs, 10 men, FEV1 10714% predicted and PaO2 930.7 mmHg) underwent a protocol of 
supervised endurance exercise. The inclusion criteria were: 1) diagnosis of COPD according 
to GOLD criteria, 2) a stable clinical condition using standard treatment with bronchodilators 
and inhaled corticosteroids, 3) absence of episodes of exacerbation or oral steroid treatment 
in the previous 4 months, 4) absence of significant co-morbidities. All procedures were 
performed in the Pulmonary Function Laboratory or the Rehabilitation Unit at the Hospital 
Clinic-IDIPAPS. The TP included twelve patients with stable COPD and normal fat free 
mass index (FFMI, 21Kg/m2) (COPDN), six COPD patients with low FFMI (16Kg/m2) 
(COPL), and twelve healthy sedentary subjects (FFMI 21Kg/m2). The study was approved by 
the Ethics Committee of the Hospital Clinic (Barcelona, Spain) and all patients gave written 
informed consent. Subjects completed all phases of the protocol as well as fully contributing 
to the sampling regime.  
Significant physiological training effects were obtained using a standard supervised interval 
training program. Table 3.1 and Figure 3.1A summarize the characteristics of the study 
groups and the training-induced effects on physiological variables. Constant-work rate 
exercise at 70% of pre-training Watts peak (Wpeak) (CardiO2 cycle Medical Graphics 
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Corporation, USA) was carried out before and after 8-weeks training with cycloergometer, 
until pre-training endurance time exhaustion. Measurements before and after training were 
obtained at isowork-rate and iso-time. This dataset and Table 3.1 have been generated by 
Josep Roca’s group. 
 COPD 
patients 
Healthy 
subjects  
   
VO2 peak, ml/min-1  Pre 896±250 1566±410 
 Post 1076±381 1819±533 
  Δ post-pre 180±183† 253±204† 
VO2 peak, %pred  Pre 69±20 88±15 
 Post 84±25 102±19 
  Δ post-pre 15±11‡ 14±11† 
Wpeak, watts Pre  56±21 111±27 
 Post  73±29 135±37 
  Δ post-pre 17±11‡ 24±13‡ 
6MWT, meters Pre  443±123 585±87 
 Post  472±132 633±68 
  Δ post-pre 29±25‡ 48±51* 
Table 3.1. Physiology measurements showing the effect of endurance training in healthy 
and COPD individuals, generated in the group of Josep Roca. 
 
3.2.3 Measurement of inflammatory mediators in serum 
Serum samples obtained at rest before training (Basal-BT) and at rest after the eight weeks 
training program (Basal-AT) were measured by Luminex xMAP technology, according to the 
manufacturer’s instructions BIO-RAD [175]. This experiment was conducted by Anna 
Stincone. A number of cytokines/growth factors were selected for analysis based on the 
results of a previous proteomic study carried out in COPD patients and controls [176]. In that 
study [176] a total of 142 cytokines/growth factors were analysed and 42 of them were 
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 differentially expressed in COPD. Our selection includes 30 analytes covering ~50% of the 
cytokines/growth factors previously identified [176], which demonstrated association to 
clinical parameters in the same study. The complete list of proteins measured and the 
corresponding results of the analysis is shown in Table 3.3 and Figure 3.1B. This dataset has 
been generated by Anna Stincone (University of Birmingham).  
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Figure 3-1. 8-weeks training study: Disease associated cytokines and Physiological 
measurements.  
The figure shows two heatmaps representing respectively the standardized values for the 
physiology and serum cytokine measurements. Data are standardized to represent above 
average values in red and below average values in green. Panel A represents significantly 
different physiological measurements in the disease groups (Healthy, L-BMI and L-BMI). 
Those variables that are also significantly changing in response to training are labelled in red. 
Panel B represent serum cytokine measurements significantly different in the disease groups 
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(Healthy, N-BMI and L-BMI). No cytokines were significantly different in response to 
training. 
 
 
3.2.4 Expression profiling of muscle biopsies 
Skeletal muscle transcriptomics was performed on open biopsies from the m. vastus lateralis 
(quadriceps). In all participants these were obtained at rest, before and after training. RNA 
was isolated using RNeasy extraction kits (QUIAGEN, USA) according to the manufacturer 
instructions.  Microarray gene expression analysis employing Affymetrix ® GeneChip 
technology was performed using Human U133 Plus2 Gene Chips according to the 
manufacturer’s suggested protocols. Data were subsequently subject to quality control to 
assess integrity of the RNA using an Agilent Bioanalyzer (Agilent). The microarrays were 
generated in the group of Josep Roca. 
These datasets were normalised using the R library gcrma, which converts CEL files using a 
robust multi-array average (RMA) expression measure with the help of probe sequences. 
Data were quantile normalised [177]. 
 
3.2.5 Identification of statistically significant differences in physiology, serum 
protein and muscle gene expression measurements. 
In order to identify differential changes in physiological and protein measurements, two-
factor ANOVA was used with disease and training as factors. Significantly different variables 
were selected using a threshold of P<0.01. Similarly, genes differentially expressed between 
sedentary and trained subjects in the three populations (healthy, COPDN and COPDL patients) 
were identified by t-test followed by Benjamimi-Hochberg multiple correction [137] using a 
false discovery rate (FDR) threshold of q<10%. 
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3.2.6 Network inference  
Building a model including mRNA, protein and physiology measurements representing 
pre and post-training samples in the 8 weeks study  
In order to develop molecular networks representing the interaction between systemic and 
local signals, physiology, blood cytokine levels and muscle mRNA expression measurements 
were integrated by standardizing each variable, across all samples to have mean of 0 and 
standard deviation of 1 using the R package QuantPsyc [178]. After this procedure, 
measurements, in different units become directly comparable. A global interaction network 
was built as the union of individual network modules, each one of them defined as a cluster 
of variables linked by a significant correlation to the profile of key biomarkers. Such 
biomarkers, which can be thought of as network hubs, were chosen to represent biological 
factors as these could be important players in the context of the clinical problem. These can 
be summarized in four distinct groups (for a detailed list see Table 3.2):  
1) Indicators of whole body physiology. 
2) Serum protein levels representing systemic inflammatory signals. 
3) Muscle mRNA expression profiles of genes encoding for receptors of cytokines and 
growth factors, known to play a role in muscle physiology. 
4) Muscle mRNA expression profiles of genes encoding for enzymes in the 
glycolysis/gluconeogenesis pathway. 
The ability to infer relationships between measured variables from observational data is at the 
core of this study. For this reason, a validated network inference technique ARACNE was 
used. This tool infers the interaction between pairs of variables using a measure of correlation 
called mutual information (MI) [179,  180]. Sparse networks are generated by eliminating 
non-significant connections according to a permutation-based statistical test. Although 
ARACNE has been used mainly in association with gene expression data it can be applied to 
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infer interactions between any variable that have quantitative measurements. ARACNE offers 
numerous advantages over more traditional measures of correlation, including the ability to 
spot non-linear correlations, which are very effective in identifying biologically relevant 
connections [179].  
In order to infer networks integrating multi-level measurements from the eight weeks training 
study, ARACNE was used to reconstruct the network neighbourhoods of muscle-expressed 
intermediate metabolism genes, immune system and growth factor receptors genes (measured 
in muscle biopsies, using microarray technology), systemic cytokines (using Luminex 
technology, measured in serum), and physiological measures (Table 3.2). Statistically 
significant network edges have been selected using a threshold p<10-7 and no edges have 
been eliminated using DPI. Significant connections were identified by applying a P-value 
threshold for significant MI values that ensure less than 5% false positives [147]. Individual 
networks generated with ARACNE were merged and the resulting network visualised using 
the software application Cytoscape [181], a force-driven layout where the strength of 
association in the graph is determined by the value of mutual information associated with the 
gene-to-gene connection. This layout allows the representation of a network structure where 
the position of the nodes is determined by the relative strength of connections. Genes that are 
strongly linked (i.e. by a high MI value) will appear closely associated in the graph, whereas 
genes with a weak association will be far apart. This procedure was applied to infer all 
networks presented in this paper.  
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Table 3.2. List of physiology, serum cytokines and immune system/growth factors 
receptors gene expression measurements used as network hubs in the ARACNE 
procedure. 
gene symbol  gene name  function 
ALDOA  ALDOLASE A  glycolysis  
GAPDH  GLYCERALDEHYDE‐3‐PHOSPHATE DEHYDROGENASE glycolysis  
PFKM  PHOSPHOFRUCTOKINASE, MUSCLE glycolysis  
TPI1  TRIOSEPHOSPHATE ISOMERASE 1 glycolysis  
PGM1  PHOSPHOGLUCOMUTASE 1 glycolysis  
PDHAI  PYRUVATE DEHYDROGENASE glycolysis  
ALDH2  ALDEHYDE DEHYDROGENASE 2 FAMILY (MITOCHONDRIAL) glycolysis  
HK1  HEXOKINASE 1  glycolysis  
DLAT  DIHYDROLIPOAMIDE S‐ACETYLTRANSFERASE glycolysis  
ACYP1  ACYLPHOSPHATASE 1, ERYTHROCYTE (COMMON) TYPE glycolysis  
PGK1  PHOSPHOGLYCERATE KINASE 1 gluconeogenesis 
DLD  DIHYDROLIPOAMIDE DEHYDROGENASE gluconeogenesis 
AKR1A1  ALDO‐KETO REDUCTASE FAMILY 1, MEMBER A1 (ALDEHYDE REDUCTASE) gluconeogenesis 
ENO1  ENOLASE 1  gluconeogenesis 
FBP2  FRUCTOSE‐1,6‐BISPHOSPHATASE 2 gluconeogenesis 
CCR5  CHEMOKINE (C‐C MOTIF) RECEPTOR 5 receptor 
CSF1R  COLONY STIMULATING FACTOR 1 RECEPTOR receptor 
EGFR  EPIDERMAL GROWTH FACTOR RECEPTOR receptor 
FGFR1  FIBROBLAST GROWTH FACTOR RECEPTOR 1 receptor 
IL‐17RA  INTERLEUKIN 17 RECEPTOR receptor 
IL1RN   INTERLEUKIN 1 RECEPTOR ANTAGONIST receptor 
IL8RB  INTERLEUKIN 8 RECEPTOR receptor 
TNFR1  TUMOR NECROSIS FACTOR RECEPTOR TYPE 1 receptor 
TNFR2  TUMOR NECROSIS FACTOR RECEPTOR TYPE 2 receptor 
TrkB   TYROSINE KINASE, RECEPTOR, TYPE 2 receptor 
VEGFR2  VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 receptor 
CD44R not sure (HA)  HERMES ANTIGEN GP90 HOMING RECEPTOR receptor 
IL‐1r  INTERLEUKIN 1 RECEPTOR, TYPE I receptor 
IL1RB  INTERLEUKIN 1 RECEPTOR, TYPE II receptor 
IL13RA1  INTERLEUKIN 13 RECEPTOR, ALPHA 1 receptor 
IFNAR  INTERFERON RECEPTOR 1 receptor 
Mig‐R  CHEMOKINE (C‐X‐C MOTIF) RECEPTOR 3 receptor 
CCR3  CHEMOKINE (C‐C MOTIF) RECEPTOR 3 receptor 
HEGFR (MET)  HEPATOCYTE GROWTH FACTOR RECEPTOR receptor 
IFNGR2  INTERFERON GAMMA RECEPTOR 2 receptor 
IFNGR1  INTERFERON GAMMA RECEPTOR 1 receptor 
BMI  BODY MASS INDEX  physiological variable
FFMI  FAT FREE MASS INDEX  physiological variable
Walk  WALK  physiological variable
HRPEAK  HEART RATE PEAK  physiological variable
HRPEAKper  HEART RATE PEAK PERCENTAGE physiological variable
VO2maxkg  WHOLE OXYGEN COMSUPTION AT PEAK OF EXERCISE physiological variable
VO2_maxper  WHOLE OXYGEN COMSUPTION AT PEAK OF EXERCISE (PERCENTAGE) physiological variable
WATTS  WATTS  physiological variable
VE  MINUTE VENTILATION  physiological variable
VE_per  MINUTE VENTILATION  (PERCENTAGE) physiological variable
VO2_max  WHOLE OXYGEN COMSUPTION AT PEAK OF EXERCISE physiological variable
BODE  BODY‐MASS  INDEX,  AIRFLOW  OBSTRUCTION,  DYSPNEA,  AND  EXERCISE 
CAPACITY INDEX 
physiological variable
age  AGE physiological variable
PaO2  PRESSURE OF OXYGEN IN ARTERIAL BLOOD physiological variable
Eotaxin‐exp2  SMALL‐INDUCIBLE CYTOKINE A11   serum cytokine
IP10‐exp2  INTERFERON‐INDUCIBLE CYTOKINE   serum cytokine
MIP‐1b‐exp2  MAJOR INTRINSIC PROTEIN OF LENS FIBER  serum cytokine
Rantes‐exp2  RANTES   serum cytokine
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IL-1beta IL-6  IL-15 MIP 1alpha  MCP-1 
IL1RA IL-7  IL-17 MIP 1beta VEGF 
IL-2 IL-8 TNF alpha IP-10  G-CSF  
IL-2R IL-10  IFN alpha  MIG  EGF 
IL-4 IL-12 IFN gamma Eotaxin FGF-basic 
IL-5 IL-13  GM-CSF  RANTES  HGF  
Table 3.3. Serum and cytokine growth factors measured using Luminex technology. 
 
Moreover, gene lists derived from statistical analysis of microarray data and from the analysis 
of interaction networks have been functionally annotated using a Fisher test as implemented 
in the web-based application DAVID [163]. A Benjamini-Hochberg FDR correction for 
multiple testing was applied and a threshold of FDR <0.01 chosen for selecting significant 
enrichment of specific Gene Ontology (GO) or Kyoto Encyclopedia of Genes and Genomes 
(KEGG) terms in the different network modules. 
 
Individual network models representing healthy and COPD muscles 
In order to address whether the transcriptional uncoupling between genes involved in tissue 
remodeling and bioenergetics was a specific feature of COPD, the procedure described above 
was also applied to healthy and COPD muscle datasets. In order to increase the resolution, 
8w training dataset with a similar microarray study recently performed by Radom-Aizik et al. 
[162] were integrated. This dataset provided microarray data representing an additional 12 
healthy and 12 age-matched COPD patients pre and post endurance training (12 weeks). This 
dataset was quantile normalized using the R library gcrma and microarray batch effects were 
corrected using an Empirical Bayes framework available in R [182]. 
 
Network models representing diabetes and muscle dystrophy muscle biopsies 
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In this chapter, two additional datasets were also analyzed for studying muscle biopsies 
derived from patients affected by diabetes and dystrophy. The first microarray dataset 
consists of skeletal muscle biopsy samples from 43 age-matched males with different degrees 
of glucose intolerance and including Type 2 diabetes mellitus (available at: 
http://expression.gnf.org/) [183]. The dystrophy dataset consist of 84 samples from patients 
representing several types of muscle dystrophy (Facioscapulohumeral muscular dystrophy 
samples, Becker muscular dystrophy, Emery Dreifuss muscular dystrophy, from Duchenne 
muscular dystrophy) (GEO accession: GSE3307) [184]. 
3.2.7 Mouse in vivo experiments 
To assess the effects of pro-inflammatory cytokines on skeletal muscle, recombinant mouse 
IL-1β (10mg/ml) was injected in a single dose into the tail vein of C57BL10 mice at a 
loading of 100 ng/mouse (4 animals per group) and samples taken from lateral gastrocnemius 
(glycolytic) and soleus (oxidative) muscles 24h later, with saline-injected animals acting as 
controls. Samples were stored at –80oC until use. RNA was extracted using an RNeasy RNA 
extraction kit (QUIAGEN). Microarray expression profiling of four independent biological 
replicates was performed using full genome oligonucleotide arrays (OPERON) after labelling 
the mRNA with the Cy-Scribe post labelling kit (Amersham) according to the manufacturer’s 
instructions. Genes differentially expressed were identified by a t-test followed by multiple 
testing correction (FDR<10%). Significant genes from the mouse experiment were mapped 
on the human COPD network by converting mouse gene identities into their human 
homologues using the database Homologene (data was normalised using the same procedures 
described for the COPD dataset).  
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3.2.8 Ingenuity Pathway Analysis  
The gene set represented by those directly connected to growth factor and cytokine receptor 
components of the network and differentially expressed in response to training in healthy 
individuals were analyzed using the Ingenuity Pathway Analysis (IPA) application (Palo 
Alto, http://www.ingenuity.com). Networks with a score greater than 20 and containing more 
than 60% of the genes differentially expressed in response to training were selected for 
biological interpretation. 
3.2.9 Molecular response of mouse quadriceps muscles to chronic hypoxia 
conditions 
In order to assess whether genes correlated to VO2max in the clinical study are indeed 
modulated in response to hypoxia, a publicly available microarray dataset has been analyzed 
in this chapter. This dataset represents the transcriptional response of C57Bl/10 mice to 2 
weeks of chronic hypoxia and compared those with matching controls kept in normoxic 
conditions. The dataset was developed by Budak et al. [185], and it is available in the Gene 
Expression Omnibus database under the accession number GSE9400. The details of the 
overall design and the dataset can be found in GEO.  
For clarity, here a concise summary of the experimental design and data generation is 
reported. Adult male C57Bl/10 mice were divided into two groups, control (room condition) 
and hypoxic, over a period of 2 weeks. The hypoxic group was gradually exposed to lower 
levels of hypoxia in a specially designed and hermetically closed hypoxic chamber. A Pegas 
4000 MF (Columbus Instruments) gas blending system was used. The oxygen level was 
gradually decreased from 21% to 8% over one week and animals were kept at 8% oxygen for 
another 7 days. After two weeks animals were euthanized using CO2 and total RNA was 
isolated from each quadriceps femoris (QF) muscle by Tri-Reagent (Ambion, Austin, TX). 
Microarray analysis was then performed using an Affymetrix Mouse Genome 430 2.0 Array 
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according to the standard Affymetrix protocol (Affymetrix, Santa Clara, CA). Data were then 
quantile normalized using the R library gcrma [177]. Differentially expressed genes between 
normoxic and hypoxic mice were identified using SAM analysis [186]. Genes that have an 
FDR smaller than 10% were used to map to the neighborhood of the VO2max in the COPD 
network. Genes linked to the GO term chromatin remodeling were identified using the web-
based tool DAVID [163].   
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3.3 RESULTS 
3.3.1 Integration of physiological and molecular responses acquired in the 8 
weeks training study within a network inference framework 
With the aim of developing an initial high level model representing the relationships between 
systemic and local signals, all available measurements were integrated (physiology, blood 
cytokine levels and muscle gene expression measurements) for the individuals recruited in 
the 8 weeks training study. These samples included both pre and post-training blood and 
biopsy samples. The individual network modules generated using the hubs in Table 3.2 were 
then tested for enrichment in GO and KEGG functional terms, which revealed a remarkably 
coherent association between target genes and the biological functions of network hubs.  
Neighbourhoods of physiological variables, such as VO2 peak, were mainly enriched in 
glycolysis/gluconeogenesis, mitochondria respiratory chain, oxidative phosphorylation (all 
positively correlated to VO2 peak), and components of the ribonucleoprotein complex and 
RNA processing (negatively correlated to VO2 peak, Figure 3.2 and Table 3.4). Genes 
associated with mRNA expression of cytokine and growth factor receptor hubs were enriched 
in functions related to tissue remodeling and immune response (generally positively 
correlated with the expression of receptors for growth factors and cytokines, Table 3.5), 
while genes associated with expression of glycolysis/gluconeogenesis enzymes were mainly 
enriched in energy metabolism-related functions (Table 3.6). Systemic inflammatory 
cytokines were weakly connected to the network (only three significant correlations with 
genes linked to physiological measurements). 
The union of the individual modules and consequent visualization with a force driven layout 
revealed a clear separation between two main sub-networks. First, a large sub-network,  
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Figure 3-2. Correlation between VO2max and its neighbourhood as inferred
by ARACNE. 
Panel A represents the functional annotation of the genes, which are positively and
negatively correlated with VO2max. Panel B shows instances of genes belonging to
mRNA export from nucleus, mRNA processing, and Ribosome functional terms.
Panel C shows instances of genes that belong to Glycolysis/Glycogenesis and to
mitochondrion respiratory chain functional terms.  
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primarily representing the association of modules built from cytokines (both plasma and 
skeletal muscle) and growth factor receptor hubs and enriched by tissue remodeling 
functions. Second, a sub-network representing the association of modules built with 
physiology and skeletal muscle glycolysis/gluconeogenesis hubs and enriched in energy 
metabolism genes (Figure 3.4). Within this sub-network, many of the physiological variables 
(PaO2, HRPEAK, HRPEAKper, WATTS, VE, VO2max, VO2maxper, VO2maxkg, BODE) 
were highly correlated (Figure 3.3) and consequently clustered together (Figure 3.4) to form 
a very compact network module. The other physiological variables (VEper, FFMI, BMI and 
age) were separated from this module and were characterized by a limited number of 
connections with gene expression variables (30 genes).
 
Figure 3-3. Correlation between physiological variables.  
This figure shows the scatterplots between physiological variables that are highly co-
regulated and form a compact subnetwork. 
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Figure 3-4. Network integrating multi-level measurements in the 8 weeks training study.  
The figure shows the network representing the relationship between physiological measurements, 
serum cytokine levels and mRNA expression profiles in the muscle, following ARACNE analysis of 
the 8 weeks training dataset. Panel A shows an outline of the network topology where individual 
network hubs have been annotated. Red nodes represent genes coding for receptors for growth factors 
and immune system mediators, blue nodes represent physiological measurements, brown nodes 
represent serum cytokines, and green nodes represent gene expression of enzymes in the glycolysis 
and gluconeogenesis pathways. Panel B shows all nodes in the network (representing 16350 genes or 
measurements). The colour of nodes follows the same code as panel A. In addition yellow nodes 
represent genes in common between cytokine and growth factor and glycolysis/gluconeogenesis 
network hubs. 
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Table 3.4. COPD interaction network.  
Representative functional terms enriched in the neighbourhood of Physiological variables. 
 
 
 
 
 
 
Hubs No. genes  Representative Functional Terms  
VE 149 [1] GOCC cytoplasm (79), intracellular part (101). [3] GOCC cytosolic large ribosomal subunit. [4] GOCC mitochondrial part. 
VO2-max 259 
[1] GOCC cytoplasm (116),GOBP cellular metabolic process 
(126). [2] GOCC cytoplasmic part (79). [3] GOCC 
mitochondrion (34). [4]  KEGG Oxidative phospohorylation (8), 
GOCC mitochondrial respiratory chain (7).  
VO2-maxkg 301 [1] GOCC cytoplasm (127). [2] GOCC intracellular organnele part (70). [6] GOCC organelle envelope (22), GOCC 
mitochondrion (28). 
Walk 144 [1] GOCC cytoplasm (78). [2] GOCC nucleolus (8).  
WATT 249 
[1] GOCC cytoplasm (124). [2] GOCC organelle part (63). [3] 
GOCC mitochondrial membrane (16). [4] GOBP Cellular 
metabolic process (119). [6] GOMF RNA bindgin (23). [9] 
GOBP macromolecule localization (25). [13] GOCC ribosomal 
subunit (6). [14] GOCC mitochondrial respiratory chain (6).   
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Table 3.5. Representative functional terms enriched in the neighbourhood of immune 
system and growth factor receptor hubs in the COPD interaction network. 
Hubs No. of  genes Representative Functional Terms
CCR3 1815
[1] GOBP negative reguation of biological process (107). 
[2] GOBP anatomical structure development (174), 
[3] GOBP cell proliferation (73). 
[4] GOCC plasma membrane (230). 
[5] GOBP cell migration (32). 
[6]  BIOCARTA Oxidative stress induced gene expression via Nrf2 (12). 
[7] GOBP positive regulation of biological process (106). 
CCR5 1350 [1] GOCC extracellular region part (65). [2] GOBP multicellular organismal development (142).
CD44R 1368
[1] GOBP biological adhesion (107). 
[2] GOCC extracellular matrix (65). 
[3] cytoskeletal protein bindgin (55). 
[4] KEGG Focal adhesion (37), KEGG ECM (23). 
[5] GOMF glycosaminoglycan bindgin (20). 
[6] GOCC collagen (13). 
[7] GOBP development process (248). 
[8] GOBP cell motility (46).
[9] GOBP ECM organization and biogenesis (13). 
[10] GOBP negative regulation of cellular process (101). 
[11] GOMF calcium ion binding (111). 
[12] GOBP cell development (100). 
[13] GOCC cytoskeleton (105).
[14] GOBP positive regulation of immune response (17)
CSF1R 410
[1] GOCC extracellular matrix (43). 
[2] GOBP response to external stimulus (48), GOBP inflammatory respinse (29). 
[4] GOMF cytoskeletal protein binding (38), 
[5] GOBP cell motility (30). 
[6] GOMF actin binding (30). 
[7] GOBP cell commnication ( 127). 
[8] GOCC collagen (12). 
[10] GOBP activation of autoimmune response (13). 
[11] GOCC plasma membrane (109).  
[14] protein kinase cascade (22). 
[17] cell proliferation (33). 
[19] GOBP cell death (33)
IGNGR1 153 [1] GOCC cytoplasmic vesicle (14). [2] GOCC intracellular part (84).
IL1R1 355
[1] GOCC extracellular matrix (30). 
[2] GOCC actin cytoskeleton (26), GOBP development process (98). 
[4] KEGG Focal adhesion (21), 
[5] GOBP actin filamanent-based process (16). 
[6] GOBP localization (87). 
[7] GOBP negative regulation of cellular process (41). 
[8] GOMF lipase inhibitor activity (4). 
[14] GOMF enzyme inhibitor activity (17). 
VEGFR 231
[1] GOBP cell adhesion (30). 
[2] GOBP multicellular organismal development (53). 
[3] GOBP blood vessel development (12). 
[4] GOBP intracellular signaling cascade (34). 
[5] GOCC intercellular junction (10), KEGG Tight junction (8). 
[6] GOBP cell motility (16). 
[7] GOCC plasma membrane (65)
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Table 3.6. Representative functional terms enriched in the neighbourhood of central metabolism 
hubs in the COPD interaction network. 
 
 
Hubs No. of  genes Representative Functional Terms
ALDOA 17 [1] GOBP Glycolysis (4), GOBP glucose catabolic process (4). [2] GOBP muscle system process (4).
DLAT 109
[1] GOCC mitochondrion (57). 
[2] GOBP generation of precursor metabolites and energy (31). 
[3] GOBP coenzyme metabolic process (20). 
[4] GOCC mitochondiral inner membrane (30). 
[5] GOBP oxidative phospohorylation (13).
[6] GOCC mitochondrial matrix (11).
[8] GOMF catalytic activity (52). 
DLD 233
[1] GOCC mitochondrion (98). 
[3] GOCC mitochondrial matrix (23). 
[4] KEGG oxidative phosphorylation (26). 
[5] GOBP cellular respiration (14), KEGG TCA cycle (8). 
[6] GOMF carbon-oxygen lyase activity (8).
[7] GOMF oxidative phosphorylation (20). 
[8] GOMFoxidoreductase activity (4),
[9] GOMF iron-sulfur cluster binding (6).
[10] GOBP carboxylic acid metabolic process (21). 
[11] GOMF lipoic acid binding (4). 
[12] GOBP carboxylic acid metabolic process (21). 
[13] GOBP metabolic process (139). 
[14] GOBP cellular biosynthetic process (29). 
[17] KEGG Alanine and aspartate metabolism.
ENO1 217
[1] GOCC extracellular matrix (16). 
[3] GOBP development process (57). 
[4] GOMF phospholipase inhibitor activity (4). 
[5] KEGG EHEC and EPEC (9).
GAPDH 31 [1] GOBP cellular carbohydrate catabolic process (7),KEGG Glycolysis/ Gluconeogenesis (6).
PDHAI 171
[1] GOCC mitochondrion (100). 
[2] GOBP metabolic process (111). 
[3] GOBP generation of precursor metabolites and energy (52), KEGG oxidative 
phosphorylation (34), GOBP ATP synthesis (15). 
[4] GOBP coenzyme metabolic process (26), KEGG GOBP cellular respiration (16), TCA (8).  
[5] GOCC mitochondrial matrix (19). 
[6] GOMF ubiquinol-cytochrome-creductase activity (6). 
[7] KEGG oxidative phosphorylation (34). 
[8] GOMF metal cluster binding (8). 
[9] GOBP metabolic process (111). 
[10] GOMF hydro-lyase activity (6). 
[11] GOBP cofactor biosynthetic process (11). 
PFKM 21 [1] GOCC contractile muscle thin filament (4), GOBP muscle contraction (4), GOCC cytoplasm(12)
PGK1 52 [1] GOBP cellular carbohydrate catabolic process (7),KEGG Glycolysis/ Gluconeogenesis (6). [3] GOCC mitochondiral membrane (8).
TPI1 67
[1] GOBP alcohol catabolic process (9), GOBP glycolysis (8). 
[2] GOCC mitochondrion (17). 
[4] GOBP metabolic process (44). 
[6] GOBP cellular biosynthetic process (13).
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3.3.2 Uncoupling between expression of tissue remodeling and bioenergetics 
modules is a specific feature of skeletal muscles of COPD patients  
In order to assess whether the separation between tissue remodeling and bioenergetics sub-
networks observed in the network constructed by integrating all measurements in the training 
study may be a specific feature of COPD, it was necessary to developed two separate 
networks representing healthy and diseased muscles (Figure 3.5).  
Our analysis, further supported by the integration of an additional dataset representing an 
independent and comparable clinical study (see Methods section for details), confirmed that 
the separation between cytokine/growth factor receptors and bioenergetics modules is a 
specific feature of COPD networks (Figure 3.5A, 3.5B) (Figure 3.7). In contrast, there was 
extensive overlap between the neighbourhood of receptors and intermediate metabolism in 
the network constructed from healthy muscle biopsies (Figure 3.2C, 3.2D and Figure 3.3).  
In order to assess whether uncoupling was a general feature of pathological muscles, network 
models representing the transcriptional state of dystrophy (Figure 3.8A and 3.8B) and 
diabetic muscles (Figure 3.8C and 3.8D) were also developed. In both cases the 
cytokine/growth factor receptor and bioenergetics sub-networks were localized in close 
proximity. It was remarkable that even in a situation where muscle functionality is severely 
impaired by the lack of important structural components, a condition typical of muscle 
dystrophy, energy and tissue remodeling functions still remain co-ordinately regulated. This 
observation further strengthens the concept that uncoupling between muscle remodeling 
pathways and bioenergetics is a specific feature of COPD muscles.  
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Figure 3-5. Healthy and COPD specific networks. 
The figure shows interaction networks built using solely expression profiling data representing 
healthy (panels A and B) or COPD (panels C and D) muscle biopsy mRNA profiles. For comparison 
with Figure 3.4, the network representing integrated healthy and COPD samples has been represented 
in Panels E and F. Figure layout and the colour coding are identical to Figure 3.4. 
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Figure 3-6. Training response of healthy and COPD individuals visualized on the 
integrated 8 weeks training network.    
The networks represent the genes up-regulated (marked in red) and down-regulated (marked in blue) 
mapped on to the interaction map inferred using the 8 weeks training multi-measurement dataset 
(shown in detail in Figure 1). Panel A shows genes differentially regulated after training in healthy 
individuals. Panel B shows genes differentially expressed after training in COPD patients with normal 
BMI. Network hubs representing genes up-regulated (red) or down-regulated (blue) are listed on the 
side of the relevant sub-networks. The drastic reduction in the molecular response to training 
associated with the cytokine and bioenergetics clusters is evident. 
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Figure 3-7. Healthy and COPD specific networks.  
The figure shows the networks obtained by ARACNE analysis with healthy (panel A) and COPD
(panel C) specific datasets (see methods section for details).  Panel B and Panel D show the
correlation between two landmark genes (IL1R and ALDOA) in the 8 weeks training study for
healthy and disease sample biopsies respectively. Note that the network models represent the lack of
correlation between tissue remodeling and bioenergetics in COPD patients.  
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Figure 3-8. Networks representing diabetes and dystrophy muscles. 
Panel A and Panel B represent the network inferred from the dystrophy dataset (see methods for 
details). Panel C and D represent the full interaction networks inferred from the diabetes dataset (see 
methods section for details). Nodes marked in red represent the neighborhood of receptors of the 
immune receptors; green nodes represent the neighborhood of central metabolism hubs. From a 
simple visual inspection it is evident in the two networks that the intermediate metabolism genes are 
closely linked to the expression of inflammation and growth factor signals. 
 
3.3.3 The molecular response to endurance training highlights a failure of 
diseased muscles to transcriptionally regulate tissue remodeling and 
bioenergetics 
Healthy individuals responded to training by modulating expression of a relatively large 
number of genes (3908, Figure 3.9A) compared to COPDN (953, Figure 3.9B) and to 
A 
C 
ACYP 
GAPDH 
ALDOA 
TPI1 
PDHAI 
PGK1 
PFKM 
MET 
ALDH2 
DLD 
TRKB 
VEGFR2 
TNFR2 
PGM1 
FBP2 
DLAT 
ENO1 AKR1A1 
IFNGR1 
CSF1R 
CD44R 
IL1R 
IL13RA1 
IL17RA 
IL1RB EGFR 
FGFR1 
IL1RN 
CCR5 
B 
Glucose_0 
CCR5 
ENO1 FBP2 
PDHAI 
PFKM 
PGK1 
DLD 
Insulin_0 
IFNAR 
Glucose_120 
EGFR 
TNFR2 
TrKB IFNGR2 
PGM1 
GAPDH 
DLAT 
ALDOA 
ACYP1 
HK1 
IL13RA1 
HEGFR 
IL1RN 
CD44R 
D
80 
 
COPDL patients (6 genes). There was a significant overlap (36%, FDR < 10%) at the gene 
level and an almost complete overlap at the pathway level (Figure 3.9) between the response 
to training in COPDN and healthy subjects whereas none of the six genes differentially 
regulated in the COPDL group were modulated in healthy and COPDN individuals (Figure 
3.9C).  
In order to identify which part of the network was modulated in response to training, these 
differentially expressed genes were mapped onto the integrated network described previously 
(Figure 3.4). Genes that were up-regulated after training appear to cluster primarily in 
proximity to receptors for the cytokines IL-1 (IL1R), CSF1 (CSF1R), plasminogen (ENO1) 
and the key receptor for the pro-angiogenesis growth factor VEGF (VEGFR2) (Figure 3.6). 
A second cluster that is also predominantly populated by genes up-regulated in response to 
training represents the neighbourhoods of glycolytic enzymes (Figure 3.6A) and to the 
epidermal growth factor receptor (EGFR). In contrast, genes that are either up or down-
regulated in response to training populated the neighbourhood of physiological variables, 
representing energy (up regulated) and mRNA processing (down-regulated) functions. The 
transcriptional response of COPDN muscles to training followed a very similar pattern 
although as reported in Figure 3.7C, the number of genes involved was much lower (Figure 
3.6B). As mentioned previously, COPDL patients do not respond to training with a detectable 
change in the transcriptional state of the muscle (Figure 3.6C). In addition to the 
transcriptional uncoupling described above, the transition between healthy and diseased 
individuals is therefore characterised by a reduction in the ability to transcriptionally regulate 
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expression of genes in both tissue remodeling and bioenergetics pathways. 
 
Figure 3-9. Expression profiling analysis of muscle biopsies.  
The figure summarizes the results of the microarray analysis of muscle biopsies representing response 
to endurance training. Panel A shows the heatmap representing genes differentially regulated in 
response to training in healthy individuals. Panel B shows the heatmap representing genes 
differentially regulated in response to training in COPD patients with normal Body Mass Index (N-
BMI). Functions enriched in the up and down regulated genes are labelled on the right side of the 
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heatmap and colour coded to discriminate between up-regulated (red) and down-regulated (green) 
functions. Panel C displays a Venn diagram showing the overlap between differentially regulated 
genes in response to training in healthy, N-BMI and COPD patients with low Body Mass Index (L-
BMI) subjects. It is evident that N-BMI and L-BMI show a progressively less pronounced response to 
training.  
 
To better characterize molecular networks associated with the growth factor and cytokines 
components of the network (see Figure 3.4 and Figure 3.5) directly connected to receptor 
hubs and differentially expressed in response to training in healthy individuals 
(predominantly located in the lower part of the network), these genes were selected and used 
as input for the Ingenuity Pathway Analysis (IPA) software. The analysis identified 17 
networks (see method section for details of the procedure). Among the most significant 
findings, two interconnected networks linked the transcription of several cytokines (IL1, 
TNFα, IFNγ, CCL2) and activation of the NF-kB complex (Figure 3.10A), leading to the 
activation of several NF-kB targets related to connective tissue formation (Figure 3.10B). 
Figure 3.11A shows the relationship between upregulation of gap junction complexes (JAM, 
JAM2, JAM3 and TJP1) and activation of important structural components of muscle fibres 
(e.g. tropomyosin). The network in Figure 3.11B shows the important functional link 
between activation of several Rho GTPases and muscle development, represented by genes 
encoding for a component of the hexameric ATPase cellular motor protein myosin (MYL5) 
and (MYH10).  
Although not all captured by the network model, 6 myogenic markers were found to be 
regulated in response to training (Table 3.7). Five of these were up-regulated. Consistent 
with what was previously observed (above), the training-induced expression of all the genes 
represented in these networks was defective in COPD individuals (Table 3.7). 
 
Genes CS/CT FDR NS/NT FDR WS/WT 
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MYO1B 2.424319 0.003434 2.358684 0.043488 NS 
MYH10 1.9779 0.010815 NS NS NS 
MYH9 1.769668 0.01157 NS NS NS 
MYO15B 1.680785 0.053249 NS NS NS 
MYLK2 -1.73438 0.060255 NS NS NS 
MYO6 1.680994 0.060255 NS NS NS 
Table 3.7. MYOD targets which are significantly different in response to training in 
healthy patients (FDR 10%, fold> 1.5).  
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Figure 3-10.  Ingenuity Networks Regulated by Endurance Training.  
This figure shows the most important findings derived from Ingenuity analysis using genes that are 
differentially expressed in response to training in healthy individuals and connected to receptor hubs 
in the previously inferred network. Panel A and Panel B represent two interconnected networks linked 
the transcription of several cytokines (IL1, TNFα, IFNγ, CCL2) and activation of the NF-kB complex 
(Panel A), leading to the activation of several NF-kB targets related to connective tissue formation 
(Panel B).  
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Figure 3-11. Ingenuity Networks Regulated by Endurance Training.  
Panel A shows the relationship between upregulation of gap junction complexes (JAM, 
JAM2, JAM3 and TJP1) and activation of important structural components of muscle fibres 
(e.g. tropomyosin). Panel B shows the important functional link between activation of several 
Rho GTPases and muscle development, represented by genes encoding for a component of 
the hexameric ATPase cellular motor protein myosin (MYL5) and MYH10. 
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3.3.4 Interleukin-1 promotes activation of tissue remodeling in vivo and mirrors 
the effect of training in healthy human subjects 
Because of the strong correlation between expression of IL-1 receptor and genes involved in 
muscle remodeling and the networks identified by the Ingenuity analysis, IL-1 might be 
responsible for inducing a significant component of the transcriptional response to training 
observed in healthy individuals. In order to test this hypothesis, the transcriptional response 
to intra-venous injections of IL-1β in mice was analyzed in both glycolytic and oxidative 
muscles. The response of mice to injection of IL1β supported our initial hypothesis. IL-1β 
treatment induced within 24 hours the up-regulation of 336 genes in oxidative muscle, 
whereas in glycolytic muscles it induced the up-regulation of 263 genes and the down-
regulation of 201 genes (Table 3.8). Genes up-regulated in both muscle fibre types were 
enriched for structural components of the sarcomere (ACTA1, NEB, CRYAB, ANKRD2). 
Apart from this, the response of the two muscle fibre types was very different. Oxidative 
muscles up-regulated genes encoding for components of the extracellular matrix and organ 
development including angiogenesis (SOX18, VEGFA, SERPINF1, ANXA2, PTEN, ENG), 
whereas glycolytic muscles modulated genes involved in oxidative phosphorylation (COX8A, 
COX5A, NDUFB8, NDUFB5, NDUFS4, NDUFV2) and ribosomal components (Ribosomal 
protein chains 10A,s5 and I37A, and mitochondrion ribosomal protein chains 35 and 45). 
The high percentage of differentially expressed genes encoding for tissue remodeling 
functions (extracellular matrix components, organ structure development, cell 
communication) and bioenergetics (oxidative phorphorylation) which included the oxygen 
sensitive regulator HIF-1, suggested that IL-1β has the potential to reproduce a component of 
the physiological transcriptional response to training that is defective in COPD patients. 
In order to assess this hypothesis, genes differentially expressed were mapped in the IL-1β 
mouse experiment on the human interaction network represented in Figure 3.4. 78% and 68 
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% (265 and 317 genes) of the genes modulated in response to IL-1β treatment in oxidative 
muscle and glycolytic muscle, respectively, in mice mapped on to the human dataset. Of 
these, 34 genes were up-regulated after endurance training in healthy individuals (Figure 
3.11). A significant proportion of these genes were, in oxidative muscle, also directly 
connected with the receptor for Interleukin 1 in the integrated network model. This 
observation further validates the model and supports a role for IL-1β in the physiological 
response to training.  
 
Tissue type  # Functional annotation 
Oxidative muscle up 257 GOCC ECM (64). GOCC sarcomere (7). GOCC lysosome (8). 
GOBP anatomical dev structure (41).  GOBP angiogenesis (6). 
GOMF oxidoreductase activity (18) . 
Glycolitic muscle up 170 GOCC myosin complex (5). GOCC sarcomere (6). GOBP 
generation of precursor metabolites and energy (13). KEGG 
oxidative phos. (8) GOCC mit (20). GOBP gluconeogenesis (5).  
Glycolitic musle down 150 GOCC extracellular space (23). GOBP protein transport (10). GOBP 
metabolic process (60).  GOCC Mit (4)  
Table 3.8. Functional annotation of genes changing in response to IL1 injection in 
oxidative and glycolityc muscle. These functions are not necessarily significantly enriched.  
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Figure 3-12.Effects of IL-1β in mouse glycolytic and oxidative muscles.  
This figure describes the effects of recombinant interleukin 1 on the transcriptional state of glycolytic 
and oxidative muscles. Panel A represents the heatmap of expression profiles in human muscle 
biopsies of genes that are differentially regulated in response to training in humans and also induced 
by IL1β in mouse muscles. Panel B shows the localisation of genes up-regulated in oxidative and 
glycolytic muscles on the COPD interaction network represented in Figure 3.4. 
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3.3.5 Decreased training-induced expression of NF-kB target genes in COPD 
muscles 
The lack of activation of tissue remodeling functions in COPD muscles, including the 
component linked to IL-1β signaling, may be a consequence of the inactivation of myogenic 
pathways due to over-activation of NF-kB signaling induced by chronic exposure of pro-
inflammatory cytokines [16]. If this hypothesis were correct, over expression of a number of 
NF-kB target genes in diseased muscles should be observed.   
A number of NF-kB targets, identified by the IPA software in the ‘tissue remodeling’ section 
of the network, were up-regulated during training in healthy individuals, but failed to respond 
in COPD patients (Figure 3.10A). Although interesting, this observation was based on a 
loose definition of NF-kB targets, as many connections reported in the Ingenuity database are 
indirect. I therefore further tested the NF-kB over-activation hypothesis by analyzing 
expression of 94 experimentally validated targets of NF-Kb known in the literature. Against 
the working hypothesis, there were not any NF-kB target genes differentially regulated 
between normal and diseased muscles. On the contrary, 8 genes were identified as 
differentially regulated in response to training in healthy individuals (all up regulated, 
10%FDR and fold>1.5) but not in COPD individuals with normal or low BMI (Table 3.9). 
These observations clearly do not support the over-activation hypothesis. On the contrary, 
they suggest that in COPD muscles training-induced activation of NF-kB is repressed. 
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genes  FOLD CS‐CT  FDR 
TFPI2  1.88  0.02 
PLAU  1.62  0.02 
CD74  1.60  0.03 
CCL2  1.69  0.04 
ENG  1.41  0.04 
CCND1  1.45  0.07 
NQO1  1.69  0.08 
CD44  1.80  0.09 
Table 3.9.NFKB Targets in response to training in healthy muscle. 
NFKB Targets which are significantly different in response to training in healthy patients.  
 
3.3.6 Expression of epigenetic histone modifiers discriminates between healthy 
and diseased muscles and is correlated with peak oxygen consumption 
In order to explore an alternative hypothesis that may explain muscle wasting in COPD 
patients, an unbiased analysis were performed to identify functional pathways differentially 
modulated between healthy and diseased muscles, by using two-factor ANOVA (taking into 
consideration both disease and training). 
Consistent with the analysis described above, tissue remodeling and energy-associated 
pathways were identified as significantly differentially expressed for both factors analysed 
(Table 3.12). However, one additional category of 20 chromatin modification enzymes were 
also differentially expressed (Table 3.11 and Table 3.10).  
 
Gene Symbol  Fold Disease vs. Healthy  ANOVA Factor Disease (FDR) 
HDAC9  2.30  6.61e‐5 
HDAC4  ‐1.48  0.05 
SIRT2  1.27  0.0016 
SIRT3  1.31 0.02 
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Table 3.10. Chromatin remodeling complex genes in healthy and disease muscle. 
 
Among these, four histone deacetylase enzymes were identified. These are known to be 
particularly relevant for controlling expression of muscle differentiation (HDAC9 and 
HDAC4, SIRT2) and bioenergetics (SIRT3) related genes. Consistent with their potential role 
in COPD muscle wasting, expression of these genes was sufficient to discriminate between 
diseased and healthy muscles (Figure 3.13A). Mapping these on the network model 
described in Figure 3.4 show that they localized close to VO2peak, (Figure 3.13B) 
suggesting that their transcription may be up-regulated by oxygen availability and/or 
oxidative capacity in the skeletal muscle. 
 
Functional Category Genes in the Function ( 10% FDR) 
GOCC Chromatin remodeling 
complex (disease factor) 
APPL1, ARID1A, ARID1B, CHD4, CIR1, HDAC4, HDAC7, 
HDAC9, MBD2, MTA1, PHF21A, RSF1, SIN3A, SIRT2, 
SIRT3, SMARCA4, SMARCB1, SNARCE1,  SUDS3, 
TBL1XR1 
GOCC histone deacetylase 
complex (exercise factor) 
APPL2, CHD3, CHD4, GATAD2A, HDAC1, HDAC11, 
HDAC3, HDAC4, HDAC5, LOC642954, MBD3, NRIP1, 
RBBP4, RBBP7, RERE, SAP18, TAL1, TBL1XR1 
Table 3.11. Functional annotation of genes identified by two-factor ANOVA. 
 
Functional category  #of genes  Factor  
GOBP RNA processing  121  Disease  
GOBP ribonucleoprotein complex biogeneis  53  Disease  
GOCC mitochondrion  198  Disease  
GOCC contractile fiber  33  Disease  
KEGG Tight junction  35  Disease  
GOCC Chromatin remodeling complex  19  Disease  
GOCC histone deacytylase complex  12  Disease  
GOMF RNA binding  245  Exercise  
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GOBP proteolysis involved in cellular protein catabolic process  206  Exercise  
GOMF enzyme binding  182  Exercise  
GOCC ribonucleoprotein complex  165  Exercise  
GOBP protein complex biogenesis  166  Exercise  
GOCC extracellular matrix part  50  Exercise  
GOBP blood vessel development  89  Exercise  
GOBP regulation of cell proliferation  236  Exercise  
GOCC contractile fiber  50  Exercise  
KEGG ECM-receptor interaction  36  Exercise  
GOCC histone deacetylase complex  17  Exercise  
GOCC ribonucleoprotein complex  29  Interaction  
GOMF GTPase activity  14  Interaction  
GOBP RNA processing  21  Interaction  
GOCC mitochondrial part  20  Interaction  
Table 3.12. Functional annotation of genes identified by two-factor ANOVA. 
 
3.3.7 Genes predicted to be linked to VO2max ARACNE are induced in a mouse 
model of chronic hypoxia 
In order to elucidate whether genes linked to VO2max in the network model are part of the 
physiological response to hypoxic conditions, I analyzed a public domain microarray study 
developed by Budak et al. (GEO: GSE9400) [185] which represents the response of murine 
skeletal muscles to 2 weeks hypoxic conditions.  
In this study, 45% of genes connected to VO2max in the network model were 
transcriptionally regulated in the mouse model of hypoxia and that a striking 82% of these 
were regulated in the direction predicted by the network analysis (Figure 3.14). Among 
these, the genes encoding for the chromatin modifiers HDAC4 and SIRT3 were present. 
HDAC4 is up-regulated, whereas SIRT3 is down-regulated in hypoxic mice compare to 
normal (Figure 3.14), which is consistent with the sign of the correlation with VO2max 
observed in the clinical study (Figure 3.13A and 3.13C).  Interestingly, many other genes 
encoding for chromatin modifiers were differentially expressed in response to hypoxia. 
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Figure 3-13. Expression of Chromatin Modification Enzymes in COPD and Healthy 
Muscles.  
Panel A represent the close localization of histone deacetylase enzymes to VO2max in the 
inferred network. Panel B is a 3D plot representing the expression of histone deacetylase 
enzymes and the separation between disease and healthy muscles. Panel C, D, E and F 
represent the scatterplots between VO2max and the expression of histone deacetylase 
enzymes. 
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Figure 3-14. Genes represented in the neighborhood of VO2max are transcriptionally 
regulated in a mouse model of hypoxia.  
This heatmap represent the expression of genes in the neighborhood of VO2max that are also 
differentially expressed in skeletal muscles, in a mouse model of hypoxia. It shows that the 
majority of these genes (82%) are regulated in the direction predicted by the network (Figure 
3.4).  The HDAC4 and SIRT3 genes are among these and are highlighted in red. Genes that 
are not modulated in the direction as predicted are shaded in grey. 
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3.4 DISCUSSION 
The networks developed in this thesis represent the first model linking molecular and 
physiology measurements in skeletal muscle of COPD patients. It provides convincing 
evidence that a failure to co-ordinately activate expression of several tissue remodeling and 
bioenergetic pathways is a specific landmark of diseased muscles.  Moreover, the model 
inferred in this study is consistent with the view that the abnormal expression of a number of 
histone modifiers potentially regulated by oxygen availability may be responsible for 
alterations in both tissue remodeling and bioenergetic functions. This hypothesis has 
important implications as it places cell hypoxia and oxidative capacity as the main drivers for 
skeletal muscle abnormalities in COPD patients  
 
3.4.1 Response to training in healthy and diseased muscles 
Several pathways were identified as transcriptionally regulated in healthy individuals in 
response to training. These involve the up-regulation of several tissue remodeling 
genes/pathways (Plasminogen receptor, VEGF, pro-inflammatory signals such as IL1) as well 
as modulation of energy and ribosome biogenesis functions. Without exception, the exercise-
induced modulation of these pathways is severely impaired in COPD individuals. 
The Ingenuity pathway analysis has revealed several detailed mechanisms associated with the 
inflammation and growth factor receptor component of the network presented in Figure 3.4.   
Two of these networks (Figure 3.10A and 3.11A) are part of a larger network linking the 
effect of pro-inflammatory signals such as IL-1, TNFα and IFNγ to the training induced up-
regulation of several components of the extracellular matrix in healthy subjects. Although 
circulating concentration of IL-1β are largely unaffected by exercise there is evidence of 
increased local IL-1β levels within skeletal muscle, likely in response to micro-injury of 
skeletal muscle with increased activity [187]. The analysis of the in vivo experiment shows 
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that indeed a component of the transcriptional response observed in healthy individuals and 
defective in COPD patients may be mediated by interleukin-1β. Moreover, mouse glycolytic 
and oxidative muscles respond similarly to IL-1β in respect to the up-regulation of structural 
components of the muscle but diverge in the regulation of genes involved in energy 
metabolism and ubiquitination (up-regulated in glycolytic muscle), or extracellular matrix 
and tissue remodeling including angiogenesis (up-regulated in oxidative muscles).  
Patients with mild to moderate COPD have a greater proportion of fatigue-susceptible 
anaerobic (glycolytic Type II) relative to fatigue-resistant aerobic (oxidative Type I) fibres, 
suggesting a slow-to-fast transition. It has been proposed that <27% Type I and >29% Type 
IIx fibres offers a pathological threshold for COPD [188]. This is consistent with a shift 
towards a more glycolytic enzyme profile, and would contribute to an increase in skeletal 
muscle fatigability [189]. Although individual fibre phenotypes are well conserved among 
mammals virtually all human skeletal muscles are of mixed composition, hence mouse 
muscles with discrete metabolic profiles were used to identify differential responses to IL-1β 
according to metabolic type.  
A mechanistic link between the activity of these tissue remodeling pathways and myogenesis 
is well supported by the current literature. For instance, the plasminogen receptor ENO1 has 
been demonstrated to be an important component of skeletal myogenesis by concentrating 
and enhancing plasmin generation of the cell surface [190]. Interestingly, ENO1 KO mice 
show severe defects in muscle regeneration following injury [190]. Components of the 
extracellular matrix, which are induced by signaling from many of the receptors present in 
the network are also mechanistically linked to myopathies. For example, Col6a1–deficient 
and Col15a1-deficient mice have a muscle phenotype that strongly resembles human 
myopathies [191, 192].  
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Inflammatory and chemo-attractant mediators are also known to be key factors in driving 
muscle remodeling in the normal physiological response to training [193] and in response to 
trauma [190].  In the latter, IL1β also promote phagocytosis of trauma-induced cellular debris 
by macrophages, which themselves can continue to secrete this cytokine up to 5 days post-
injury [187]. Ccr2 null mice with cardiotoxin induced injury has been shown to have a 
delayed angiogenesis and Vegf production compared to wild type mice with muscle fibre size 
increase observed only after restoration of tissue Vegf [194].  Other studies have also shown 
the crucial role of VEGF in angiogenesis and in muscle regeneration [195, 196]. 
There is also strong evidence that bioenergetics and tissue remodeling pathways are linked 
[197]. It has been shown that genes coding for components of collagen V and collagen VI 
play an important regulatory role in ECM maturation, where reduced expression promotes 
apoptosis, mitochondrial dysfunction and muscle degeneration [197]. Other studies have 
shown that bioenergetics knockouts, such as H6PD null mice is responsible for inducing 
severe skeletal myopathy by altering sarcoplasmic reticulum redox state [198]. 
 
3.4.2 Decreased training induced expression of NF-kB target genes in COPD 
muscles 
A number of in vitro and in vivo studies have been used in the past to support the hypothesis 
that a systemic inflammation-driven mechanism leads to inactivation of myogenic pathways 
in COPD muscles.  The analysis presented in this chapter is the first attempt to challenge this 
hypothesis using genome-wide data, and in a clinically relevant setting. There was no 
evidence of over-expression of NF-kB target genes in COPD muscles. On the contrary, a 
subset of direct (Table 3.9) and indirect targets (Figure 3.10A) of NF-kB were up-regulated 
in healthy individuals in response to training but not in COPD patients (p < 0.05). These 
98 
 
results are consistent with a recent observation demonstrating failure to activate NF-kB in 
response to acute training in a small subset of COPD patients [81]. Taken together, these 
results suggest that training-associated inactivation rather than over activation of NF-kB may 
be a feature of diseased muscles. 
Additional observations also argue against a primary role of chronic inflammation in muscle 
wasting. For example, although an increased levels of cytokines in COPD patients were 
observed (Figure 3.1B) with respect to normal individuals, only a few links between the 
concentration of these cytokines and the muscle transcriptional state were identified. These 
results imply that systemic inflammatory signals may have a smaller effect on muscle 
physiology than previously thought. This latest observation is consistent with previous 
reports showing that TNFα levels measured in COPD muscles were not significantly higher 
than in healthy muscles [67]. 
 
3.4.3 Is there an epigenetic basis for muscle wasting in COPD? 
Since the NF-kB over-activation hypothesis is unlikely to explain the inhibition of muscle 
remodeling observed in COPD, what could be an alternative mechanism for muscle wasting 
in COPD? 
There are several pieces of evidence in favour of the hypothesis that an imbalance in 
expression of oxygen-correlated chromatin modifying enzymes, which have shown to be a 
landmark of COPD muscles. This could explain failure to modulate both tissue remodeling 
and bioenergetic functions in response to training in these patients. Figure 3.13 shows that 
the expression of SIRT2, SIRT3, HDAC4 and HDAC9 is sufficient to discriminate healthy and 
diseased muscles. At the individual gene level, healthy muscles are characterized by a higher 
expression of HDAC9, SIRT3 and by a lower expression of HDAC4 (Table 3.10) with 
respect to COPD muscles. 
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The role of HDAC9 and HDAC4 in muscle development is well documented [199]. For 
example, HDAC9 is a transcriptional repressor involved in feedback control of muscle 
differentiation, acting in concert with MEF2 to repress activity-induced genes [200], while 
HDAC4 is up-regulated in pathological conditions such as muscle denervation [201], and it 
has been described to be a critical regulator of muscle atrophy by activation of E3 ubiquitin 
ligases [202]. It is possible, therefore, that a lower expression of HDAC9 and a higher 
expression of HDAC4 in COPD muscles may be linked to a reduced ability to activate 
muscle remodeling. Abnormal expression of SIRT2 may also contribute to a failure to 
activate an appropriate muscle remodeling response. SIRT2 is a NAD+-dependent histone 
deacetylase that regulates muscle gene expression and differentiation by forming a complex 
with MyoD [203]. When over-expressed, this retards muscle differentiation. Conversely, cells 
with decreased SIRT2 differentiate prematurely. Interestingly, the activity of SIRT2 is 
dependent on the redox state of the cell [203], which showed evidence of being abnormal in 
COPD muscles [204, 90, 160]. In the network neighborhood of SIRT2, TXN2 was identified. 
TXN2 is known to play an important role in protection against oxidative stress [205]. 
Similarly, GAB1 is shown to play a role in oxidative stress signaling [206] and it is identified 
in the neighborhood of HDAC9 in the network. Since changes in ROS production are known 
to influence the expression of HDACs [207], the inferred network may represent this 
important control mechanism. 
SIRT3 is a NAD+-dependent histone deacetylase that may account for the characteristic loss 
of transcriptional modulation of bioenergetic genes in response to training in COPD muscles. 
SIRT3 is localized in the mitochondrial matrix, where it regulates the acetylation levels of 
metabolic enzymes, including acetyl coenzyme A synthetase 2 [208, 209]. Mice lacking both 
SIRT3 alleles show hyperacetylation of several mitochondrial proteins, associated with 
decreased levels of fatty-acid oxidation, and display a selective inhibition of electron 
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transport chain Complex I activity leading to reduction in basal levels of ATP in several 
organs [210]. These and other data implicate protein acetylation as an important regulator of 
mitochondrial function in vivo, and it is therefore feasible that an altered expression of SIRT3 
in the muscles of COPD individuals may contribute to the observed imbalance in 
mitochondria functionality. It is interesting that SIRT3 in the model is positively correlated 
with VO2peak, suggesting that the lower levels of expression of this enzyme observed in 
COPD muscles may be the consequence of tissue hypoxia. Consistent with this, histone 
deacetylase (HDAC) inhibitors reduce HIF-1α protein expression leading to down-regulation 
of VEGF and other angiogenesis-related genes [211], potentially explaining the reciprocal 
relationship between extent of muscle capillarity and the degree of COPD [212]. The 
abnormal expression of a relatively small number of histone modifying enzymes could 
therefore account for a wide spectrum of abnormal responses observed in the muscles of 
COPD patients, and may also explain the limited efficacy of training as a therapeutic option.  
This view is supported by our observation that indeed hypoxia induces modulation of a 
number of chromatin modifiers in a mouse model of chronic hypoxia and that indeed SIRT3 
and HDAC4 are among them (Figure 3.14). 
 
3.5 Conclusion 
In this chapter, the most accurate system level representation of COPD muscles to date was 
built. Further work is, however, needed to elucidate the precise mechanism for muscle 
inactivation. If the mechanism for muscle wasting suggested by our observations on HDACs 
were to be validated in a clinical setting this would open up a very exciting therapeutic 
avenue. The use of non-toxic histone deacetylase inhibitors such as valproate has already 
shown promising in treatment of haematological cancer [213,  214,  215], and may help to 
restore mitochondrial functionality and the ability to activate muscle remodeling in COPD 
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patients. In this context it is possible that the appropriate pharmacological regime coupled 
with physical rehabilitation may lead to recovered muscle functionality, and improved quality 
of life. 
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 CHAPTER 4: THE DEVELOPMENT OF A 
NOVEL NETWORK MODULARIZATION 
PROCEDURE FOR MULTI-LEVEL DATA 
INTEGRATION 
 
4.1 INTRODUCTION 
Despite the fact that the networks inferred and discussed in the previous chapter represent 
thousands of nodes and edges, their interpretation were relatively straightforward. This was in 
part a consequence of the fact that the networks were built using a biology driven network 
inference pipeline (see Figure 3.4). Unfortunately, this strategy is not generally applicable. 
Large-scale networks are in fact usually challenging to interpret and in this context, 
modularization approaches provide suitable tools for identifying sub-networks linked to 
important biological functions or disease outcomes. Several modularization approaches have 
been developed so far [151, 216, 155, 154, 217].  These approaches are either aiming to 
identify sub-networks whose genes are differentially regulated between various experimental 
conditions [151], [216] or are highly co-regulated [155, 154].  Ideker et al. [151] proposed a 
heuristic approach aiming to identify modules in protein-protein interaction networks that are 
enriched with differentially expressed genes. In their paper, Ideker et al. demonstrated the 
usefulness of this approach by integrating yeast protein interaction with gene expression data 
measured from 20 perturbations to the yeast galactose utilization pathway. Scott et al. 
addressed the same challenge using a graph theory approach based on Steiner trees [217]. In 
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their method, they applied an approximation algorithm developed by Klein et al. [218]. 
Dittrich et al. has also tackled this problem using Steiner trees, but they have used an 
algorithm developed by Lubic et al. [219], which can solve Steiner Tree problem to 
optimality. Therefore, this methodology had excellent performances on the simulated data 
and over-performed in all instances compared to the heuristic based methodology. Other 
approaches have been developed to identify functional modules, with highly co-regulated 
nodes [155, 154]. In these methodologies, edges based scoring functions are introduced in 
order identify modules with high scores, which consist of edges that are highly co-regulated.   
However, a methodology integrating such node and edge properties is still missing. If 
available, such procedure would allow the identification of network modules integrating three 
different levels of information. For example, protein-protein interaction modules that are 
enriched of genes differentially expressed between two or more experimental groups and also 
co-regulated across a large numbers of experimental perturbations (e.g. different genetic 
backgrounds or across a patient population). Here, this challenge has been addressed by 
developing a new methodology derived from the modularization method published in Dittrich 
et al. [216]. On simulated data, this methodology has a high sensitivity and specificity in 
recovering network modules of different sizes and with varying degrees of association. Its 
application to integrate mass spectrometry, expression profiling and knowledge datasets in a 
real world biological system has revealed a new mechanism controlling cell proliferation in 
human Glioma. 
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4.2 MATERIAL AND METHODS 
4.2.1 The Modularization Approach 
The proposed methodology aims to identify sub-networks within a larger network, whose 
elements share several functional properties. Various properties could be used to construct 
and score the initial network depending on the question to be addressed. Hence, it allows 
integrating three distinct levels of information. This is achieved by a scoring function that 
integrates nodes (first level) and edges (second level) properties in an underlying network 
structure (third level). In the application case described in this chapter the underlying network 
is represented by a large gene interaction network derived from a public domain knowledge 
database Human Protein Reaction Database (HPRD). The node properties are encoded from 
p-values derived from a mass spectrometry experiment representing molecular interactors of 
the RhoE protein. Edge properties are derived from the correlation between pairs of gene 
expression profiles representing the development of a tumour. In this particular case, the aim 
is to identify sub-networks with potential interactors of RhoE that are highly coregulated 
during the tumour development. 
The problem of identifying network modules has recently been shown that it could be solved 
using Prize-Collecting Steiner Tree Problem (PCST) [217, 216]. Briefly, in PCST nodes in 
the network represent profits and edges represent costs. Networks are scored by computing 
the sum of the profits subtracted by the sum of the cost of its members. The goal is to identify 
sub-networks with the highest score. Hence, the node scoring function should transform low 
p-values with higher node profits. Similarly, since highly correlated genes have higher 
correlation coefficients the edge scoring function should express these gene-to-gene 
connections with a lower edge cost.  The graph scored using such scoring functions can then 
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be used as an input to the algorithm developed and implemented in [219] in order to find the 
network with the highest score. 
4.2.1.1 Constructing interaction networks 
The first step is the construction of the underlying network.  The selection of the data source 
is a crucial step. A number of gene and protein interaction databases have been developed in 
the past few years. Some of them are publicly available (for a review [220]) and others are 
accessible in the context of commercial software packages [221]. In this application, the 
HPRD database has been used [222, 223]. HPRD is the most comprehensive human protein-
protein interaction database being developed to date and contains the large majority of 
interactions (75%) available in other similar databases such as BIND, DIP and BIOGRID 
[220]. Using the BioNet R package, an interaction network representing 9392 different 
proteins linked by 36504 literature-curated interactions have been extracted. 
4.2.1.2 Scoring the network 
Once the interaction network is constructed, the nodes and the edges in the networks are 
scored as described below. 
Node Scores 
Each node is scored as a function of a p-value derived from a statistical test. This can be the 
output of any statistical procedure comparing two or more experimental groups. It may also 
represent a measure of confidence that assign a particular property to a node such as a target 
gene. The score for each node is defined as:  
)log(pscoreNodeg  ,            (1) 
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where g is the score of the gene g and p is the associate p-value of the gene g derived from 
the differential expression analysis. This basic score for each gene allow us to obtain larger 
scores for smaller p-values. 
Edge Scores 
Each network edge is scored as a function of a correlation coefficient. This can be either a 
standard correlation coefficient or mutual information. For smaller datasets a descriptive 
measure of dependency such as the Spearman correlation coefficient may be more 
appropriate whereas MI can be more effective with larger sample size (n>40) [147].  
 
The score of the edge e between genes ig  and jg ,  is defined as:  
wggIscoreEdge jie *)),(log( ,   (2) 
where, I is the correlation coefficient (or MI) between genes ig  and jg , and w is a weight. 
The final scoring function to maximize is dependent on the edge (2) and node score (1), 
therefore the contribution of the cost (i.e., edge score) can be increased or decreased using the 
weight parameter w in (2). The size of the identified sub-network depends on this parameter.  
In the study case data, the Spearman correlation between genes in the tumour data has been 
computed in R. 
4.2.1.3 Scoring sub-networks 
The aim of the procedure is to identify the highest sub-networks that are scored by computing 
the sum of the profits subtracted by the sum of the cost of its members. For a given sub-
network A with a set of nodes N and a set of edges E, the module score scoreA is then defined 
as follows:  
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The scores of a node gscoreNode  and the score of an edge escoreEdge  are computed by 
applying equations (1) and (2) respectively.  
4.2.1.4 The algorithm to identify sub-network with highest score in the 
interaction network 
In order to identify the sub-network with the highest score in the interaction network, the 
algorithm developed and implemented in [219] was used. This algorithm has been shown by 
Ljubic et al. [219] to solve the Prize Collecting Steiner Tree (PCST) problems to optimality. 
Ljubic et al. have first transformed the mathematical problem of identifying the sub-network 
with the maximum score into an equivalent problem called Steiner arborescence problem. 
The authors have then shown that a feasible arborescence with minimum total edge score 
corresponds to an optimal PCST [219]. Here, in Figure 4.1, an example is shown 
demonstrating the transformation of an undirected graph into a Steiner arborescence. To 
identify minimum Steiner arborescence tree, they have used integer linear formulation and a 
branch and cut framework using the software dhea [219]. For this, several types of constraints 
(connectivity, asymmetry and flow balance) are introduced and violated constraints are 
identified iteratively until all constraints are satisfied [219]. 
108 
 
 
Figure 4-1. Transformation into Steiner Arborescence problem for identifying optimal 
Prize Collecting Steiner Tree.  
Panel A is an example of a graph G with three nodes of weight 3, 10 and 0 and with edges of 
weight 2 and 7. The optimal sub-network in this graph has a score of 11 and contains the 
nodes scored by 3 and 10 (calculated using equation 3). In order to identify the optimal sub-
network, the graph is first transformed into a Steiner arborescence problem. For this, first an 
artificial root R is inserted in the graph (Panel B). Then a direct edge from R to all other 
nodes in G with score higher than zero is introduced and the edge is scored using equations in 
Panel C. Arcs between all other nodes are introduced and the cost is recomputed using 
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equations in Panel C. A feasible arborescence with minimum total edge score corresponds to 
an optimal PCST, i.e. a best solution. 
  
This software is implemented using IBM ILOG CPLEX Optimizer, which is a high-
performance mathematical programming solver for integer linear programming. For 
academic users, CPLEX is available with no-charge via IBM’s Academic Initiative program. 
4.2.1.5 Correcting the network score for random effects 
It is of crucial importance to test the likelihood of the module of being occurred by chance. 
On this account, the z-score of the sub-network separately for edges and nodes were 
computed as follows: 
For a given sub-network A of size K = k, an edge z-score is then defined as: 
k
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            (4) 
where kµ  and k  are respectively the mean and standard deviation of network edge scores 
(as defined in [2]) computed for 1000 random sub-networks of size K. 
Similarly, for a given sub-network A of size K = k, the node z-score is defined as: 
k
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            (5) 
where kµ  and k  are respectively the mean and standard deviation of network node scores 
(as defined in [2]) computed for 1000 random sub-networks of size k. In this application, 
these were estimated from the module score (calculated using equation (4) and (5)) 
distribution derived from resampling 1000 random sub-networks of size K.  
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4.2.1.6 Searching for independent multiple sub-networks  
The edge scoring function allows controlling the contribution of the cost by using the 
parameter w in equation (2). This results to the identification of sub-networks with various 
sizes. Each identified subnetwork is associated with a z-score computed from resampling 
random sub-networks of the same size by using equation (4) and equation (5). It is possible to 
compare these networks by their z-scores and choose the network with the highest z-score 
divided by the square root of the edge or node size respectively. 
The sub-network with highest score is removed from the interaction network and then the 
search procedure is restarted to identify other independent sub-networks iteratively. These 
iterations are repeated until there are no networks with acceptable p-values calculated using 
(3) and (4). The original algorithm can provide also the suboptimal solutions using hamming 
distance [219]. However, the iterative procedure allows identifying completely independent 
networks that are relatively small and easy to interpret.  
4.2.1.7 Method validation on a simulated search space derived from a real data 
In order to assess the performance of the method, two simulated datasets have been generated 
to represent search spaces with different properties. The objective was to first generate 
networks with a real network topology but with non-statistically significant nodes and edge 
properties. Within these networks, modules of a defined size were then selected and scored 
with varying degrees of statistically significant node and edge properties. The aim was to test 
the ability of the procedure to recover these modules. 
Construction of the simulated search space 
The real underlying network structure was derived by protein-protein interaction data 
extracted from the HPRD database and covering the whole gene complement represented in 
Affymetrix platform (Human U133 Plus2 Gene Chips). This has resulted in a network 
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consisting of 4540 nodes (genes) and 14903 edges (interactions). In order to score the 
network edges, MI values were computed from a randomized gene expression dataset. This 
dataset represent 44000 probes and 54 samples and it is described in Chapter 3 section 3.2.2. 
Significant network modules were constructed as follows. Three modules of size 22 in one 
simulated dataset and three of size 55 in the other dataset were first selected randomly from 
the global network. Within these networks, modules edges were scored by sampling MI 
values from normal distributions representing high, medium or low statistically significant 
MI intervals (Figure 4.2).  The intervals are defined by partitioning the area between the 90% 
quantile of the MI values from real dataset and the random dataset as described in [154]. 
Genes belonging to the selected modules are set signal p-values uniformly distributed 
between 0 and 0.10 and background noise p-values uniformly distributed between 0 and 1 as 
proposed in [216]. 
 
Figure 4-2. Generation of a priori defined modules in the simulated search space. 
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Method performance 
In order to test the accuracy of the procedure, the precision and recall were computed for 
recovering different size and degree of gene-to-gene correlation (see method section for 
details). The modules with the highest degree of internode mutual information were identified 
by the procedure with a high recall and precision, regardless of the network size. More 
precisely, the module of size 22 has a recall of 0.8 and a precision of 1 (Figure 4.3A) and the 
module of size 55 has a recall of 0.9 and a precision of 1 (Figure 4.3B). Network modules of 
intermediate node correlation (Figure 4.2) were also identified with high recall and precision. 
The smaller module (22 nodes) has a recall of 0.79 and a precision of 0.90 (Figure 4.3C), 
whereas the largest module (55 nodes) was identified with a precision of 1 and recall 0.74 
(Figure 4.3D). Network modules of low correlation between nodes has resulted to precision 
1  and recall of 0.62 for the large module (55 nodes) and precision of 0.84 and recall of 0.52 
for the small module (22 nodes). 
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Figure 4-3 Accuracy of the identified modules.  
Panel A and B represent the modules pre-defined in the high MI interval respectively with 55 
nodes or 22 nodes. Panel C and D represent the modules pre-defined in the intermediate MI 
interval respectively with 55 nodes or 22 nodes. 
 
Comparison of using p-values vs. FDR as an input to node scoring function 
As using corrected p-values as an input in the node scoring function could influence the 
performance, the p-values have been corrected by performing a Benjamini-Hochberg 
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multiple correction. The node scores in the simulated search space was consequently 
recomputed, which was then used as an input in the methodology. The performance was then 
reassessed for large module in the high MI interval. From the identified modules 4 out of 6 
were also identified using p-values as node scores with an overlap higher than 80% (Table 
4.1). This analysis has shown that the highest scored module with the largest score allows 
identifying a priory defined network with 55 nodes with a recall of 0.98 and precision of 1.  
Run  Nodes scored from p-values  Nodes scored from  FDR  Overlap  
 Recall  Precision  Size  Recall  Precision  Size   
1  0.55 1 30 0.66 1 36 83% 
2  0.90 1 49 0.90 1 49 100% 
3  0.98 1 53 0.98 1 53 100% 
4  1 0.29 88 1 0.55 96 91% 
Table 4.1. Comparisons of modules identified from different node inputs.  
This table represents the modules identified using p-values for scoring the nodes (column 1) 
and Benjamini-Hochberg corrected p-values (column 2). These modules share a large overlap 
(larger than 80%) between the two inputs. 
 
Performance compared with other algorithms 
Two other methods have been used for comparing the performance with the methodology 
presented here. For this, the same simulated search space presented in section 4.2 with a 
priori defined networks of 55 nodes has been used as an input to FUMO [154] and 
jActiveModules [151]. FUMO aims to identify functional modules with high mutual 
information and jActiveModules aims to identify functional modules with genes differentially 
expressed between experimental conditions. Table 4.2 shows that FUMO identify modules 
with high recall but low precision. The modules identified by jActiveModules have high 
precision but low recall. Overall, the method presented in this chapter has a better 
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performance than these two methods. The algorithm used in this chapter has been also shown 
to outperform jActiveModules by Dittrich et al. [216].  
Module #  FUMO jActiveModules Integrative approach 
 Precision Recall Precision Recall Precision Recall 
m1 0.63 0.18 0.15 0.80 1 0.90 
m2 0.94 0.27 0.17 0.91 1 0.74 
m3 1.00 0.15 0.17 0.89 1 0.62 
Table 4.2. Performance comparison with other methods.  
This table shows the accuracy of the modules in high, intermediate and low MI intervals 
identified by FUMO (first column), by jActiveModules (second column) and by the 
integrative approach presented in this chapter (third column). 
 
4.2.2 Application to real data 
The chicken chorioallantoic membrane (CAM) model and expression profiling 
The transcriptional dynamics of tumor cells in a model of human glioblastoma cancer 
development (U87 cell line) was studied. This data has been generated in the group of 
Bikfalvi. U87 human glioma cells (American Type Culture Collection) were maintained in 
DMEM with 10% FBS, antibiotics, and l-glutamine. Fertilized chicken eggs (Gallus gallus) 
(EARL Morizeau, Dangers, France) were handled as described [224]. 
On embryonic day 10, a plastic ring was placed on the CAM, and 3 million to 5 million U87 
cells in 20 μl of medium were deposited after gentle laceration of the surface. Digital photos 
were taken under a stereomicroscope (Nikon SMZ800). When required, tumor size-matching 
was done based on tumor volume calculation: V = 4/3πr3, with .  
CAM and glioma tissue was extracted together from CAMs at 10 time points in 12 hour 
intervals over 5 days and snap frozen in LN2. Total RNA was extracted by using RNeasy 
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mini kit (Qiagen, Courtaboeuf, France). RNA quality and quantity were assessed by agarose 
gel electrophoresis and optical density measurement. RNA was reverse transcribed (cDNA 
Synthesis System Kit, Roche Diagnostics), purified and labelled using Cy3 (Megascript D7 
Kit, Ambion, Austin, TX). Labelled cRNA containing both chicken and human cRNA were 
hybridised to Agilent Chicken V1 and Human GE V2 microarrays following manufactures 
standard protocols. Arrays were scanned using an Agilent HD Array scanner. The 
microarrays were generated by Sarah Durant, Philipp Antczak and Kim Clarke (University of 
Birmingham). 
Detection of potentially cross-hybridising probes on the Chicken and Human arrays 
Two colour microarrays were used to determine human and chicken probes that could 
potentially cross hybridise to chicken and human microarrays respectively and thus 
contribute to a false positive signal. RNA from pre-implantation CAM and U87 cells were 
labelled with Cy3 and Cy5 dyes respectively. Pooled labelled cRNA from CAM cells and 
U87 cells were hybridised to both Agilent Chicken V1 and Human GE V2 arrays. The 
microarray data was quantile normalised and the background signal for each dye was 
subtracted. A contribution score was then calculated for each human probe on the chicken 
array and vice versa. The score is defined as the signal intensity divided by the total signal for 
both dyes. Probes with a signal higher than 50 in a linear scale and a contribution greater than 
15% were defined as potentially cross-hybridising. 9128 human probes and 5272 chicken 
probes were removed from further analysis. This dataset was processed by Kim Clarke 
(University of Birmingham). 
Normalization and Annotation of the Human and Chicken Arrays 
Array data was quantile normalised and the background signal was subtracted using the 
statistical software package R. Where multiple probes were available for a gene, the highest 
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average expression amongst those probes was used for further analysis. This dataset has been 
processed by Kim Clarke (University of Birmingham). 
Survival analysis 
In order to test whether the module derived from the approach developed in this thesis is also 
predictive of clinical outcome, a publically available dataset [225] has been analyzed. This 
dataset consists of 24 grade III and 50 grade IV glioblastoma patients. For each patient the 
survival time has been recorded either to current time if the patient is alive or to the day of 
death. An analysis has been performed by the authors in the original study published in [226] 
that allowed grouping patients into poor and good survival groups using a partial least 
squares procedure. In this thesis, the differentially expressed genes have been identified 
between the poor and good survival groups using a t-test. The t-statistics has been used to 
rank the genes in order to test by using a GSEA analysis whether there was a significant 
enrichment in the module identified by the modularization approach developed in this 
chapter. 
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4.3 RESULTS 
4.3.1 A novel modularization approach identifies new role for RhoE during 
tumour development in CAM 
It has been shown that RhoE has a role in the regulation of cell proliferation and survival in 
U87 cells in vitro [227]. In this study, the role of RhoE targets in an in vivo CAM model was 
addressed. I have aimed to identify modules describing the regulation of effector functions 
controlled by RhoE during the development of a fully vascularised tumour. For this, the 
transcriptional data derived from an in vivo CAM model and putative RhoE targets identified 
by immuno-precipitation followed by mass spectrometry were integrated in the 
modularization framework described in this chapter. First, the interaction network was built 
of 3399 genes and 9640 interactions resulted from the integration between the HPRD 
database and the Human tumour cell time course dataset available from the CAM model.  
The nodes and edges were then scored using the equation (2) and (3). The identified modules 
in this case are aiming to identify highly co-regulated genes in the neighborhood of the 
putative RhoE interactors. In total, 4 modules have been identified by this procedure (Table 
4.3, Figure 4.4A and Appendix Figure A4.1). These modules are functionally enriched in 
genes related to cell cycle, DNA repair, cell death, proliferation and extracellular matrix 
components (Table 4.1). The module with the best scored (m1) shows that RhoE is strongly 
linked with nuclear proteins involved in DNA replication (Figure 4.4A). The genes in the 
identified module can separate between low and high survival in glioma patients classified 
with grade 3 and grade 4 tumours. Consistent upregulation of genes in patients with bad 
prognosis with median survival of 237 days compare to good prognosis patients with median 
survival of 4.8 years identified by GSEA analysis (Figure 4.4B). 
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M#  size  Z-score p-value  Functional Annotation  
m1  47  12.96  < 1e-16  GOCC nuclear lumen [26]. GOBP DNA metabolic process 
[13]. KEGG cell cycle [8]. SMART MCM [4].  GOBP DNA 
replication [8]. GOBP DNA repair [7]. GOBP Apoptosis [11].  
m2  71  11.03  < 1e-16 GOCC nuclear lumen [32].  GOMF ATP binding [16]. GOBP 
DNA repair [7].  GOBP Cell death [12].  
m3  41  7.44  < 1e-11 KEGG Cell cycle [6]. GOBP Regulation of cell proliferation 
[9]. KEGG ECM-rec interaction [4]. GOBP Positive reg of cell 
proliferation [9].  
m4  51  6.34  < 1e-6  GOBP Protein transport [11].  GOCC nuclear lumen [16].  
m5  34  1.80  0.07   
Table 4.3. Modules identified from the search procedure.  
The second column indicates the size of the module, the third column is the z-score derived 
from (4), the forth column represents the associated p-value, and the fifth column represent 
the functional annotation of the module derived from DAVID.   
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Figure 4-4. The module identified by integration of the CAM model, RhoE targets and 
interaction networks and the survival analysis.  
Panel A shows the module identified by the approach in this chapter. Panel B shows the 
heatmap of the genes significantly different between SC1 and SC2 patients that are enriched 
in the module as identified by GSEA analysis. The heatmap shows that these genes are 
upregulated in patients with low survival (SC2) and downregulated in patients with high 
survival (SC1). 
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4.3.2 Experimental validation shows that RhoE is localized in the nucleus and its 
inactivation alters the localization of MCM3 
The network has shown that RhoE is strongly linked with nuclear proteins involved in DNA 
replication (e.g. MCM3). To test whether RhoE is involved in nuclear localization, western 
blot and immuno-fluorescence staining analysis were carried out by two collaborators Sarah 
Durant and Dr. Neil Hotchin. The results have shown that RhoE is localized in the nucleus in 
U87 cells (Figure 4.5) and MCM3 accumulates in the nucleus of RhoE-depleted cells 
(Figure 4.6). 
 
Figure 4-5. RhoE is localized in the nucleus. 
Western blot and immune fluorescence staining shows that RhoE is localized in the nucleus 
in U87 cells (Panel A) 
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Figure 4-6. RhoE inactivation alters the localization of MCM3. 
Western blot and immune fluorescence staining shows that MCM3 accumulates in the 
nucleus of RhoE depleted cells. 
 
4.4 Discussions and Conclusions 
In this chapter, a novel modularization approach has been developed and tested. This 
procedure allows the integration of several datasets into one framework. The performance on 
the simulated data has shown accurate identification of a priori defined networks. The case 
study has also shown the usefulness of the method in generating new hypothesis that are 
experimentally testable.  
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Identification of overlapping modules 
As genes can be associated with several functions, the modules in reality could be 
overlapping and the modules might have fuzzy borders. The methodology described in this 
chapter allows only identifying non-overlapping modules. One way to overcome this issue is 
to identify several sub-optimal solutions at each iteration using the hamming distance as 
proposed in the original algorithm (dhea) developed by Lubic et al. [219]. This would allow 
identifying networks that share common genes between the functional modules. 
Other applications 
The approach developed in this chapter can be used to integrate various types of data as long 
as the nodes are associated with p-values and edges with a metric similar to correlation. The 
initial interaction network can be constructed as presented in this chapter from the literature 
or by using pairwise correlation from the data. Other types of application of this methodology 
could be based in integrating genome-wide association study (GWAS) focussing on SNPs 
association with a disease and co-regulation from gene expression dataset. In a recent study, 
GWAS and PPI information was integrated into a modularization approach in breast cancer 
and pancreatic cancer [228]. For this, the authors have used the most significant SNP for each 
gene which is located within the 20kb immediately upstream or downstream of the gene 
[228]. In the methodology described in this chapter, a similar approach can be used to score 
the nodes and co-regulation from gene expression could be used to score the edges allowing 
the integration of multi-level datasets.   
Another application of this methodology could be to identify network modules whose genes 
are transcriptionally correlated through a sample series and at the same time differentially 
regulated between two or more experimental conditions in two different systems. In this case, 
the interaction network is represented by a graph where a differential expression p-value is a 
node property and gene-to-gene correlation is an edge property.  Indeed, in the next chapter, 
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this approach will be performed to integrate a clinical dataset, differentiation data of hMSCs 
and interaction networks into one framework for studying bone and cartilage degradation in 
various conditions. 
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 CHAPTER 5: DYNAMICAL MODELS FOR 
UNDERSTANDING  BONE AND CARTILAGE 
DIFFERENTIATION FROM MESENCHYMAL 
STEM CELLS IN NORMAL AND 
PATHOLOGICAL SCENARIOS 
 
 
5.1 INTRODUCTION 
hMSCs have the ability to differentiate towards bone, fat and cartilage cells and as such they 
are key for the maintenance of the musculoskeletal system. Aberrant differentiation of 
hMSCs has been observed in ageing and in various diseases including multiple myeloma and 
arthritis [104, 106, 107, 108]. In ageing, the number of adipocytes in bone marrow increases, 
resulting in the appearance of fatty marrow [104].  The interplay with fatty marrow reduced 
osteoblastic bone formation and increased osteoclastic bone resorption causes sustained bone 
loss [104]. Reduced osteoblastic differentiation and increased activity of osteoclasts has also 
been shown to contribute in rheumatoid arthritis [229, 230, 231, 232] and in multiple 
myeloma [106, 107, 108].  
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Activation and inhibition of several signaling pathways, growth factors and hormones have 
been found to play a crucial role in the process of hMSC differentiation towards the three 
lineages in both healthy tissue and patients with bone and cartilage degradation. For instance, 
PPARG activation is required for normal adipogenesis and the activity of PPARG has been 
observed to be increased with ageing, which could contribute to increased activity of 
adipogenesis in ageing. Moreover, PPARG inhibition is required for normal osteogenesis and 
the high activity of PPARG can at least partially explain the reduced osteogenesis activity 
during ageing. The transcription factor RUNX2 is known to be a regulator of osteogenesis 
activity, which has been shown to be inhibited in hMSCs from MM patients potentially by 
soluble factors (IL7), Wnt antagonist (DKK1), secreted frizzled (sFRP3 and sFRP2), and 
VCAM [106, 107].   
Although these studies have contributed to the identification of several key pathways, the 
exact mechanisms of hMSC differentiation are still unclear. Several microarray studies 
aiming to understand the dynamics of differentiation of hMSCs towards bone [38,	233] and 
cartilage [234] have been previously reported. However, construction of time dependant gene 
regulatory networks reflecting these processes have not been achieved yet. This represents a 
crucial task as it could enhance our understanding of the differentiation processes.  In this 
chapter, the development of the first genome-wide dynamical models of hMSCs 
differentiation towards the three lineages is described. On a general level, these models 
successfully identify several signaling pathways in the most upstream events leading to the 
activation of effector pathways such as ossification and ECM in the osteogenesis and the 
chondrogenesis model. These models also allowed the identification of potential candidates 
that could enhance the efficiency of differentiation in ageing and in disease condition. More 
specifically, this study predicts that knock-down of DUSP6 and over-expression of MYC in 
hMSCs derived from MM patients could enhance the osteogenic differentiation. It also 
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predicts that inhibition of TBX3 in hMSCs derived from elderly individuals could enhance 
osteogenic differentiation. The analysis pipeline developed is general and could potentially be 
used for identification of targets in other diseases associated to bone or cartilage degradation.
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5.2 MATERIAL AND METHODS 
5.2.1 Datasets 
5.2.1.1 hMSCs differentiation and microarray datasets 
Osteogenic differentiation from hMSCs 
This data has been published by Piek et al [38], but for clarity the details of the differentiation 
protocol is reported here. hMSCs were purchased from Lonza (Walkersville, MD) cultured  
in vitro up to passage 8 and then differentiated towards bone, cartilage and fat cells. For 
osteogenic differentiation, 2.0×10^4 cells per cm2 were seeded in DMEM supplemented with 
10% fetal bovine serum (a selected lot from Lonza Walkersville, Inc.), 100 U/ml penicillin. 
The next day, cultures were sub-confluent and cells were switched to osteogenic 
differentiation medium (DM) composed of high-glucose containing Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Lonza Walkersville, 
Inc.), 100 U/ml penicillin, 100 μg/ml streptomycin, 10−7 M dexamethasone (DEX), 0.2 mM 
ascorbate and 10 mM β-glycerophosphate, and 10−8 M 1α, 25-dihydroxyvitamin D3 
(1,25(OH)2D3; Calbiochem. Cells treated with DM in the absence of dexamethasone (further 
referred to as −DEX) were used as negative controls and are also referred to as “untreated.” 
Medium was refreshed every 3 days. Histochemical staining and flow cytometric analysis of 
ALP-positive cells indicated that 1,25(OH)2D3 strongly potentiated osteoblast differentiation 
induced by DEX, resulting in cultures that contained more than 70% ALP-positive cells after 
9 days of treatment.  
hMSCs differentiation towards adipocytes  
For adipogenic differentiation, 4.0 x 104 cells per cm2 were seeded DMEM supplemented 
with 10% fetal bovine serum (a selected lot from Lonza Walkersville, Inc.), 100 U/ml 
penicillin and 100 µg/ml streptomycin. The next day, the cells were switched to adipogenic 
differentiation medium (AD), which consisted of the above proliferation medium now 
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supplemented with 10-6 M dexamethasone, 10 μg/ml insulin (R&D Systems), 10-7 M 
rosiglitazone (Campro Scientific, The Netherlands), and 500 μM IBMX (3-isobutyl-1-
methylxanthine, Sigma-Aldrich, St. Louis, MO). Medium was refreshed every 3 days.  Cells 
treated with proliferation medium (PR) were used as controls.   (Generated in the group of 
Everardus J.J. van Zoelen) 
hMSCs differentiation towards chondrocytes 
For chondrogenic differentiation, hMSCs were trypsinized and 2.5x 105  cells pelleted in a 10 
ml round bottom tube (Greiner Bio-One, Monroe, NC) for 10 min at 250xg. Cell pellets were 
subsequently cultured for 21 days in chondrogenic differentiation medium, consisting of 
proliferation medium supplemented with 6.25 μg/ml insulin, 6.25 μg/ml transferrin, 6.25 
ng/ml sodium selenite, 5.35 μg/ml linoleic acid, 400 μg/ml proline, 1 mg/ml sodium 
pyruvate, 10-7 M  dexamethasone, 50 μg/ml sodium L-ascorbate (all obtained from Sigma-
Aldrich, St. Louis, MO) , in the absence (INC) or presence (TF) of 10 ng/ml recombinant 
TGFβ1 , and supplemented with 50 ng/ml GDF5  (TG). Medium was refreshed every 3 days. 
Growth factors were obtained from R&D Systems. (Generated in the group of Everardus J.J. 
van Zoelen) 
Microarray datasets 
In total, 396 RNA samples were obtained from triplicate experiments of all three lineages, 
four biological conditions and each measured at 11 time points (0, 1, 3, 6, 12, 24, 48, 72, 120, 
192 and 288 hours after onset of treatment). RNA was extracted using TRIzol® according to 
the protocol provided by the manufacturer (Invitrogen). For each sample, 5 μg of RNA were 
reverse transcribed into double-stranded cDNA, and used as a template for the preparation of 
biotin-labeled cRNA, as previously described (Vaes, et al., 2006). A total of 10 μg of biotin-
labeled cRNA was hybridized to the Human Genome U133A Array (Affymetrix), after which 
hybridization signals were amplified using a streptavidin–biotin amplification procedure. 
Arrays were hybridized and scanned with a GeneChip G3000 scanner (Affymetrix). Data 
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were quantified using GCOS 1.2 software (Affymetrix). (Generated in the group of Everardus 
J.J. van Zoelen) 
5.2.1.2 Multiple Myeloma 
hMSCs were extracted from the bone marrow of 10 healthy donors, 10 premalignant patients, 
and 10 Multiple Myeloma patients (5 with bone lesion and 5 without bone lesion) was 
performed. Patients with MM were recruited from specialist clinics at the Royal 
Wolverhampton Hospitals NHS Trust and Heart of England NHS Trust (United Kingdom). 
The study received approval from the local ethics committees at South Birmingham, 
Birmingham East, North, and Solihull, and informed written consent was obtained in 
accordance with the Declaration of Helsinki in all cases. Bone marrow aspirates (~1ml) were 
obtained from patients at various stages of disease and mononuclear cells were purified by 
density centrifugation using Lymphoprep (Nycomed, Oslo, Norway). Plasma was collected 
after cell separation and snap frozen at -80°C. Microarray gene expression analysis 
employing Affymetrix ® GeneChip technology was performed using Human Exon 1.0 ST 
Array Gene Chips according to the manufacturer’s suggested protocols. This dataset has been 
generated by Dr. Sarrah Essex (University of Birmingham, UK).  
5.2.1.3 Ageing 
Linkage with ageing cells has been explored using a microarray dataset developed by Wagner 
et al [235], dataset available in GEO, accession number GSE12274 (Affymetrix Human 
Genome U133 Plus 2.0 Array). This represents the transcriptional state of bone marrow 
mesenchymal stem cells from individuals ranging from 21 to 95 years old (4 young age: 21, 
24, 24, 25; 4 middle age: 44, 50, 53, 55 and 4 elderly age: 79, 85, 85, 95 patients).  
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5.2.1.4 RA-OA 
hMSCs were extracted from the bone marrow of 12 rheumatoid arthritis patients and 6 
osteoarthritis patients diagnosed on the basis of characteristic x-ray findings and the absence 
of features suggestive of inflammatory arthritis. Ethical approval for the use of this material 
was given by the local research ethics committee and all patients gave written informed 
consent (LREC reference 5735). Fibroblasts were maintained in medium consisting of 81.3% 
RPMI 1640, 10% FCS, 0.81X MEM non-essential amino acids, 0.81mM sodium 
orthopyruvate, 1.62mM glutamine, 810U/ml penicillin and 81μg/ml streptomycin, at 37°C in 
a humidified 5% CO2 atmosphere. mRNA was extracted from all fibroblasts at passage 5, 
under identical conditions.  Microarray gene expression analysis employing U133 plus 2.0 
Affymetrix® Genechips was performed. This dataset has been generated by Filer A in the 
group of Buckley CD (University of Birmingham, UK).  
5.2.2 Data processing and differential expression analysis 
5.2.2.1 Microarray data processing 
The microarray generated from the differentiation of hMSCs (Human Genome U133A Array) 
and the ageing data (Human Genome U133 Plus 2.0 Array) were normalized using the R 
library rma, which converts CEL files using a robust multi-array average (RMA) expression 
measure with the help of probe sequences. Data were quantile normalised. 
The myeloma data (Human Exon 1.0 ST Array Gene Chips) has been normalized following 
the RMA workflow for Affymetrix Gene ST available in the R library oligo [236]]. Gene 
intensities were calculated using core probeset, which are supported by RefSeq annotation 
and expected to lead to more reliable signal [237]. Data were quantile normalised. 
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5.2.2.2 Identification of statistically significantly expressed genes during differentiation of 
hMSCs towards cartilage, bone and fat cells 
To identify genes that are differentially expressed during differentiation of hMSCs into the 
three lineages, ANOVA analysis has been performed comparing the 10 time points for each 
treatment. The p-values derived from ANOVA analysis have been corrected by performing 
Benjamini-Hochberg multiple correction [137]. Genes differentially expressed were selected 
using a threshold of false discovery rate (FDR) smaller than 5% unless otherwise stated. 
5.2.2.3 Identification of statistically significant differences in diseases and in ageing 
In order to establish a link between the differentiation of hMSCs and abnormal 
microenvironment of Myeloma patients, RA-OA patients and ageing individuals, a 
differential expression analysis has been performed. For this, a t-test was performed to 
address the transcriptional differences: between myeloma patients with and without bone 
lesion, between healthy and myeloma patients. To identify genes that are positively or 
negatively co-regulated with ageing, spearman ranking coefficient and calculated the 
associated p-values by using a bootstrap approach. To identify genes that are significantly 
different between RA-OA patients, a SAM analysis have been performed [186].  
5.2.3 Overview of the modelling strategy  
The overarching objective of this study is to construct regulatory networks underlying normal 
hMSC differentiation and identify abnormal response in ageing and in relevant human 
pathologies. The overview of the analysis strategy is summarized in (Figure 5.1). 
The task of inferring a global gene regulatory network from functional genomics datasets is 
very challenging, mainly because of the relatively small number of samples available 
compared to the number of variables to model. Here, this challenge has been addressed using 
two complementary approaches. In the first approach, initially the gene expression dataset 
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have been simplified using a procedure that identifies a relative small number of clusters of 
highly correlated genes. The average expression profile is then used as a measure of gene 
module transcriptional activity. Different modules are then linked into a directed network 
using time delay ARACNE, a well validated network inference procedure. These high-level 
dynamical models therefore represent the relationship between the transcriptional response of 
a relatively small number of gene modules. From these models, sub-networks have been 
identified, which are linked to key differentiation steps (e.g. the regulation of important 
effector functions) or perturbed in aged or diseased hMSCs (Figure 5.1A). In the second 
complementary approach, the network modularization procedure described in Chapter 4 has 
been applied to directly integrate pathway information (either physical interaction or pathway 
diagrams such as KEGG) with co-transcription in normal cell differentiation and differential 
expression in ageing and diseased hMSCs (Figure 5.1B). Using the results of a RNAi 
screening [45] a separate analysis integrating pathway information, co-transcription and the 
knowledge of genes that when inactivated induce a loss of differentiation have also been 
performed (Figure 5.1C).  
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Figure 5-1. Overview of the analysis strategy.  
This figure shows the overview of the analysis strategy. Panel A shows the inference of high-
level dynamical models representing chondrogenic, adipogenic, and osteogenic 
differentiation from hMSCs.  Panel B represents the network modularization procedure to 
directly identify gene regulatory networks transcriptionally regulated in normal 
differentiation and enriched in genes that are differentially expressed in aged and diseased 
hMSCs. The same approach was also used to integrate osteogenesis differentiation data, with 
siRNA screening and interactions networks (Panel C). The dynamical models were mapped 
to the modules for further characterization (Panel B and Panel C). 
 
5.2.4 Development of high-level dynamical models of hMSC differentiation 
This modelling strategy is based on an initial step aiming at reducing the complexity of the 
transcriptional response to a relatively small number of gene modules, characterized by 
highly correlated gene expression profiles. These modules were identified by performing a 
SOTA clustering [238] using a 90% variability threshold in each cluster.  Once the procedure 
has identified the optimal number of clusters, the average gene expression profiles (cluster 
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centroid) are computed in each module and this is used as the input of the network inference 
procedure Time Delay ARACNE [239].  Time Delay ARACNE computes mutual 
information between pairs of genes at various time shifts and determines the significant 
connections by using a stationary bootstrap [239]. This led to graphical models representing 
the dynamics of cell differentiation towards bone, fat and cartilage cells. The significant 
connections were selected by using a threshold that is expected to lead to 2.5% false positive. 
For this, the parameter standard deviation multiplier is set to 2 (ksd=2) with a time delay set 
to 1 (d=1). Heatmaps representing the average expression profiles of each module in the 
models have been generated. In the time course profile of the module, the first point with a 
minimum of 50% of the change in the expression occurs has been assigned as the earliest 
change. Each module was then annotated for functionally enriched KEGG and GO terms, 
using the web-based tool DAVID [138, 139]. A threshold of 10% FDR was chosen to define 
statistically enriched pathways. 
5.2.5 Identification of modules linked to ageing and diseases in the 
differentiation models 
In order to identify network modules whose activity is affected in ageing and disease, each 
module is tested for enrichment in genes expressed in hMSCs and correlated with age 
(dataset with GEO accession GSE12274) or in genes differentially expressed between 
hMSCs derived from healthy and diseased individuals (datasets derived from MM patients 
and RA-OA patients). This was achieved by applying the GSEA methodology. In this tool, 
first genes are ranked by a metric derived from phenotypic correlation or differential 
expression analysis between experimental conditions (such as t-statistics). Then a score is 
computed for identifying at the top or bottom of the ranked list significant enrichment in sets 
of genes that could be defined by the user [240]. In this analysis, gene modules in the 
differentiation models are used as functional sets and the genes are ranked using t-stats in the 
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disease datasets and correlation coefficient in the ageing dataset. A weighted enrichment 
statistic was chosen to calculate the enrichment score that reflects the degree to which a 
module is overrepresented at the top or bottom of the ranked list. A cut-off of 10% FDR was 
selected to define significantly overrepresented modules in the disease and ageing data. 
5.2.6 Model validation using knowledge databases 
I have tested whether the interactions between the modules in the differentiation models are 
also supported in the literature using a workflow implemented in the commercial knowledge 
managements system Metacore [241] (Figure 5.2). The tool allows identifying enrichment of 
interactions between sets of genes by using all types of interactions (binding, transformation, 
phosphorylation, dephosphorylation, cleavage, covalent modification, transport, catalysis, 
transcriptional regulation) that are included in the database. The modules that are in the 
differentiation models and subsets of modules that are over-represented in ageing or disease 
datasets are used as sets in the tool. The significantly over-connected sets are identified using 
the z-score and p-values (Figure 5.2). The z-scores are computed by comparing the number 
of links between interacting modules (r) with the expected mean value obtained from the 
hypergeometric distribution (obtained by multiplying number of incoming and outgoing links 
between modules and divide by the total number of links in the database) [241]. The p-values 
are also computed using the hypergemoteric distribution [241]. 
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Figure 5-2. Metacore analysis to validate the interactions in the differentiation models, 
figure as published in MetaCore from GeneGo Inc.  
This analysis allows identifying the links between components in the differentiation model 
that are also supported in the literature. The significant interactions between datasets are 
identified using the z-score and associated p-values. The z-scores are computed by comparing 
the number of links between interacting datasets (r) with the expected mean value obtained 
from the hypergeometric distribution (obtained by multiplying number of incoming and 
outgoing links between datasets and divide by the total number of links in the database). 
 
5.2.7 Direct inference of gene sub-networks representing hMSC differentiation 
in the normal physiological process and in ageing and disease  
In addition to mapping the genes that are affected in disease in the differentiation models, the 
novel modularization approach (described in Chapter 4) is applied for the direct identification 
of gene networks linked to hMSCs differentiation in normal individuals, ageing or disease. 
This methodology allows identification of modules, which share multiple properties in large 
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biological networks derived from KEGG and p-p interaction networks extracted from the 
HPRD database (Figure 5.1B). The procedure identifies the borders of the modules by 
maximising a scoring function that integrates node properties (e.g. genes differentially 
expressed in ageing or in myeloma) with edge properties (e.g. gene expression profile 
correlation during the differentiation time course).  
The same method has also been used to identify potential key regulators of osteogenic 
differentiation by integrating the results of an RNAi screening for osteoblast differentiation 
genes [45] (Figure 5.1C). In this case, the nodes of the network were scored by the RNAi 
screening results and the edges were scored by the correlation computed from the osteogenic 
differentiation data. 
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5.3 RESULTS 
5.3.1 Transcriptional changes during differentiation of hMSCs towards bone, 
cartilage and fat cells 
The first step of the analysis strategy (Figure 5.1) is to identify genes differentially expressed 
in hMSCs differentiation. This analysis has lead to 2506, 1673, 1659 significantly 
differentially expressed genes during adipogenic, osteogenic and chondrogenic differentiation 
respectively. These genes were clustered by SOTA analysis in 48 modules in adipogenesis, 
40 modules in osteogenic differentiation and 49 modules in chondrogenic differentiation 
(Appendix Table A.5.1, Table A.5.2, Table A.5.3).  
Functional analysis of individual modules has shown significant functional enrichment in 
several processes, many known to be relevant in hMSC differentiation. In adipocytes 
differentiation, clusters were functionally enriched in PPARG signaling, glutathione 
metabolism, response to oxidative stress, mitochondrion, DNA replication, valine, leucine 
degradation, fatty acid metabolism, cell cycle, regulation of cell proliferation (Table 5.1). 
The modules representing the differential expression during osteogenic differentiation were 
enriched in ECM, Ossification, Wnt signaling, focal adhesion, growth factor activity, 
apoptosis, and skeletal system development (Table 5.2). The modules of the chondrogenic 
differentiation were enriched in regulation of cell proliferation, cell cycle, ECM, growth 
factor activity, inflammatory response, mesenchymal cell differentiation, oxidation reduction, 
Wnt signaling, mitochondrion (Table 5.3).  
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Cluster #  # of 
genes 
Functional Annotation 
C11 125  
1. GOCC mitochondrion [37], (4.78). 3. Response to organic nitrogen [5], (2.2).  4. 
Lipid biosynthetic proc [10], (2.79).  
C12 57  1. GOCC Mitochondrion [10], oxidation reduction [9], KEGG thryptophan [3](2.12).  
C13 82  1. KEGG PPAR signaling [5], (2.42). 2. GOBP lipid homeostasis [4], (2.09).  3.  
C16 34  1.  KEGG Lysosome [6], (4.21).  3. GOBP Embryonic organ dev. [5],  (2.26).   
C19 124  
1. GOBP Resp to oxidative stress [11], (2.66). 3. KEGG Glutathione met [6], (2.29).  4. 
GOBP Protein complex biogenesis [13] , (2.27).  7. GOMF regeneration [6], (1.92). 
11. Regulation of cell proliferation  
C22 28  1. INTERPRO Fibronectin  type 3 [4], (1.35). 2. GOMF TF activity [6], (0.5).   
C27 49  1. KEGG TGFB signaling [4], (1.77).  
C30 104  
1.  GOCC ECM [13], collagen  [5], (3.96). 3. GOMF Integrin binding [5].  4. Protein 
complex binding [8] (1.82).  6.  GOMF Oxidation reduction [8] (0.96).  
C37 137  1. GOBP Cell cycle [26], (13.56)  
C38 138  1. GOBP Cell cycle [31], (15.27) 
C39 20  1. GOBP RNA splicing [3], (1.47).  
C40 15  1. Regulation  of transcription [4], (1.49)  
C41 87  2. GOMF Calcium ion binding [14], (2.44). 3. GOMF Actin binding  [9](2.2).  
C44 138  
1. GOCC Chromosomal part [14], (3.9). 4. KEGG Cell cycle  [11], (2.33). 9. GOBP 
Regulation of cell morphogenesis involved in differentiation  [35 (1.28).  
C5 93  6. GOBP Fatty acid metabolic process [7], (1.6)  
C51 91  2. GOBP DNA replication [11], (3.14). GOMF ATP binding [19]  
C6 108  
1. GOCC mitochondrial part [35], (8.77). 5. GOBO energy derivation by oxidation of 
organic compunds [12], (4.94).  6. Valine, Leucine degradation  [10], Fatty acid met 
[5], (4.46)  
Table 5.1. Functional annotation of the genes in modules identified in the adipocytes 
differentiation  
The functions in bold are statistically significant at 10%FDR. Only modules with enrichment 
are included in this table. 
 
Clusters 
# of 
genes Functional annotation 
C10 56  2. Ossification  [3] , (1).  
C13 15  1. GOCC ECM [4], (1.06).  
C17 19  1. GOBP Response to hormone stimulus [8], (3).  
C20 41  1. GOBP Response to organic substance [10], (2.89). 3. GOBP MAPK [3], (1.36).  
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C21 43  2. KEGG B cell rec signaling pathway [3], (1.81).  
C33 72  1. GOBP cell cycle [25], (14.74).  7. DNA repair [13], (4.03).  
C39 37  1. Ossification [3], (1.47).   
C40 53  1.  GOBP Amino acid activation [9], (5.56). 2. Resp to hypoxia [7], (3.48).  
C44  23  
1. GOBP Apoptosis [6], (2.54). 2. Regulation of cell proliferation [8], GOMF Cytokine 
activity [4] (2.03).  
C45 74  
6. GOCC Adherens junction [6], (1.32).  7. GOMF growth factor activity [6], (1.3). GOBP 
Cell proliferation [6], (1.25).  
C47 56  
1. KEGG Focal adhesion [6],  Wnt signaling [4] (1.56). 2. GOMF Calcium ion binding [10], 
(1.5).  
C50 12  1. GOCC ECM [5], (1.42).  
C51 17  1. GOCC ECM [5], (1.28).  2. GOBP Reg of cell proliferation [4], (1.13).  
C52 36  1. GOCC ECM [11], (3.29).  2. Ossification [4], (2.43). 3. GOBP cell adhesion [7], (1.66).  
C7 78  
1. GOBP regulation of signal transduction [6], (1.66). 2. GOMF Oxidation reduction [8], 
(1.57).  
C8 73  
1. GOCC ECM [18], (6.62). 2. GOBP Inflammatory resp. [9], (2.62). 5. GOCC apoptosis 
[11] (1.7). 7 .GOBP Glutathione met proc  [3], (1.56).  
C9 90  1. GOCC ECM [14], (3.22).  2. GOBP Skeletal sys dev [8] (1.55).  
Table 5.2. Functional annotation of genes in modules identified from the osteogenic 
differentiation data.  
The functions in bold are statistically significant at 10%FDR. Only modules with 
enrichement are included in this table. 
 
Clusters # of genes Functional annotation 
clust #1  33  1. GOCC ECM [9], (2.54). 4. Regulation of cell proliferation [7], (1.31).  
clust #12 57  1. GOMF Enzyme inhibitor activity [5], (1.05).  
clust #13 25  1. GOBP Response to organic substance [6], KEGG ErbB sig pathway [3], (1.75).  
clust #19 47  
1. GOBP Negative reg of cell proliferation [7], (2.41). 2. GOBP Regulation of 
hydrolase activity [5], (1.27).  
clust #2 40  
1. GOCC ECM [6], (2). 3. GOBP Regulation of inflammatory resp [3], (1.54). 4. GOBP 
Mesenchymal cell differentiation [3], (1.2).  
clust #21 14  1. GOBP Regulation of apoptosis [6], (2).  
clust #24 26  1. GOCC ECM [8], (2.14).  
clust #25 36  3.  GOBP Reg of cell proliferation [6], (1.09).  
clust #3 32  
1. ECM [13], (4.4). 2. GOBP Ossification [4], (2.73). 3. GOMF Growth Factor binding 
[4], (2.2).   
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clust #31 99  2. GOCC Focal adhesion [7], (2.55). 3. GOMF Ras GTPase binding [5], (2.27).  
clust #32 39  1. GOBP Oxidation reduction [6], (1.97).  
clust #33 43  
1. GOBP Apoptosis [6], (1.3). 3. KEGG Wnt signaling [3], (1.15). 4. GOCC 
mitochondrion [7], (1).  
clust #35 40  
1. GOBP cell cycle phase [6], (1.73). 2. GOMF ATP binding [10], (1.72).  4. GOBP 
phosphate metabolic process [8], (1.3).  
clust #36 16  1. GOBP cell cycle [4], (1.9).  
clust #37 13  1. GOBP cell cycle [8], (4.41).  
clust #39 30  
1. GOBP Regulation of phosphorylation [6], (2.31). 2. GOMF growth factor activity 
[5], (2.02).  
clust #40 39  
1. GOBP Cell cycle [8], (1.54). 4. GOBP negative regulation of cell differentiation 
[4],(1.21).  
clust #56 45  1. GOCC ECM [11], (2.92). 5. GOMF Calcium ion binding [7], (1.17).  
clust #58 40  1. GOBP Neuron differentiation [4], (1.44).  
clust #7 13  1. GOBP Inflammatory resp [3], (1.9). 2. GOCC ECM [5], (1.61).  
clust #9 13  1. GOCC ECM [5], (1.99).  
Table 5.3. Functional annotation of genes in modules identified from the chondrocytes 
differentiation data.  
The functions in bold are significantly enriched (10%FDR). Only modules with enrichement 
are included in this table. 
 
5.3.2 High level dynamical models of hMSC differentiation 
Osteogenic differentiation model  
The analysis above describes the complexity of the transcriptional response of hMSCs during 
differentiation with a relatively small number of co-ordinately regulated gene clusters 
(modules), each one with a specific functional enrichment profile. In order to develop an 
interpretative model representing the dynamics of cell differentiation, a dynamical modelling 
approach has been applied to a dataset representing the average gene expression profile of 
each module. The inferred model represents a temporal hierarchy of transcriptional profiles 
where the most upstream module (C21) include genes represented in the KEGG receptor 
signaling pathway (NFKBIA, FOS, PIK3CA) that are upregulated as early as 1h post 
143 
 
stimulation (Figure 5.3). The other most upstream module C44 is downregulated 6h after 
stimulation and this module is enriched in genes represented in the gene ontology terms 
regulation of cell proliferation (IL6, CCL2, IL8, KLF11, LIF, ADAMTS1, PLAU, NGF) and 
cytokine activity (IL6, CCL2, IL8, LIF). Modules in the intermediate response are enriched 
in genes belonging to the functional terms growth factor (C45), oxidation reduction (C7), cell 
cycle (C25) and response to hypoxia (C40). Consistent with the timeframe of phenotypic 
differentiation, more downstream modules (C51, C52 and C13) are linked to the gene 
ontology terms  ECM and ossification (FHL2, MMP2, CTGF, IGFBP3).  
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Figure 5-3. The osteogenic differentiation from hMSCs.  
This figure shows the hierarchical models representing the differentiation process towards 
bone cells (Panel A). Each module (node) in the model represents a number of genes that 
share similar expression pattern during the differentiation. The averaged expression pattern of 
genes in each module is represented in Panel B. Data are standardized to represent above 
average values in red and below average values in green. The modules were functionally 
annotated individually using DAVID analysis. The interactions between modules are inferred 
using the time delay ARACNE.    
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Adipocytes differentiation model  
The model representing hMSC differentiation towards adipocytes shows a similar high level 
structure with more upstream modules representing signaling and regulatory pathways and 
more downstream nodes representing effector functions (Figure 5.4, Panel A).  For instance, 
C22 that is upregulated after 12h (Figure 5.4, Panel B) contains the transcription factor 
MYC, the receptors IFNGR1 and IL10RB. The other early modules are functionally enriched 
in DNA replication (C51), ATP binding (C51), oxidative stress response (C19), glutathione 
metabolism (C19), regulation of cell morphogenesis involved in differentiation (C44), and 
cell cycle (C44 and C38). The late components show downregulation of module C30 
enriched in ECM (LOX, COL1A2, TIMP2, LAMB2, COL16A1, SPARC, COL5A2, 
COL5A1, ERBB2IP) and collagen (COL1A2, COL16A1, COL5A2, COL5A1) after 72h and 
upregulation of module C5 enriched in fatty acid metabolism after 120h (ACOX1, ELOVL6, 
MECR, SC5DL, ABCD2, ACSL4, HPGD).  
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Figure 5-4. The hMSCs differentiation towards adipocytes  
This figure shows the hierarchical models representing the differentiation process towards 
adipocytes (Panel A). Each module (node) in the model represents a number of genes that 
share similar expression pattern during the differentiation. The averaged expression pattern of 
genes in each module is represented in Panel B. Data are standardized to represent above 
average values in red and below average values in green. The modules were functionally 
annotated individually using DAVID analysis. The interactions between modules are inferred 
using the time delay ARACNE.    
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Chondrocytes differentiation model  
Similarly to the two previous differentiation models, several signaling components appear at 
the upstream of the model (Figure 5.5, Panel A). The most upstream module represented by 
C39 is enriched in growth factor activity (FGF5, FGF2, DKK1, NRG1, NGF). The average 
expression pattern of this module decreases after 12h (Figure 5.5, Panel B). Other upstream 
nodes such as C40, C19 and C11 also contain cytokines/growth factor receptors (IL1R1, 
IFGR) and signaling components (SMAD3 and STAT1). The intermediate modules are 
enriched in cell cycle, regulation of cell differentiation, enzyme inhibitor activity and ECM. 
The more downstream nodes are enriched in oxidation reduction, ECM and calcium ion 
binding.  As expected, the known markers of chondrocytes appear in downstream modules 
such as in C56 (ACAN) and C3 (COMP). Interestingly, C3 also contains hypertrophic 
cartilage biomarkers such as MMP13 and COL10A1 and this module have increased 
expression pattern overtime. 
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Figure 5-5. The hMSCs differentiation towards chondrocytes.  
This figure shows the hierarchical models representing the differentiation process towards 
chondrocytes (Panel A). Each module (node) in the model represents a number of genes that 
share similar expression pattern during the differentiation. The averaged expression pattern of 
genes in each module is represented in Panel B. Data are standardized to represent above 
average values in red and below average values in green. The modules were functionally 
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annotated individually using DAVID analysis. The interactions between modules are inferred 
using the time delay ARACNE. 
 
5.3.3 The transcriptional state of undifferentiated hMSC identifies model 
components linked to bone fragility in ageing and disease 
The models described above represent a credible sequence of early signaling events followed 
by the activation of effector pathways known to be involved in the differentiation towards 
bone, cartilage or fat. Although these models represent physiological cell differentiation they 
can be used to formulate hypothesis on the mechanisms underlying the degeneration of the 
muscle-skeletal system in ageing and diseases. In order to achieve this objective, each gene 
module is tested for enrichment in genes correlated to age of the donors or in genes 
differentially expressed in relevant disease conditions (e.g. myeloma and arthritis). Using this 
approach, several modules have been detected within the osteogenic, adipogenic and 
chondrogenic differentiation models (Figure 5.6). 
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Figure 5-6. Linking the modules in the differentiation models with diseases and ageing  
This figure shows the components of the adipogenic, osteogenic and chondrogenic 
differentiation (Panel A, Panel B, Panel C respectively) that are enriched with genes 
differentially expressed in disease or in ageing identified by GSEA analysis.   Red and green 
components represent positive and negative correlation with ageing respectively. Purple and 
yellow components represent up and down regulation in MM compared with control. Blue 
components represent upregulation in MM patients with bone lesions vs. MM patients 
without bone lesions. Components marked with a red and green star represent upregulation 
and downregulation in OA patients compared with RA patients respectively.  
 
Age dependent hMSC differentiation modules  
The analysis performed using the GSEA has identified 8 modules that are enriched of genes 
correlated to the age of hMSCs donors. 
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The adipogenesis modules over-represented with the downregulated genes in ageing are functionally 
enriched in genes represented in the GO terms oxidation reduction and mitochondrion, whereas the 
genes that are upregulated during ageing are enriched in genes represented in the GO terms calcium 
ion binding, Wnt signaling, blood vessel development and GTPase regulator activity (Table 5.4). The 
adipogenesis and osteogenesis modules that are overrepresented with upregulated genes during ageing 
have a high degree of overlap (26%). The overlap includes NOTCH2, signaling components such as 
WNT5A, WNT5B, MAP4K5, RAC2, CXCL6, IL4R, FGF2. The overlap is also preserved at 
functional levels as these osteogenesis modules are functionally enriched in Wnt signaling pathway, 
ECM, blood vessel development, GTPase activity (Table 5.4). On the other hand, the modules of 
adipogenesis and osteogenesis models that are overrepresented with upregulated genes during ageing 
have a small overlap with those in the chondrogenesis model. The upregulated genes during ageing 
that are over-represented in chondrogenesis modules are functionally represented in oxidation 
reduction activity and apoptosis.  
 
 
 
Enrichment in the adipogenesis Enrichment in the osteogenesis  Enrichment in chondrogenesis  
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Table 5.4. Functional annotation of genes that are changing during ageing contributing 
to over-representation of modules in differentiation models  
Functions in red are identified from the list of genes that are positively co-regulated with 
ageing, whereas functions in green are identified from the list of genes that are negatively 
coregulated with ageing. First, second and third column represent the functional enrichement 
of ageing-genes over-represented in osteogenesis modules, adipogenesis modules and 
chondrogenesis modules respectively. 
 
MM dependent hMSC differentiation modules  
Patients affected by MM develop bone lesions that can seriously affect quality of life and 
survival (Chapter 1, section 1.3.2 for an overview).  Here, the approach is based on the 
hypothesis that bone lesions are at least in part the result of a defective differentiation 
towards bone and cartilage. Hence, each module is tested in the differentiation models for 
enrichment in genes differentially regulated in MM.  Two different comparisons are 
considered. These are: 1) hMSCs derived from MM patients with bone lesions compared to 
hMSCs derived from MM patients with no bone lesions; 2) hMSCs derived from healthy 
individuals compared to MM patients regardless of their bone lesion status. 
This analysis identified modules in the three differentiation models that were significantly 
enriched in disease genes. The genes enriched in the osteogenesis modules are functionally 
enriched in growth factors, fibroblast growth factor receptor  (FGF5, FGF1, FGF2), regulation of 
apoptosis, GTPase activity, blood vessel development (SEMA5A, ARHGAP22, TGM2, RBPJ, FGF1, 
FGF2, RASA1, PLAU), positive regulation of cell differentiation (LIF, INHBA, BDNF, IL6, KLF10, 
NRG1, FGF2) and cell adhesion  (Table 5.5). The genes enriched in the chondrogenesis modules are 
functionally enriched in actin cytoskeleton, protein complex biogenesis, regulation of apoptosis 
(TUBB2C, SMAD3, STAT10), regulation of cell adhesion (SMAD3, NRG1, THBS1, TPM1, 
CITED2), angiogenesis (VEGFC, THBS1, CXCL12, ANXA2) and regulation of cell migration 
(Table 5.5). The genes in the adipogenesis modules are functionally enriched in glycolysis (LDHA, 
153 
 
ENO2, PFKP, HK1, PGK1), positive regulation of signal transduction, GTPase binding, blood vessel 
development (SHB, VEGFC, RASA1, CYR61, ANXA2) and cell adhesion (Table 5.5).  
Osteogenesis‐MM  Adipogenesis‐MM  Chondrogenesis‐MM  
C1. GOMF growth factor activity 
[10],  
 fibroblast growth factor receptor [3]  
  
 C2. GOCC actin cytoskeleton [10]  
C1. GOCC actin cytoskeleton [13]
 KEGG Glycolysis 
/Gluconeogenesis [5] 
 
C4. Regulation of apoptosis [15]   C6. Regulation of apoptosis [11] 
C5. GOMF GTPase activity [6]  C7. GOMF small GTPase 
regulator activity [10] 
C15. GTPase activity [6] 
C6. GOBP blood vessel development 
[8]  
C23. GOBP Blood vessel dev 
[5] 
C8. GOBP Blood vessel dev [6]
C7. GOBP regulation of cell 
proliferation [17],   
GOBP Positive regulation of cell 
differentiation [7]  
  
C8. GOBP enzyme linked receptor 
protein signaling pathway [12]  
 C10. GOBP enzyme linked receptor 
protein signaling pathway [9] 
C13 GOBP positive regulation of 
signal transduction [6]  
C4. GOBP positive regulation 
of signal transduction [8] 
C27. GOBP positive regulation of 
signal transduction [6]  
C16. GOBP Cell adhesion [9]  C35. GOBP Cell adhesion [7]  C7. GOBP Cell adhesion [6]  
Table 5.5. Functional annotation of genes that are changing in MM contributing to 
over-representation of modules in differentiation models 
 
RA-OA dependent hMSC differentiation modules  
This analysis identified modules only in the osteogenesis models that were significantly 
enriched in RA-OA genes (Figure 5.6). The genes enriched in the osteogenesis modules (C33, 
C8, C20) are functionally with inflammatory response (IL1R, IGF2, THBS1, CD40) and 
transcription factor activity (SOX4, FOXM1, TRIM22).  
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Common osteogenic differentiation modules over-represented in MM, in RA-OA and in 
ageing 
The two upstream modules of the osteogenesis model are over-represented in MM patients 
and in ageing (C45, C47). The subsets of genes contributing to the enrichment of these 
modules are upregulated in MM patient compared with control and these are positively 
coregulated with ageing. Moreover, C47 is also over-represented with genes that are 
upregulated in RA patients compared with OA. As C45 and C47 are downregulated after 12h 
and 24h, the downregulation is required during the normal osteogenic differentiation. 
However, the high expression level of these genes in the bone marrow of ageing individuals, 
MM patients and RA patients points out that these components might potentially contribute 
to the abnormal osteogenic differentiation.  
5.3.4 Knowledge driven validations and construction of gene networks 
controlling hMSC differentiation 
The model described above represent a high level view of the transcriptional response during 
differentiation. By identifying gene modules whose transcription is affected in ageing and 
disease, areas of the differentiation networks that are likely to be important for physiological 
differentiation as well as being crucial for pathogenesis have been identified. Although this 
allows formulation of general hypothesis, it does not provide a tool to identify regulatory 
networks at gene-level resolution. In order to address this challenge knowledge from the 
literature has been integrated into the models. In addition to increase in resolution, this 
approach also allows some degree of model validation. 
To first validate the interaction in the differentiation models using the information available 
in the literature, an analysis has been performed in Metacore that allows identification of 
significantly over-connected interactions between the modules. This analysis has shown that 
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an important proportion of these interactions are significantly supported in the literature. 
More precisely 36%, 30% and 21% of the interactions present respectively in the adipocytes, 
osteogenic and chondrocytes differentiation models are also significantly supported in the 
literature (Table 5.6, Table 5.7, and Table 5.8). Several links between the subset of the 
modules that are over-represented in disease or ageing and the rest of modules are also 
supported in the literature (Table 5.9). 
Set 1 Set 2 Actual p-value z-score
C11 C13 137 1.807E-12 7.833 
C11 C29 148 5.669E-06 4.712 
C12 C38 193 6.046E-12 7.442 
C12 C13 77 3.713E-08 6.126 
C12 C29 90 4.394E-04 3.584 
C13 C29 169 9.086E-09 6.117 
C13 C27 62 2.988E-04 3.776 
C27 C37 102 3.697E-03 2.843 
C29 C30 141 4.761E-06 4.765 
C29 C41 178 4.766E-03 2.706 
C37 C38 460 3.123E-36 13.93 
C39 C51 47 3.992E-03 2.908 
C43 C51 40 1.224E-03 3.387 
C8 C13 55 2.491E-05 4.571 
Table 5.6. Knowledge based validation of interactions in adipocytes differentiation 
model 
The first two columns in the table Set1 and Set2 represent clusters in the differentiation 
model. The third column is the number of connections between genes in Set1 and Set2 that 
are supported in the literature.   
 
Set 1 Set 2 Actual p-value z-score 
C45  C20  56 3.793E-03 2.903 
C45  C20  56 3.793E-03 2.903 
C41  C33  353 2.269E-30 12.77 
C19  C33  77 1.614E-11 7.826 
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C39  C41  173 3.046E-07 5.365 
C45  C44  60 1.233E-04 4.064 
C50  C46  7 4.135E-02 2.172 
C40  C5  19 2.308E-02 2.274 
C41  C8  284 5.240E-09 6.087 
C20  C8  75 1.504E-02 2.31 
C25  C8  42 2.945E-02 2.05 
C41  C9  237 1.552E-04 3.774 
C20  C9  67 2.931E-02 2.015 
Table 5.7. Knowledge based validation of interactions in osteogenic differentiation 
model 
The first two columns in the table Set1 and Set2 represent clusters in the differentiation 
model. The third column is the number of connections between genes in Set1 and Set2 that 
are supported in the literature.   
 
Set 1 Set 2 Actual p-value z-score 
C1  C2  31 6.658E-03 2.768 
C11  C37  14 1.676E-05 5.631 
C19  C21  18 3.341E-03 3.204 
C2  C4  31 8.553E-06 5.163 
C2  C31  71 1.955E-04 3.881 
C2  C56  27 2.160E-04 4.141 
C2  C24  25 1.240E-03 3.51 
C31  C33  67 3.036E-03 2.963 
C4  C42  10 5.734E-05 5.522 
C7  C31  43 6.672E-05 4.355 
C9  C37  15 1.521E-07 7.512 
Table 5.8. Knowledge based validation of interactions in chondrocytes differentiation 
model 
The first two columns in the table Set1 and Set2 represent clusters in the differentiation 
model. The third column is the number of connections between genes in Set1 and Set2 that 
are supported in the literature.   
Model  Set 1  Set 2 Actual p-value z-score 
adipogenesis clust #13 Ageing-C11 72 1.577E-11 7.891
adipogenesis Ageing-C13 Ageing-C11 34 2.604E-07 6.162
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adipogenesis clust #29 Ageing-C11 80 4.010E-05 4.326
adipogenesis clust #38 Ageing-C12 160 8.533E-12 7.468
adipogenesis clust #13 Ageing-C12 57 5.124E-08 6.219
adipogenesis clust #29 Ageing-C12 77 7.359E-06 4.806
adipogenesis Ageing-C13 Ageing-C12 25 3.147E-05 4.864
adipogenesis clust #11 Ageing-C13 88 1.090E-09 6.842
adipogenesis clust #12 Ageing-C13 40 1.294E-05 4.895
adipogenesis clust #29 Ageing-C13 105 8.548E-05 4.053
adipogenesis clust #51 Ageing-C43 32 2.793E-03 3.121
adipogenesis clust #38 MM-C C37 169 3.769E-08 5.823
adipogenesis clust #13 MM-C C44 67 9.268E-04 3.386
chondrogenesis clust #31 C39 MM-C 45 2.912E-04 3.861
chondrogenesis clust #37 C39 MM-C 13 6.222E-04 4.112
chondrogenesis clust #31 C40 MM-C 52 1.814E-03 3.191
chondrogenesis clust #37 C40 MM-C 17 3.173E-03 3.246
osteogenesis  clust #44  MMBL-MMNBL C45 18 3.134E-03 3.232 
osteogenesis clust #44 MM-C C45 29 9.068E-05 4.416
osteogenesis clust #20 MM-C C45 25 7.134E-03 2.78
osteogenesis clust #41 MM-C C39 158 4.836E-09 6.267
osteogenesis clust #41 MM-C C33 166 1.231E-11 7.385
osteogenesis clust #44 Ageing C45 20 3.019E-03 3.214
osteogenesis  clust #33  Ageing C41  87 5.805E-20 11.37 
Table 5.9. Knowledge based validation of interactions in differentiation models 
(adipogenesis, chondrogenesis and osteogenesis) and diseases components 
 
In order to obtain further information on the genes that may be involved in the underlying 
mechanism of differentiation in normal or in disease, the genes in the over-connected key 
upstream and downstream modules were used to construct gene regulatory networks in 
Metacore. These networks revealed several targets that could potentially influence the 
differentiation processes which are also aberrant in ageing or in diseases.  
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Figure 5-7. Gene regulatory networks derived from adipogenesis modules 
These networks are derived from the Metacore analysis using as input the genes in the modules of ad. 
Panel A shows the gene regulatory network constructed using early component (C12) that are 
abnormal in ageing (C43, C44) and late component in the adipogenesis module (C5). This network 
shows that STAT5A is directly regulating several metabolic components and it is downregulated 
during ageing. Panel B shows the gene regulatory network constructed using early components that 
are abnormal in MM patients (C42, C44) and late components in the adipogenesis module (C5, C12, 
C32). This network reveals that small GTPases upstream components that are also abnormal in 
hMSCs of MM patients are interacting with several effector downstream components. 
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Gene regulatory networks identified by integrating knowledge in the adipocyte 
differentiation model 
The gene regulatory networks identified by Metacore analysis from the adipocytes 
differentiation model suggests that the transcription factor STAT5A (gene module C12) may 
be directly regulating several genes encoding for metabolic enzymes represented in the 
downstream gene module C5 (PDK4, ACOX1 and AGT) (Figure 5.8, Panel A).  STAT5A 
transcription is upregulated 24h after the differentiation stimulus (Figure 5.4, Panel B) and it 
is negatively correlated with ageing (Figure 5.9).  
Several small GTPases (RhoA, RhoC, RhoGDI) are in the upstream modules of the adipocyte 
differentiation model (C42, C44) and are interacting with apoptosis genes (CASP1, CASP7), 
calcium binding proteins (S1008A, S1009A, S100B) and catalase (CAT, GCLC), which are 
on the downstream modules  (C5, C32) (Figure 5.8, Panel B). The small GTPases are also 
significantly up-regulated in MM patients compared with control patients (Figure 5.10).  
 
Figure 5-8. Expression pattern of STAT5A in ageing.  
This figure shows the heatmap of STAT5A during ageing. STAT5A is upregulated in young 
individuals (red) and downregulated with ageing. 
 
 
Figure 5-9.  Expression pattern of small GTPases in MM.  
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This figure shows the heatmap of small GTPases in MM patients with and without bone 
lesions and control individuals. These genes are upregulated in MM patients (red) and 
downregulated in control patients (green) 
 
Gene regulatory networks derived from the chondrocytes differentiation modules 
Consistent with several findings, known regulators of chondrogenic differentiation including 
transcription factors SOX9 and TRPS1 are directly connected to several genes in the three 
downstream modules (C2, C3, C57) containing articular and hyperthrophic chondrocytes 
biomarkers (Figure 5.11, Panel B). These modules are also potentially regulated via SMAD3 
activation (in C40), (Figure 5.11, Panel A), which is upregulated in Myeloma patients 
compared with control (Figure 5.12).  
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Figure 5-10. Gene regulatory networks derived from chondrogenesis modules. 
 These networks are derived from the Metacore analysis using as input the genes in the 
modules of chondrogenesis. Panel A shows the gene regulatory network constructed using 
early components that are abnormal in MM and late components of the chondrogenesis 
module (C3). Panel B shows the gene regulatory network constructed using early components 
and late components in the chondrogenic modules (C2, C3, C57). 
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Figure 5-11. Expression profile of SMAD3 in MM. 
This figure shows the heatmap of SMAD3 in MM patients with and without bone lesions and 
control individuals. It shows that SMAD3 is upregulated in MM patients (red) and 
downregulated in control individuals (green). 
 
Gene regulatory networks derived from the osteogenic differentiation modules 
Two potential key players have been identified in the upstream modules that might have an 
influence in the most downstream modules in the osteogenic differentiation model. These are 
RBPJ component of notch signaling (in C39) (Figure 5.13, Panel A), and ETV5 (in C41) 
(Figure 5.13, Panel B), which are downregulated after 12 hour and 24h respectively. 
Interestingly, these two genes have higher expression in myeloma patients with bone lesions 
than patients without bone lesions and control individuals. Therefore, this observation leads 
to the hypothesis that knocking down these genes in MM patients might enhance the 
differentiation towards bone cells. 
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Figure 5-12.  Gene regulatory networks derived from osteogenesis modules  
These networks are derived from the Metacore analysis using as input the genes in the 
modules of db. Panel A shows the gene regulatory network constructed using early 
components that are abnormal in MM and late components of the db modules (C51, C52). 
This network shows that RBP-J is a potential regulator of late components including 
osteocalcin. Panel B shows the gene regulatory network constructed using early components 
and late components in the db modules (C2, C3, C57).This network shows that ERM (ETV-
5) is a potential regulator of late components including MMP2. 
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5.3.5 Identification of gene regulatory networks integrating biological 
knowledge, gene co-expression and disease linkage  
The procedure identified several networks that consist of genes highly co-regulated in the 
normal hMSCs differentiation process and at the same time these are differentially expressed 
in disease or ageing. These modules revealed a number of novel potential targets that may 
play an important role in healthy and pathological scenarios.  
One of the most interesting modules derived from the integration of the osteogenic 
differentiation and myeloma data is significantly enriched in response to hormone stimulus, 
signaling pathways, blood vessel development, regulation of apoptosis, ECM, cell migration, 
ossification and Jak-Stat signaling pathway (Table 5.10). The module revealed that MYC 
plays a central role and it is interacting with several genes that are aberrantly expressed in 
MM patients (Figure 5.14). Overexpression of Myc in hMSCs from healthy patients treated 
with BMP2 has been shown to enhance osteogenic differentiation [38]. Myc is 
downregulated in the MM patients compared with control individuals. Hence, an experiment 
overexpressing Myc in hMSCs derived from MM patients represents an excellent setting to 
test whether it could enhance the osteogenic differentiation in these patients. 
The module with the highest score derived from the integration of ageing and adipocytes 
differentiation datasets is functionally enriched with response to hormone stimulus, 
regulation of apoptosis, TCA cycle, small GTPases mediated signal transduction, adherens 
junction, lipid homeostasis, mitochondrion (Table 5.11). This module contains several 
known factors required for adipogenesis differentiation including PPARG, RXRA and 
CEBPA.  Most of the genes identified connecting several of these genes and RAC1 also 
belongs to upstream module C44 in ad (Figure 5.15). This is consistent with the previously 
identified gene regulatory networks using the hierarchical models and Metacore. In this 
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analysis, several small GTPases have been identified to be  upstream of the adipocytes 
differentiation model and connected with effector functions. 
 
Figure 5-13. Module identified integrating interaction networks, osteogenic dataset, and 
MM patients  
This module has been identified using the novel modularization approach that allows integration of 
interaction networks, osteogenic dataset, and MM dataset (Panel A). It shows that Myc is a hub gene 
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and its expression is down-regulated in hMSCs of MM patients. The genes interacting with Myc are 
also significantly different between MM and control hMSCs (Panel B). 
 
Module enriched from osteogenesis-MM  
GOBP Response to hormone stimulus [19]  
GOBP Blood vessel development [14]  
GOBP Enzyme linked receptor protein signaling pathway [14]  
GOBP Regulation of apoptosis [20]  
GOCC ECM [23]  
GOBP Positive regulation of cell motion [8], GOBP cell migration [11]  
GOBP Response to oxidative stress [6]  
GOBP ossification [5], GOBP osteoblast differentiation [3]  
KEGG Jak-STAT signaling pathway [7]  
 
Table 5.10. Functional annotation of modules identified by integrating interaction 
networks, osteogenic differentiation data and MM 
 
 
Functional annotation of the module from ad-ageing  
GOBP Response to hormone stimulus [11]  
GOMF transcription factor binding [17]  
GOBP Regulation of apoptosis [16]  
KEGG TCA cycle [5]  
GOBP Small GTPases mediated signal transduction [9]  
GOCC adherens junction [7]  
GOBP lipid homeostasis [4]  
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GOCC mitochondrion [14]  
Table 5.11. Functional annotation of modules identified integrating interaction 
networks, adipocytes differentiation data and ageing.  
Functions in bold are significantly enriched (10%FDR). 
 
Figure 5-14. Gene regulatory networks derived from interaction networks, adipocytes 
dataset, and ageing.  
This module has been identified using the novel modularization approach that allows 
integration of interaction networks, adipocytes dataset, and ageing data (Panel A). This panel 
shows that several markers of adipocytes are down-regulated in ageing. This module also 
shows that RAC1 plays a role of a hub connecting several components, which place RAC1 as 
a potential regulator.  
 
5.3.6 Direct integration of RNAi osteoblast differentiation phenotypic screenings 
into network discovery procedure 
Recently, a novel study has reported 54 potential targets that can enhance the osteogenic 
differentiation measured with ALP activity [45]. In order to identify potential regulators of 
these targets, the modularization method described in the previous chapter has been applied. 
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In this application, the node scores are derived from the RNAi screening and the edge scores 
are derived from the correlation between genes in the osteogenic differentiation data.  One 
module has been identified from this analysis (Figure 5.16), which contains several potential 
regulators such as chromatin modifiers SIRT2 and HDAC6, the GTPase HRAS and the 
growth factor receptor EGFR. HRAS is a hub gene in the module and interestingly a previous 
study has reported that MSCs from mouse stimulated with strontium differentiates towards 
bone cells though HRAS signaling pathway and knock-down of HRAS causes reduced ALP 
activity and mineralization. Indeed, EGFR signaling [242] and SIRT2 [243] have been 
reported to reduce the differentiation potential of MSCs from mouse towards bone. The hub 
of the module HRAS has been previously shown to regulate negatively the differentiation of 
mouse derived MSCs induced with strontium [244]. In this study, the authors have reported 
that the knock down of HRAS in these cells has lead to reduced mineralization and ALP 
activity 14 and 21 days after the initiation of differentiation towards bone cells [244]. Hence, 
HRAS might also be an important player in hMSCs and a regulator of the other validated 
targets in the module.   
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Figure 5-15. Module derived from direct integration of RNAi phenotypic screenings and 
normal differentiation of hMSCs.  
Knock-down of genes represented in purple has leaded to enhanced ALP activity [45].  Edges 
represented in red are positively coregulated during the time-course of normal hMSCs 
differentiation, whereas edges represented in green are negatively coregulated in the same 
data. 
 
5.3.7 Linking the siRNA screening and the differentiation model with the disease 
condition leading to bone deformation 
In the siRNA screening study [45], 7 out of the 54 potential targets are also significantly 
different in the osteogenic differentiation timecourse data. The authors have done further 
studies for 12 targets out of 54 by measuring mineralization in which 6 have proven to 
enhance the differentiation towards bone cells. 3 out of these 6 targets are also in our model. 
One of these DUSP6, belonging to the one of the most upstream module C44 (Figure 5.3, 
Panel B), is also significantly upregulated in the MM patients compared with healthy 
individuals (Figure 5.16). Another hit is TBX3 (C13 in the model) and it is significantly 
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upregulated in ageing. Therefore, inhibiting DUSP6 in hMSCs from MM patients and TBX3 
in elderly patients can enhance the differentiation towards octeogenic cells.  
 
Figure 5-16. Expression pattern of DUSP6 in MM patients  
This figure shows the expression pattern of DUSP6 in MM patients with and without bone 
lesions and control individuals. DUSP6 is downregulated in control individuals (green) and 
upregulated in MM patients. 
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5.4 DISCUSSIONS 
5.4.1 Inhibition of Notch leads to enhanced osteogenesis in MM patients with 
bone lesions 
The inferred osteogenesis model lead to the hypothesis that downregulation of RBPJ is 
required during osteogenesis and higher levels of RBPJ is observed in the MM patients with 
bone lesions compared with control individuals. RBPJ is a transcriptional regulator that plays 
a central role in Notch signaling, a signaling pathway involved in cell-cell communication 
that regulates a broad spectrum of cell-fate determinations. The potential role of RBPJ in 
bone formation is supported by the observation that constitutively active Notch has been 
shown to suppress the endochondral bone formation and osteoblastic differentiation [245, 
246]. Moreover, in a recent study the knock down of Notch has been shown to enhance 
osteogenic differentiation from hMSCs, which were collected from Myeloma patients with 
bone lesions [107].  
5.4.2 The role of Myc in the MM patients 
Myc is a hub in the network module obtained by integrating interaction networks, 
osteogenesis and MM datasets. This is consistent with the observation that overexpression of 
Myc in hMSCs from healthy patients treated with the differentiation factor BMP2 has been 
shown to enhance osteogenesis [38]. Interestingly, Myc is downregulated in the MM patients 
compared with control individuals. Hence, an experiment overexpressing Myc in stem cells 
derived from MM patients represents an excellent setting to test whether this could enhance 
the osteogenesis process in these patients. 
The same network locate the gene MAP2K1 in direct connection with MYC. Continuous 
inhibition of MAPK signaling pathway with the specific inhibitor MAP2K1 has been shown 
to promote early osteoblastic differentiation and mineralization [247]. The fact that MM 
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patients have higher level of MAP2K1 compared with control patients suggest that MAP2K1 
might be at least in part responsible of the abnormal osteogenesis capacity in these patients.  
  
173 
 
5.5 Conclusions 
This study allowed constructing the detailed gene regulatory networks describing the 
adipogenesis, osteogenesis and chondrogenesis model. Systems biology approaches have 
been very useful to achieve this task. The inferred models could be used by the community to 
identify potential targets to better understand the normal differentiation process and in disease 
conditions. Indeed, a number of potential testable targets have been identified and these 
might enhance osteogenesis process in multiple myeloma patients with bone lesions and in 
ageing. Further work is required for experimental validations of these targets. In-vitro tests 
followed by animal models represent an excellent potential for the validation of these targets 
and understanding their role in bone formation. 
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 CHAPTER 6: GENERAL DISCUSSION 
 
6.1 A new perspective in understanding muscle wasting in COPD patients 
In this thesis, the effectiveness of systems biology approaches were shown for the integration 
of various sources of information that allowed us to tackle several questions including the 
role of systemic and local inflammation in skeletal muscle wasting in COPD patients. 
Application of such approaches lead to the first model in the community underlying the 
molecular abnormalities in the skeletal muscle of these patients. The work carried out in 
Chapter 2 and Chapter 3 has shown that muscles from COPD patients have a lack of response 
in tissue remodelling and bioenergetic pathways. One possible mechanism for the 
abnormalities observed in COPD muscle has been previously hypothesized to be based on 
systemic inflammation [72]. The work carried out in Chapter 3 has not identified a link 
between the systemic inflammation, and the muscle transcriptional state. Instead, a potential 
epigenetic mechanism that might drive the skeletal muscle wasting in these patients has been 
proposed. Therefore, this analysis has lead to the hypothesis that treatments based on histone 
deacetylase inhibitors might be a potential direction for developing effective drug treatments 
for muscle wasting in COPD. Indeed, a recent study using myotubes from dystrophic mice 
treated with VPA for 24h lead to hypertrophy and decreased apoptosis [248]. Several future 
studies are required to establish the usefulness of this treatment and the safety. Further 
experimental models could be studied to elucidate the effectiveness of such treatments before 
setting up clinical trials. For instance, a smoking mouse model treated with and without VPA 
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and exercise training or a hypoxic mouse model could provide additional experimental 
validation for disease treatment. Various doses and time points should also be studied for the 
optimization of the treatment. Multi-level measurements would be necessary to understand 
aberrant molecular mechanisms and link these with the phenotypic changes and the response 
to treatment. This could include physiological measurements and omics datasets such as 
microarrays, metabolomics and proteomics. The analysis of such data could be carried out as 
inspired by the approaches presented in this thesis using reverse engineering and 
modularization techniques for integration of the various data types. In the case of the animal 
models being successful further clinical studies could be carried out. It would certainly be 
appropriate given the results of this thesis to study epigenetic markers in COPD patients 
before and after drug treatments combined with exercise training, using technologies like 
ChIP-seq. Sequencing technologies would be an excellent tool to identify specific genetic 
traits that lead to muscle wasting in COPD patients as only 40% suffer from it. This strategy 
might even allow the identification of sub-patient groups and predicting the likelihood of 
suffering from muscle wasting. Such clinical trials would require the collaboration between 
clinicians, wet lab scientists and systems biologists. Collaboration efforts from different 
backgrounds are absolutely crucial for the developments of effective treatments. 
6.2 Future work and challenges in using stem cells for degenerative diseases 
6.2.1 From normal osteogenic and chondrogenic differentiation models to bone 
and cartilage deformation 
In this thesis, models highlighting precise molecular changes during the differentiation 
process were developed from normal hMSCs using integrative systems biology approaches. 
Constructing such models from disease patients associated with bone lesions and cartilage 
differentiation aids allows understanding the disease mechanisms and identifies potential key 
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players. As such data is currently not available, generating time-course microarrays from 
hMSCs of these patients represent an excellent future experimental setting. For the 
constructions of the models, the same approach presented in Chapter 5 could be performed. 
Potential key players that play a role during normal osteogenesis in vitro were identified and 
these seem to be abnormal in ageing and MM bone marrow. Validation of these targets in 
vitro could lead to identify targets that could enhance differentiation in disease condition. For 
this, overexpression of Myc, knock-down of DUSP6 in cells collected from MM patients and 
knock down of TBX3 in cells collected from individuals representing young and old 
individuals represent a possible experimental setting. If these experiments can indeed lead to 
enhanced osteogenesis process in these patients, it would be a great opportunity to carry out 
time-course microarrays. This will allow understanding the response to these treatments in 
the process of differentiation in these patients. 
 
6.2.2 From in-vitro studies towards effective treatments in diseases with bone 
lesions or bone loss 
If the key players that are hypothesized to enhance osteogenic differentiation process in this 
thesis are successfully validated in-vitro, animal models would represent an excellent setting 
to investigate the potential of these targets and pave the way for future clinical trials. Indeed, 
a recent study has shown that inhibition of Notch signaling has enhanced the osteogenesis 
process from MM patients in vitro [107]. However, inhibition of Notch signaling through 
injection with DAPT in MM mice had no remarkable effect on tumour burden in the bone, on 
the number of the osteoblasts and bone formation. The authors concluded that for a more 
effective treatment other anti-MM drugs could be combined with Notch inhibitors. These 
experiments are encouraging and the models developed in this thesis could be used in a 
similar manner for further validations in vitro from patients and in animal models. The 
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approaches I have used could also shed light on sustained bone loss in ageing or in 
osteoporosis patients. However, there is a lack of transcriptomics datasets and studies from 
the bone marrow microenvironment of osteoporosis patients. Studies investigating the 
osteogenesis process in these patients and capturing molecular changes during the 
differentiation process would be extremely useful for the community.  
For clinical trials, there could be several options including direct delivery of the therapeutic 
gene, or hMSCs cell based delivery combined with gene targeting. There have been several 
encouraging clinical trials for stimulating bone formation using hMSCs treatment. The 
allogenic transplantation of bone marrow derived MSCs to children with severe osteogenesis 
imperfecta has shown that MSCs can engraft after transplantation and improvements on 
growth velocity were also observed [249]. Although cell based therapy using hMSCs has 
very important potential for degenerative diseases and several encouraging phase I and phase 
II clinical trials were carried out [250], there are still concerns in the safety of their usage.  
6.2.3 The challenges using hMSC cell based therapy 
Some of the major concerns are based on long-term culture and genetic manipulation of 
hMSC cells as this might result in a malignant transformation [251]. In the usage of 
autologous hMSCs treatment for disease or ageing, there is a potential issue with the loss of 
function of the cells. For the allogenic transfer the cells could be harvested from healthy 
donors, but the immunomodulatory effects needs to be taken into account. Long term follow 
up of patients are also necessary to understand the future implications of the treatments. 
Safety measures should be well established before these treatments would be made available. 
For the use of allogenic stem cells, stem cells banks represent an important potential. 
However, the limited number of cells to isolate from the bone marrow coupled with the loss 
of cells after storage makes this option undesirable. Adipose derived stem cells represent a 
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good alternative to bone marrow derived stem cells as the sample collection is less invasive, 
and a larger number of cells could be collected [252]. Several studies have been investigating 
the differences between adipose derived and bone marrow derived stem cells [253, 254]. 
Although adipose derived stem cells can also differentiate towards bone and cartilage, the 
differentiation is less effective compared with bone marrow derived stem cells [253, 254]. 
More research is required in this field to enhance the differentiation of adipose derived stem 
cells and take advantage of these features.  
6.3 Cutting edge translational medicine and systems biology 
This thesis demonstrates the effectiveness of systems biology approaches for studying 
complex human diseases. A number of independent study cases that are associated with 
musculoskeletal disorders have been studied. The main aim was to identify molecular 
mechanisms underlying the abnormalities observed in various components of the 
musculoskeletal system by using systems biology approaches. Understanding disease 
mechanisms is crucial for the development of effective treatments. Indeed, in recent years 
with the development of the genome-wide analysis tools, translational medicine has been a 
very active research area. The ultimate aim is to elucidate molecular mechanisms underlying 
complex diseases for the identification of biomarkers, patient classification, development of 
effective treatments, risk assessment of treatments, and prediction of disease progression. 
Application and development of system biology approaches are crucial to address these 
challenges by providing mechanistic models, which would allow simulation of pathological 
processes and predict the response to various interventions. Advances in this field will lead to 
optimized treatments specific to each individual. 
Currently, several projects are funded for development of personalized medicine. For 
instance, the Virtual Physiological Human initiative (VPH-I) is aiming at developing patient 
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specific models for various diseases by using a multi-level integrative approach [255]. The 
initiative consists of a number of projects and relies on collaborative multi-disciplinary 
efforts involving clinicians, scientists from different backgrounds and industry partners. In 
the context of respiratory diseases, the project AIRPROM is aiming to developing patient-
specific models to predict the impact on the airways in response to various changes occurring 
at the gene, cell or tissue level. To achieve this ambitious goal, they are developing a systems 
biology framework, which will allow integrating genomics, transcriptomics, proteomics, 
physiological measurements and imaging data from asthma patients.  The integration of 
multi-level datasets is key for the success of this type of projects and the development of 
patient-specific medicine. With the development of next generation sequencing, more 
information could be measured including individual DNA sequences (SNPs etc) and more 
detailed RNA species including miRNAs and other small RNA species [256]. Data 
generation using these new technologies has until recently been very costly, however it is 
becoming more affordable. Certainly in the near future more studies will take advantage of 
these technologies. To tackle the challenge of analysing such vast amount of data of various 
types, development of new platforms (software), frameworks and integrative analysis 
strategies are required.  Platforms with graphical user interface (GUI) are especially 
important as it provides tools for a broad range of users. There are publicly and commercially 
available tools such as Taverna [257] and BioXM [221] that allows integration of pipelines of 
analysis strategies, which could be then used by others. In recent years, efforts have also been 
made to integrate data analysis strategies into these tools. For instance, the strategy presented 
in chapter 2 and chapter 3 based on high level pathway analysis and the reverse engineering 
approach for integrative analysis is available in BioXM [221].  Although the novel 
modularization approach presented in chapter 4 is not yet integrated in these tools, a GUI 
implementation would provide access for an additional user base.  
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Supplementary Material Chapter 2 
PC KEGG 
SH 
mean TH mean diff 
Functional 
Group 
PC1 Focal adhesion 1.53 -3.02 4.55 
tissue 
remodeling 
PC1 Pyruvate metabolism 1.82 -2.35 4.17 Metabolism 
PC1 Glycolysis / Gluconeogenesis 1.44 -2.54 3.98 Metabolism 
PC1 Insulin signaling pathway 1.40 -2.29 3.69 Signaling 
PC1 Adipocytokine signaling pathway -1.39 2.17 3.56 Inflammation 
PC1 Prostate cancer 0.76 -2.66 3.43 Signaling 
PC1 ECM-receptor interaction -1.77 1.56 3.33 ECM 
PC1 Alanine and aspartate metabolism 1.23 -2.08 3.31 Metabolism 
PC1 
Cytokine-cytokine receptor 
interaction 0.83 -2.42 3.25 Inflammation 
PC1 Wnt signaling pathway 1.34 -1.91 3.25 Signaling 
PC1 Fatty acid metabolism 1.52 -1.72 3.24 Metabolism 
PC1 Chronic myeloid leukemia 0.85 -2.30 3.15 
PC1 Melanoma 0.63 -2.51 3.14 Signaling 
PC1 
Valine, leucine and isoleucine 
biosynthesis 1.25 -1.77 3.02 Biosynthesis 
PC1 Ribosome 1.86 -1.16 3.02 
PC1 MAPK signaling pathway 1.08 -1.89 2.97 Inflammation 
PC1 ErbB signaling pathway 0.64 -2.32 2.97 
tissue 
remodeling 
PC1 GnRH signaling pathway 0.92 -2.01 2.93 
tissue 
remodeling 
PC1 Renal cell carcinoma 0.91 -1.99 2.91 
PC1 Propanoate metabolism 1.04 -1.84 2.88 Metabolism 
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PC1 
Complement and coagulation 
cascades 0.90 -1.98 2.88 
PC1 Pancreatic cancer 1.09 -1.79 2.88 Signaling 
PC1 Colorectal cancer 0.72 -2.09 2.81 
PC1 
Phosphatidylinositol signaling 
system 0.80 -1.92 2.72 Signaling 
PC1 
Nicotinate and nicotinamide 
metabolism -0.22 2.47 2.69 Metabolism 
PC1 B cell receptor signaling pathway 1.00 -1.68 2.68 Inflammation 
PC1 Glioma 0.56 -2.12 2.67 
PC1 
Natural killer cell mediated 
cytotoxicity 0.79 -1.84 2.64 
PC1 Notch signaling pathway 1.15 -1.47 2.62 Signaling 
PC1 T cell receptor signaling pathway 0.90 -1.59 2.49 Inflammation 
PC1 Toll-like receptor signaling pathway 0.84 -1.62 2.46 Signaling 
PC1 Type II diabetes mellitus 0.37 -2.09 2.46 
PC1 Melanogenesis 0.64 -1.80 2.44 
PC1 Long-term potentiation 0.83 -1.55 2.38 
PC1 VEGF signaling pathway 0.70 -1.62 2.33 Signaling 
PC1 Jak-STAT signaling pathway 0.61 -1.72 2.32 Inflammation 
PC1 Small cell lung cancer 1.12 -1.20 2.32 
PC1 
1- and 2-Methylnaphthalene 
degradation 0.69 -1.59 2.28 
PC1 Acute myeloid leukemia 0.64 -1.64 2.28 
PC1 mTOR signaling pathway 0.45 -1.82 2.27 Signaling 
PC1 
SNARE interactions in vesicular 
transport 0.61 -1.66 2.27 
PC1 Gap junction 1.08 -1.16 2.24 
tissue 
remodeling 
PC1 
Benzoate degradation via CoA 
ligation 1.03 -1.19 2.22 
PC1 Long-term depression 0.84 -1.38 2.22 
PC1 Glycerophospholipid metabolism 0.63 -1.55 2.18 Metabolism 
PC1 Fc epsilon RI signaling pathway 0.60 -1.54 2.14 Signaling 
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PC1 Aminoacyl-tRNA biosynthesis 1.07 -1.04 2.12 Biosynthesis 
PC1 Butanoate metabolism 0.90 -1.19 2.09 Metabolism 
PC1 Bladder cancer 0.30 -1.76 2.05 Signaling 
PC1 TGF-beta signaling pathway -0.52 -2.56 2.04 Signaling 
PC1 Arginine and proline metabolism 0.19 -1.78 1.97 Metabolism 
PC1 Bile acid biosynthesis 0.54 -1.41 1.95 Biosynthesis 
PC1 Non-small cell lung cancer 0.70 -1.21 1.91 
PC1 Endometrial cancer 0.90 -1.00 1.91 
PC1 
Porphyrin and chlorophyll 
metabolism 1.12 -0.73 1.85 Metabolism 
PC1 Maturity onset diabetes of the young -0.89 0.94 1.83 
PC1 Alkaloid biosynthesis II 0.72 -1.06 1.78 Biosynthesis 
PC1 3-Chloroacrylic acid degradation 0.44 -1.33 1.78 
PC1 Cysteine metabolism 0.96 -0.75 1.71 Metabolism 
PC1 Huntington's disease 0.25 -1.18 1.43 
PC1 
Glyoxylate and dicarboxylate 
metabolism 0.51 -0.89 1.40 Metabolism 
PC1 Taste transduction 0.44 -0.96 1.40 
PC1 
Pentose and glucuronate 
interconversions 0.68 -0.63 1.31 
PC1 Glutamate metabolism 0.33 -0.97 1.29 Metabolism 
PC1 Galactose metabolism -1.16 0.03 1.19 Metabolism 
PC1 ABC transporters - General 0.47 -0.71 1.18 
PC1 Biosynthesis of steroids -0.11 0.94 1.05 Biosynthesis 
PC1 Parkinson's disease -0.58 0.45 1.03 
PC2 Tight junction -0.61 2.26 2.88 
tissure 
remodeling 
PC2 Tyrosine metabolism 1.05 -1.74 2.79 Metabolism 
PC2 p53 signaling pathway 0.62 -1.81 2.43 Signaling 
PC2 Ribosome 0.34 2.43 2.09 
PC2 Phenylalanine metabolism -0.86 1.22 2.08 Metabolism 
PC2 Glioma -0.42 1.30 1.72 Signaling 
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PC2 Histidine metabolism 0.83 -0.75 1.58 Metabolism 
PC2 
Urea cycle and metabolism of amino 
groups -0.02 1.48 1.51 Metabolism 
PC2 Fructose and mannose metabolism -0.29 1.14 1.43 Metabolism 
PC2 Endometrial cancer -0.09 1.23 1.33 
PC2 Hedgehog signaling pathway 0.30 -0.95 1.25 Signaling 
Table A2.1. This table shows all pathways which has a difference of >=1 between 
sedentary healthy and trained healthy individuals (fdr<10%) using the dataset 
generated by Radom-Azik. 
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PCs Kegg 
SH 
mean 
TH 
mean diff Groups 
PC1 Cell Communication  -1.76 3.92 5.68 
PC1 ECM-receptor interaction  -1.71 3.89 5.60 ECM 
PC1 Focal adhesion  -2.82 1.86 4.67 
tissue 
remodeling 
PC1 Small cell lung cancer  -1.21 2.79 4.00 
PC1 Pancreatic cancer  -1.71 1.09 2.81 Signaling 
PC1 Cell adhesion molecules (CAMs)  -1.06 1.62 2.68 
PC1 TGF-beta signaling pathway  -1.02 1.57 2.59 Signaling 
PC1 Axon guidance  -1.24 1.08 2.33 
PC1 
Pathogenic Escherichia coli infection - 
EHEC  -0.83 1.37 2.19 
PC1 
Pathogenic Escherichia coli infection - 
EPEC  -0.83 1.37 2.19 
PC1 Natural killer cell mediated cytotoxicity  -0.82 1.15 1.97 
PC1 Type I diabetes mellitus  -0.50 1.19 1.69 
PC1 PPAR signaling pathway  1.77 0.11 1.66 Signaling 
PC1 Inositol phosphate metabolism  1.10 -0.56 1.65 metabolism 
PC1 Benzoate degradation via CoA ligation  1.00 -0.65 1.65 
PC1 Nitrogen metabolism  0.29 -1.33 1.62 metabolism 
PC1 Renal cell carcinoma  1.30 -0.31 1.60 
PC1 Prion disease  0.46 -1.06 1.52 
PC1 Endometrial cancer  -0.40 1.09 1.49 
PC1 Taste transduction  -0.86 0.61 1.47 
PC1 T cell receptor signaling pathway  -1.01 0.34 1.34 Signaling 
PC1 Phosphatidylinositol signaling system  1.09 -0.23 1.32 
PC1 Oxidative phosphorylation  -0.48 0.78 1.25 
PC1 Complement and coagulation cascades  0.96 -0.28 1.24 
PC1 Pyrimidine metabolism  0.31 -0.91 1.22 metabolism 
PC1 Gap junction  -0.19 0.94 1.13 
tissue 
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remodeling 
PC1 Huntington's disease  0.79 -0.29 1.09 
PC1 Carbon fixation  -0.27 0.77 1.04 
PC1 
SNARE interactions in vesicular 
transport  0.71 -0.30 1.01 
PC2 Focal adhesion  0.55 -4.20 4.75 
tissue 
remodeling 
PC2 Leukocyte transendothelial migration  1.30 -1.89 3.19 
PC2 Adherens junction  -1.15 1.28 2.43 Signaling 
PC2 MAPK signaling pathway  -1.54 0.87 2.41 Signaling 
PC2 Bladder cancer  -1.66 0.43 2.09 Signaling 
PC2 mTOR signaling pathway  -1.21 0.85 2.06 Signaling 
PC2 Neuroactive ligand-receptor interaction  0.81 -1.03 1.84 
PC2 Prostate cancer  0.00 -1.81 1.81 Signaling 
PC2 Melanoma  0.16 -1.58 1.74 
PC2 Regulation of actin cytoskeleton  -1.13 0.56 1.69 
tissue 
remodeling 
PC2 Gap junction  -0.58 1.07 1.65 
tissue 
remodeling 
PC2 p53 signaling pathway  0.43 -1.20 1.63 Signaling 
PC2 Non-small cell lung cancer  0.65 -0.92 1.57 
PC2 B cell receptor signaling pathway  0.62 -0.92 1.54 
PC2 Axon guidance  0.08 -1.36 1.44 
PC2 Long-term depression  0.23 -1.13 1.37 
PC2 Colorectal cancer  -1.00 0.31 1.32 Signaling 
PC2 Glioma  0.42 -0.85 1.27 
PC2 Acute myeloid leukemia  0.66 -0.60 1.26 
PC2 Phosphatidylinositol signaling system  -0.36 0.89 1.25 Signaling 
PC2 Chronic myeloid leukemia  -0.44 0.81 1.25 
PC2 PPAR signaling pathway  -0.34 0.83 1.16 Signaling 
PC2 Dorso-ventral axis formation  -0.37 0.64 1.01 
Table A2.2: This table shows all pathways which has a difference of >=1 between 
sedentary and trained healthy individuals (fdr<10%) using the new dataset. 
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PC KEGG pathway SD mean TD mean diff Group 
PC1 Small cell lung cancer 1.62 -1.55 3.17  
PC1 
Cytokine-cytokine receptor 
interaction 1.56 0.04 1.52 inflammation 
PC1 
Glycosylphosphatidylinositol(GPI)-
anchor biosynthesis 0.56 -0.45 1.01 metabolism 
PC2 MAPK signaling pathway 0.64 -1.88 2.52 inflammation 
PC2 Jak-STAT signaling pathway -0.72 1.33 2.05 inflammation 
PC2 Prostate cancer 0.56 -1.32 1.89 Signaling 
PC2 
Cytokine-cytokine receptor 
interaction 0.54 -1.27 1.81 inflammation 
PC2 
SNARE interactions in vesicular 
transport -0.55 1.18 1.73  
PC2 mTOR signaling pathway -0.72 0.97 1.69 inflammation 
PC2 Glycerophospholipid metabolism -0.29 1.01 1.30 metabolism 
PC2 Colorectal cancer -0.35 0.94 1.30 Signaling 
PC2 T cell receptor signaling pathway -0.37 0.80 1.17 inflammation 
Table A2.3. This table shows all pathways which has a difference of >=1 between 
sedentary COPD and trained COPD patients ( fdr<10%) using the dataset generated by 
Radom-Azik. 
 
PCs Kegg SD mean TD mean Groups 
PC1 Aminosugars metabolism  -0.45 0.56
Metabolis
m 
PC1 Ribosome  -0.36 0.84
PC2 
Fructose and mannose 
metabolism  0.34 -0.96
Metabolis
m 
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Table A2.4. This table shows all pathways which has a difference of >=1 between 
sedentary and trained disease individuals (fdr<10%) using our dataset. 
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Figure A4.1. Module 2 derived from the modularization procedure. 
Purple nodes represent putative targets of RhoE and edges in red represent positive co-
regulation of genes in the CAM dataset, whereas green edges represent negative co-
regulation. 
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Clusters  Genes  
C10 
HTRA1, NBL1, CTSK, FBLN2, SERPINF1, CRLF1, DDIT4, C1orf54, SEPP1, SUSD5, 
LGMN, PDZRN3, COL8A2, RGS3, C2orf28, DYNC1I1, CSRP2, RETSAT, FYN, CLMN, 
PPP1CB, COPZ2, IFI6, COX7A1, GLT25D2, WIPI1, RGL1, ABCC5, CLTCL1, CREG1, 
PITX2, LUM, GPNMB, GJA1, LRRN3, ZNF532, SATB2, GNG11, FDXR, HHLA3, 
SULT1A1, CUTC, ZNF302, TMEM135, ARL4A, ZMAT3, ARHGAP5, TMEM45A, PHYH, 
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TM2D1, PTPRG, STK38L, TMEM168, PTPN13, IFI44, CCNB1IP1 
C13 
SCRG1, ASPN, SGCD, CA2, LRRC17, CSTA, CD200, RCAN1, USP46, KAL1, DDR2, 
NRIP1, TBX3, SDC2 
C16 
STMN2, NINJ2, IBSP, MXRA5, MGP, ALPL, MAFB, IDI1, TRIM2, HOMER2, SNCAIP, 
HAS1, EDNRA, MSX1, FADS2, ME1, FAM46A, POP5, PREPL, MDFI, ATP1B1, BAG2, 
PMEPA1 
C17 
FADS1, HEY1, SOCS2, WFDC1, CHRDL1, COL3A1, HMGCS1, A2M, AACS, KCNE4, 
RAP2A, ALDH1B1, SQLE, SPAG9, OCA2, GREM2, LIN7A, FLRT3, ATP6V1G1 
C18 
DCN, CCDC68, MIOS, IFNGR1, CRISPLD2, FOXO1, GPC4, FAIM, MPZL1, GPX7, 
C4orf18, MBNL2, CLN5, ANTXR1, CHN1, MAP3K7IP2, PON2, GBP1, RHOQ, PLSCR1, 
PTPLA, SLC2A10, CTNNB1, SAP30, OXR1, ZNF22, SNX2, ACSL3, SGCE, BAX 
C20 
HIP1, CRYAB, AMPH, PIK3R1, ACSL1, TXNIP, DLX5, FKBP5, TRIM22, IL1R1, COPS8, 
SNAI2, IL6ST, FOXO3, FHL1, PRKAG2, ID1, GSR, RBMS3, TWSG1, RGS2, GTF2I, 
KCTD12, CALD1, EPS8, GPR176, TMEM50B, ADAM10, RDX, SH3BGRL, NNT, PXMP3, 
THBS1, GADD45B, CD46, KPNA3, RNF146, TSPAN3, TRAM1, PCYOX1, AKIRIN1, 
HMGB3L1 
C21 
NFKBIA, FOS, ZFP36, KLF7, SCARB2, CLIC4, C19orf6, UTRN, CALU, ERLIN1, 
PHACTR2, LMAN1, EML4, HP1BP3, EDIL3, TMED2, VAMP3, PRRX1, YIPF5, SYPL1, 
UBXN4, LOX, AGPS, FERMT2, CAPRIN1, RNFT1, PTPN12, GNAS, FAS, ACTR2, 
C6orf62, GDE1, ENSG00000185389, SCYL2, GRAMD3, SRGN, SEC11A, OSMR, TMCO3, 
PRKAR1A, ENSG00000213002, RAB23, PIK3CA, NMD3, CLDND1 
C25 
DUSP5, PMAIP1, SPRY4, KLF6, BCAT1, EPRS, PRNP, DCBLD2, ARF6, ZNF281, 
HIST1H4C, SSR3 
C33 
WHSC1, FANCI, H2AFZ, ZWINT, NCAPH, TUBB2C, MELK, SNRPB, CSE1L, TYMS, 
TUBG1, UBE2C, TK1, BUB1B, SLC25A5, CCDC99, HJURP, KIF2C, KIAA0101, KIF4A, 
RFC5, NCAPG, TUBA1C, DDX39, ASF1B, TUBA1B, TRIP13, DBF4, AURKB, LRRC59, 
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SHCBP1, TPX2, DEF8, TACC3, TTK, KDELR3, KIF15, FOXM1, KIF18A, MAD2L1, 
TMEM194A, H2AFX, LMNB2, CENPE, MKI67, RACGAP1, BARD1, ESPL1, ECT2, 
CCDC109B, RNASEH2A, HMGB2, ACOT7, CENPM, CENPI, SMC2, FGFR1OP, KIF11, 
EIF5A, NCAPG2, TAF5, KIF18B, KIF14, ACTL6A, RPA1, LMNB1, VANGL1, SOAT1, 
PSIP1, DHFR, NEIL3, ITGB3BP 
C39 
LYPD1, TUFT1, PSPH, RND3, DACT1, LRRC8D, ANKRD57, AMIGO2, CAMTA2, 
GPR177, SC65, UPP1, EML1, MRPS10, RBPJ, TULP4, C9orf91, PDGFC, INTS7, FANCL, 
LMO4, RABGGTB, KLF10, CEP170, COQ10B, ZCCHC8, LIMS1, AMMECR1, GALNT3, 
TMEM131, APOLD1, MOSPD1, CCDC59, PYROXD1, SP3, RBM16, EFHA1 
C40 
DUSP14, MARS, SLC1A4, SHMT2, LONP1, WARS, P4HA1, SLC3A2, GARS, YARS, 
TARS, EIF4EBP1, TRIB3, PHGDH, GDF15, ASNS, SLC7A5, PLAT, TFRC, CTH, SARS, 
G0S2, NARS, CBS, VLDLR, PCK2, FOXD1, AARS, CARS, CEBPG, HSPA9, SLC31A1, 
VEGFA, MOCOS, PLOD2, SLC7A11, GPR1, FHOD3, CHAC1, GOT1, MTHFD2, IER5, 
LEPRE1, TPBG, BCL10, SDC1, NUCB2, KDSR, CAP2, CSGALNACT1, BNIP3, LY96, 
HERPUD1 
C45 
NRG1, LAMC2, LPCAT4, DOK5, DNMBP, PTPRK, AHNAK2, ENO2, FLNC, BDNF, PLK2, 
RAGE, MAFF, KRT16, KRT34, DVL1, SMURF2, ARHGAP22, RGS20, INHBA, TBC1D2, 
SDC4, Mar-03, PLXNA1, GPRC5A, RABGEF1, TRIB1, DOK1, TEAD4, HBEGF, TACC2, 
ABL1, DGKI, NMNAT2, MGC4294, SH2B3, FHOD1, PTHLH, SH2D4A, FGF2, LGR4, 
ELOVL6, CDYL, KRT33B, TNFSF9, FADD, LARP6, CD55, CDCP1, SPTAN1, LDB2, 
SEC16A, TCIRG1, HGS, KIAA1644, DGCR8, LMNA, GALE, SLC14A1, DCI, ZNF365, 
ATF3, ZFPM2, KIAA0802, C10orf72, IL4R, CDC42BPB, MAD1L1, CLIP2, CXCL6, ESM1, 
PER3, AFAP1, CARM1, SF3A2 
C46 
PLP2, RGS10, RRAS2, PHLDA1, SERPINE2, ASAP2, ADAM12, GSTO1, KRT7, MICAL2, 
AXL, SLC20A1, EFHD2, SERPINE1, NT5E, SLC16A2, PHLDA2, AEBP1, WNT5A, PKM2, 
NTM, BLM, DRAP1, UGDH, MSN, SPP1, ATP6V0E2, FAM62A, DEK, MFAP2, NMT2, 
ARSJ, NMB, ERCC6, ERCC6L, CHIC2, MGAM, KIF22, HMGA1, MEX3D 
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C47 
PRKCA, SEMA5A, C21orf7, CALB2, KCNN4, COL5A3, OPCML, PLAUR, GABBR2, 
MALL, TMEM158, ALDH1A3, TM4SF1, MEST, RGS4, KRT19, FJX1, ITGA3, TNFAIP3, 
MLPH, HMGA2, CTNNAL1, PORCN, AK5, S100A2, ITPR3, LRP8, LPXN, CA12, CCND1, 
FGF5, CAMK1, HPCAL1, NEK7, CDT1, ARHGAP29, DPYSL3, PRSS3, ANXA10, BCAR3, 
PKIA, EIF6, CDA, SERPINB2, EXO1, FGF1, RAC2, C11orf41, KRT81, PLCXD1, TGM2, 
DCTPP1, GPR126, SIK1, ZYX, INHBB 
C5 
SNED1, PC, RFTN1, C3, RABGAP1, POM121L9P, PISD, HSPB7, ABCC3, PGM1, STAT6, 
GSTT1, PTGIS, ST5, B4GALT5, RARRES3, HDAC5, FCGRT, C1RL, ADARB1, CCDC69, 
AKAP12, UBE2L6, OLFML2A, TENC1, PPL, CLEC3B, LXN 
C50 
S100A10, HEG1, TIMP3, CD44, CHI3L1, SYNJ2, LOXL2, TRIOBP, FXYD5, UGCG, FZD7, 
TJP2 
C51 
MMP2, CALHM2, QSOX1, SPOCK1, FHL2, STAT1, CDH13, BST1, DSP, NID2, MAP4K4, 
C5orf30, PRKCDBP, IGF2BP2, CBR3, ARNT2, ZNF217 
C52 
MMP2, S100A10, HEG1, TIMP3, IGFBP3, CD44, CHI3L1, CALHM2, QSOX1, SYNJ2, 
SPOCK1, FHL2, LOXL2, STAT1, TRIOBP, CDH13, FXYD5, BST1, DSP, UGCG, NID2, 
MAP4K4, FZD7, C5orf30, MYO1B, CD9, PRKCDBP, IGF2BP2, CBR3, C6orf145, TJP2, 
ARNT2, TGIF1, CTGF, FAP, ZNF217 
C6 
MXI1, TGFB2, MYO6, BCL6, METTL7A, SAMHD1, AOX1, IMPA2, C1orf63, CEBPD, 
ABCA8, RCAN2, MAP3K5, RNASE4, SORBS2, FBXO42, CFLAR, SSB, ZFP36L2, CCNG2, 
CEP70, SESN1, ALDH3A2, PNRC1, OPN3, NEO1, RNF141, GCNT1, TLR4, NCRNA00084, 
SLC26A6, AKR1C3, ZCCHC11, FBLN5, PIGG, IL10RB, ALOX15B, ABCA6, C17orf48, 
HSD17B11, BBX, HPS5, POLI, REV3L, SLC38A2, NUDT4, DSE, MAT2B, TWIST1, CLK4, 
CLASP1, HMG20B, ARMCX1, FNBP1L, ABCC4, C1orf25, SAV1, MAP4K3, PLSCR4, 
KRCC1, AGL 
C7 
AHCY, SH2B1, TCEAL1, CDKN1C, SORT1, LOC727942, SSBP2, ITGBL1, ITGA10, 
ALDH6A1, P2RY5, LEPROT, TCEAL4, FZD5, IFITM1, PRKD1, ID3, DAAM2, TSC22D3, 
WASF3, HSPA2, STON1, TNS3, GAS1, LEPR, CPM, SAT1, CAT, PPP1R3C, BDH2, HSPB2, 
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LMOD1, SVEP1, STOM, NEDD9, CLIC3, NNMT, PALLD, ID2, PTK2B, NFIL3, FZD4, 
CYBRD1, PRRX2, ENAH, SMAD6, FAM117A, PDCD4, RRAS, RCBTB2, IRX5, CIDEC, 
HIST1H1C, ADH5, PYCARD, APOL2, CNN2, TCTA, PLA2G16, PIR, ECH1, GMPR2, 
ANGPT2, SIX1, CCDC53, MMD, ZBTB1, LMBRD1, PPAP2B, STAT2, ZFHX4, ARL6IP5, 
PTPLB, USP13, PGD, PAPSS1, GNAI1, DPYD 
C8 
TP53I3, NGFRAP1, STEAP3, FBLN1, C1S, TRIB2, SOX4, C5orf23, ID4, ANGPTL2, CFH, 
OLFML3, MID1, HIST1H2AC, EPHX1, GPD1L, GSN, SELENBP1, GGT5, PLAC8, 
SERPING1, GCHFR, CD24, IGFBP2, ANGPT1, MMP7, FRZB, IGF2, CFD, MTCH1, GAS6, 
PLXND1, GPX3, IFITM2, TPD52L1, ENC1, HCFC1R1, GABRE, CTSO, NELF, CYP1B1, 
SMPD1, SLC5A3, APOL1, GPX1, PTGDS, LDLR, PDE1A, TRAPPC6A, SPATA20, 
HIST1H2BK, ASAP3, BACE1, BBS1, GLS, TBC1D16, HSD11B1, SULF1, THNSL2, C5, 
VAMP5, SLC22A18, APOB, ARSE, SMARCD3, CTSF, SNAI1, C7orf10, SETMAR, 
SETBP1, RAMP1, ELANE, MYC 
C9 
ABAT, SFRP1, IL13RA1, CALCOCO2, LPAR1, CYB5A, GSTA4, LASS6, STAT3, 
SLC27A3, SSPN, TPST1, PPAP2A, NPR3, GHR, LSP1, CKB, HNMT, MCAM, C4orf31, 
MAOA, TNC, ACAN, LMCD1, FZD1, SRPX, RAB31, BAMBI, MME, PROS1, PRELP, 
ECM2, TIMP4, ZBTB16, ACTC1, CD302, COL11A1, CORIN, COMP, OLFML2B, OMD, 
HMOX2, EYA2, ADAMTS2, EFHD1, FBXL2, FAM13A, FAM69A, EPAS1, IL11RA, APOD, 
GLT8D2, CST3, FMOD, PGF, LIMCH1, C11orf67, SLC38A4, DCXR, KAZALD1, ACTA2, 
RANBP17, PPARG, FTO, ITM2B, TP53TG1, DECR1, IDH2, LAMA2, LAMB1, PPFIBP2, 
IDH1, ACOT13, COQ2, C1QTNF1, ISCU, AIM1, PAPPA, NXN, IFI44L, GMFG, MXD4, 
INSIG2, PDGFD, FAM3C, CNN1, USP33, MARCKS, ISG15, SUCLG2 
Table A5.1. Genes in each component of the osteogenesis model. 
 
clust  
# 
Genes  
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C11 
HADHB, PPP2R1B, HIST1H2AC,  IDH1, ACSF2, PALMD, PLA2G16, NR1H3, SCD, GHR, RBP4, ADIPOQ,  LPL, 
GPD1,  PEX19,  ALDH9A1,  ALDH1L1,  PPIF,  ACO1,  FHL1,  LPIN1,  MOSC1,  SEMA3G,  AOC2,  CALCRL,  LIPA, 
PNPLA2,  ITGA7, PECR, MCCC2, NIT2, HIST1H2BD, TALDO1, SLC27A3, C20orf3, ECHDC3, UQCRC2, SPRY1, 
DUSP6,  PIGP,  HSDL2,  TMEM97,  C2CD2, NDUFB5,  HADHA,  C1orf38, MOCS1,  SLC25A20,  FASN,  COX7C, 
CCNH, LRRC8B, NCOA4, MEGF9,  INSIG1, ELOVL5, ASH2L, BTD, CHP, C1orf50, SAMM50, LPCAT3, NPTXR, 
GYS1, ADRA2A, TMED5, MYL5, LBP, APOD, CFH, APOC1, SNAPC5, SORT1, MRPS14, BTG2, ACOT13, PEBP1, 
LIAS, ENPEP, NECAB3, SDHD, MRPS33, ALDOC, SUOX, C21orf33, ARL6IP5, C20orf27, FMO2, C14orf139, 
CYB5P4, FXYD1, TMEM53, ALPL, TMEM22, EFNA1, MAOB, ETFB, FAM162A, PLEKHG6, SDCBP, KIAA0664, 
RPLP2, C11orf71, THTPA, RAC3, LRPPRC, ACADS, CRYL1, PEMT, PIK3CA, DDT, A2M, APOB, MOAP1, FAH, 
OPLAH, COX10, USP25, PEG10, NDUFAF4, UROS, HSD17B8, ECSIT, SCP2, HIST1H2BN 
C12 
CAT, FAM134B, SERPINF1, MAOA, CYB5A, METTL7A, MME, CHRDL1, ACSL1, CIDEC, CD302, ADFP, G0S2, 
DHCR24, FZD4, GPC4, MMD, MCCC1, ALDH3A2, TMEM140, STAT5A, DCXR, SDR39U1, CDC42EP4, KCNK3, 
GPR64, ECH1, CDO1, PCCA, CABC1, SELENBP1, FAM13A, TSPAN31, CCBL2, CCNG1, ASAH1, PIGZ, MRPL34, 
PHYH, GALT,  TLN2,  SURF1,  STAR,  SLC5A6, GCLC, RBPMS, PBLD,  LYRM1,  STK39, HIST1H2BK, GADD45A, 
SH3PXD2A, C14orf147, GPHN, ZNF91, TOB1, TMEM100, P2RY5, PIGH 
C13 
CLMN, PPARG, ATP1A2, CEBPA, ACACB, HP, CFD, ADH1B, PRKAR2B, TIMP4, PLIN, AOC3, CHI3L2, FABP4, 
APOE, HK2, RETSAT, TMEM135, ALDH4A1, PSAP, GBE1, ACSL5, RAP2A, ABHD5, OSBPL1A, PDCD4, CSAD, 
SEPP1, HNMT, MAFB, AKAP1, CITED1, PLTP, CEPT1, HPR, TMCC1, EPAS1, DCLK1, ANXA6, NRN1, AQP3, 
TSPAN14,  PAPSS1,  GPX4,  PCOLCE2,  CXCR7,  GBP2,  TMBIM1,  FMO3,  TSPAN6,  QRSL1,  RNASE4,  PTPLB, 
GBP1,  INHBB, WDR3, ACOX2, LIPT1, FCGRT, FMO4, COG2, ANG, TXNL4B, LAMA4, STXBP1, TRIB1, WFS1, 
CILP,  LDLR, FERMT2, SYNPO,  LMO4, ASPH, MUT, ECM2, EPS8, HSPB6, LBR, C8orf33, APBB1IP, RMND1, 
GNAI1, ZFAND1 
C16  PLXND1,  FBLN1,  ANGPT2,  LAMA2,  ABCC3,  SIDT2,  PCSK5,  GUSB,  HEBP1,  SCPEP1,  IDUA,  MARCKSL1, POM121L9P, ADA,  EYA1, CTSF, C1GALT1C1,  IL17RC, MEGF8, CTSC,  LGALS3BP, DBC1,  PLD3,  TNFRSF1A, 
ZMAT3, CTSO, TRIM22, EIF4B, IL11RA, OSR2, CAMLG, MKL2, TPP1, PRKD1, HSPB2 
C19 
BCL6,  CREG1,  AKR1C3,  SOBP,  STOM,  GPD1L,  AKR1C2,  IGFBP2,  GPX3,  EPHX1,  NID1,  ZBTB16,  CCDC69, 
COL11A1,  HSD11B1,  CPM,  MGP,  SRPX,  TBC1D16,  SERPING1,  GGT5,  ANGPT1,  ALDH6A1,  RXRA,  LEPR, 
GSTA4,  PC, GLTSCR2,  PPAP2A,  SAT1,  C2orf28,  LETMD1,  PIR,  PISD,  DAAM2, WASF3,  TMEM111, GPX1, 
FTH1,  BTG1,  AACS,  C1QTNF1,  BBS1,  TGFBR3,  FOXN3,  IGBP1,  LMO3,  TSKU,  PTX3,  TRAPPC6A,  LEPROT, 
AGTR1, IFT122, TNFRSF21, ABHD14A, WDR19, PGD, SIX1, ABCA8, RNF130, ABCB6, EIF4A2, CRBN, PAPPA, 
LMOD1,  LASS6,  PEX6,  G6PD,  COX15,  NUDT4,  FOXC1,  USP33,  TP53TG1,  LHFP,  RPL22,  RSL1D1,  CEP68, 
FDXR,  GSN,  DHRS3,  ABHD4,  CRTAP,  FNTA,  IFI6,  PUS3,  MAN2B1,  ROCK2,  MYCBP2,  CCNB1IP1,  OXA1L, 
NELF, MYO6, RHOBTB3,  FAM59A, GCHFR, COX11, STEAP1, OPN3,  IGF1,  LMCD1, FKBP5, ASB13,  STIM1, 
TXNIP, THNSL2, CFLAR,  SETMAR, EIF3E, CSTA, ADM, C17orf48, TM2D1, NCRNA00084, CRYAB, PABPC4, 
HSPA2, SNX2, TMEM168, HHLA3, PCYOX1, ENSG00000185389, NNT, AZI2, GNS 
C22  TCEAL4, COPS8, SSBP2, PTPRM, REV3L, MXI1, C5orf23, IFNGR1, FRZB, MPPE1, RASSF4, HOXA10, TCEAL1, SMARCD2,  NPR3,  MYC,  PTPRG,  FAM110B,  LAMB1,  AKAP12,  SLC6A8,  TENC1,  DEPDC6,  SLC35A1, 
LOC727942, IL10RB, GSR, GLT25D2, GCLM 
C25 
PHF20, PHKA1, PITPNC1, SOCS2, FOS, RORA, SLC25A12, PTGER2, NXF1, UGP2, BMI1, RBMS3 
C26 
MT1M,  CHST7, MT1E, MT1X, MT1F,  IMPA2,  PHC2,  PANX1,  C10orf26, MT4, MIOS,  IL15,  TBL1X,  TMX4, 
FBN2,  CRISPLD2,  DLG5, MT1P2,  HIP1,  TPST1,  ZNF395,  PPP3CA,  BTBD3,  FYN,  CMTM6,  KCTD12,  SRGN, 
WISP1, ZFHX3, CHN1, MGA, DZIP1, CCDC53, MAPKAPK2, SSFA2, MORF4L2, SLC25A37, WIPI1, NAV2, KLF7, 
UGCGL2, NINJ2, CTNNB1,  IFI44L, PDE7B, DDIT4, MAN2A1, ENPP2, UGCGL1,  IGF2BP2, ZFP36L2, PDZRN3, 
CLK2, HDAC4, SPATS2, C4orf18 
C27 
LTBP1, TBC1D1, HAS1, SH3BP4, ATP1A1, ITGA5, FARP1, GFPT2, GNG11, ABL1, ID2, ID1, ODZ3, GGH, ID3, 
DNAJC15, NUDT1,  BCL3,  FOXF2,  POLD4,  SLC39A14, DNAJC1,  EMP2,  PLSCR1, GPR1,  PNPLA6,  SLC38A2, 
ACYP1, TMEM204,  FBLN5, CTSZ, C20orf149, ZMIZ1, CALR, BRD3, STEAP3,  IFI44, ZC3H4, TRIP10, BICC1, 
UPF3A, IL13RA1, PHF21A, WDR37, CCDC28A, PGF, DIRAS3, NUP37, TWSG1, C7orf42 
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C3 
DHRS11, HOXB6, QDPR, SCCPDH, SV2A, SERPINI1, AVPI1, SCML1, C11orf48, C14orf109, BNIP3, GNE 
C30 
SDC4, RGS10, CA12,  COL5A1,  FXYD5,  LXN,  PLOD3,  PENK,  TIMP2, RCN3,  LOXL1, MVP, QSOX1,  FKBP11, 
TMED3, DNASE1L1, AEBP1, TCIRG1, CHI3L1, PTGES, LEPREL2, ECM1, FAP, GOLM1, GTF2IRD1, ARMCX2, 
COL1A2,  LDOC1,  S100A6,  FZD2,  FLRT2,  CAPZB,  SLC10A3,  TUSC3,  PPIB,  THY1,  LOX,  TAX1BP3,  PDLIM2, 
NPDC1, TBC1D8B, CDK5RAP2,  SNX7, ZYX, CDC42EP1, PRAF2, COBRA1, RBM9,  FAM176B,  SPARC, CDR2, 
IRF9, CYTSA, AMPD2, CPNE1, MAP1B, COL5A2, DCTN1, PLEKHO1, RNF34, COL16A1, FAM128A, SMAD7, 
SCRN1,  ABR,  ZDHHC7,  RABAC1,  EPHA2,  TPM2,  TXN,  SLC7A11,  LAMB2,  ERBB2IP,  BCL10,  RAB11FIP5, 
C6orf145, TXLNA, HNRNPUL1, ZDHHC6, SETD5, CDH13, CLIP2, FSTL3, H1FX, SF3A3, PRR11,  IER5, FBXL7, 
C14orf132, TRIM28, SGCE, INPP1, EVL, MOXD1, KDM3A, TMEM50A, CARM1, C12orf24, MICALL2, DFNA5, 
HS3ST3A1, MEPCE, CAD, KIAA0947 
C32  AHNAK, CLSTN1, DKK1, DDOST, GANAB, ASMTL, GLG1, BACE2, RPS6KA2, MAP2K2, HECA, MIF, PLOD1,
VKORC1, P4HTM, FSTL1, S100PBP, GLT8D2, UBP1, HMGN4, ZFC3H1, ARID4B 
C37 
CCNA2, HAPLN1, NT5E, CRIP2, DPYSL3, TPX2, PBK, TUBA1C, CDKN3, ASPM, PFKP, FOXM1, CYTL1, TFPI2, 
KIF20A, PRC1, KIF2C, MLF1IP, CENPF, PHLDA1, PLK1, TOP2A, NCAPD2, KIF4A, NUSAP1, CEP55, CCNB2, 
UBE2C, BIRC5, TBC1D19, KIAA0101, DLGAP5, GOT2, TACC3, SGK1, C7orf10, PSRC1, CCNB1, ACOT7, HRAS, 
GLIPR1, GPSM2,  STMN1,  LGALS1, RACGAP1, KIF15, COLEC12, ODC1, TK1,  SCARA3, RNASEH2A, DOCK5, 
PLCE1,  RPL39L,  DDAH1,  SQRDL,  KLHDC3,  CENPM,  RPA3,  PFN1,  MAD2L1,  PAFAH1B3,  HYOU1,  CALM3, 
KIF14, HMMR,  CIT,  S100A4, ARNTL2, NANS, ARF3, ANXA2,  FAM158A, ANXA5,  RAB27A,  CKS2,  CALM1, 
FGFR1OP, IRAK1, RPN1, STK24, LRRC15, PGK1, WEE1, ITGA3, EPB41L2, C18orf10, MYO5A, GOLT1B, OIP5, 
IMPA1,  FAM64A,  TROAP,  HMGB3,  GNAI2,  CREB3,  NPTN,  DEPDC1,  ADORA2B,  CYR61,  APPL2,  UXS1, 
BUD31, P4HA1, TMEM48, HMGB1, PAMR1, IMPAD1, PHF10, DGKZ, SAP30L, SEMA3C, ARL4A, VASP, BEX1, 
LDHA, PAF1, DERL2, GUK1, CDC37, ACAN, C3orf14, CDK2AP2, AP1G1, GMNN, CDA, CLIC4 
C38 
WHSC1, RRM2, C5orf13, CDC2, CBX5, FANCI, CENPE, AURKB, TUBA1B, TPM1, SLC38A1, NDC80, ZWINT, 
H2AFX,  PRKCDBP, NCAPG2,  CRABP2,  BDNF,  ZWILCH,  CENPA,  RAB3B, MKI67,  LEPREL1,  LRRC17, WARS, 
TRIP13,  SPC25,  PGM3,  TUBB3,  MELK,  TTK,  STIL,  EZR,  NTM,  ARMET,  CDCA8,  PCK2,  ANP32E,  NCAPG, 
RANGAP1, AURKA, BUB1B, SAE1, UCK2, GTSE1, KIF11, ASNS, SNRPB, CENPN, ASF1B, APOBEC3B, CTNNA1, 
ESPL1,  CALM2,  NAGK,  C21orf45,  KIF18A,  SPAG5,  RFC4,  YKT6,  GAS2L1,  CDCA3,  SHCBP1,  ORC6L,  LIG1, 
DBF4, TMEM184B, REEP4, LMNB2, HSPA13, DDX39, GNB1, H2AFZ, ECT2, PLOD2, KIF22, LIMCH1, SLC1A1, 
NPC1, NCAPH, CSE1L, ACTN4, SDF2L1, UBL3, DR1, DCBLD2, CTGF, TBC1D4, VRK2, PSMG1, VRK1, SMC2, 
EIF4EBP1,  C18orf24,  ARPC1A,  PSMC3,  CCDC109B,  ELAVL1,  NUP155,  PLEKHB2,  SIVA1,  KIF18B, 
HNRNPA2B1, ATAD2, GADD45GIP1, HAT1, C13orf34, FANCG, BLM, RANBP9, KIAA0355, SSR1, CDC7, YAP1, 
EIF5A, SPP1, DYNLT3, MAPK1, MAP3K6, HNRNPH3, C13orf27, FANCL, GMFB, TAF5, RAD54B, FAM129A 
C39  SLC7A5,  SLC3A2, GPRC5A, KLF4, C12orf44, KIAA1279, ATP1B1,  FUS, PTP4A1,  SPHK1, PLEKHA1, MMP1, 
C1orf9, SMAD1, SGMS1, HSPA4, CRY1, PRPF4, CSTF3, POLE3 
C40  GABPB1, CDR2L, DLX2, JARID2, NT5DC3, HSPB8, BAG3, EIF2AK3, ANKRD57, TBPL1, DNAJB9, B3GNT2, CTH, 
SIK1 
C41 
SH3BGRL3, AXL, EMP3, SIPA1L1, TYMS, FSCN1, ELTD1, TMED9, MAGED2, KRT7, PPP1CA, CDH2, MAGED1, 
PRRX2, CDK2AP1, MYH9, TUBA1A, GALNT10, PTBP1, EHD3, SEC61A1, TPD52L2, SEPW1, CAPG, CAPRIN2, 
ARPC5, S100A10, SSRP1, SEC61G, CAPNS1, SUMO3, HOMER3, ASAP2, MSN, RAI14, TGIF1, TBCB, DBN1, 
COMMD4,  M6PRBP1,  HMGA1,  GRB10,  ARMCX6,  HSBP1,  THBS2,  ANXA11,  C1GALT1,  TEAD4,  EIF4E2, 
GNG12, PRSS23, PPP4C, MLPH, CALU, MCFD2, LRRFIP1, UBA1, COPZ2, S100A11, GMPS, LRRC8D, DYRK4, 
NOTCH2, RBM10, VAT1, KIAA1199, RBM3, PLEC1, CARS, CBX1, CANT1, ACOT9, KIAA0746, MYOF, GALNT1, 
ANKLE2, ARFGAP1, RIT1, PHGDH, STT3A, HDAC1, MFSD10, TLN1, CALD1 
C42  TRIOBP,  SEC13,  CAP1,  EFHD2,  PSMD2,  RRBP1,  ARPC2,  RHOC,  PRR16,  EHBP1L1,  RNH1, DRAP1,  LMNA, SERPINH1, HK1, C11orf24, SFXN3, C16orf45, FAT1, CTBP2, PDLIM7, KLC1, PLXNA1, LSM7, NMI, ATP13A2, 
C21orf59, TUBA4A, SEC61B, SRM, ARHGDIA, DVL1, SRP54, TRPV2, DEF8, FAM38A, LIMS2, PRPF3 
C43 
KDELR3, FTSJ1, GARS, PLAT, CREB3L1, GREM1, SERPINE1, RAC2, LYPD1, SHMT2, MCM5, HPCAL1, PDLIM4, 
EIF1, KIAA1644,  PORCN,  SMAGP,  PHLDA2, RRM1, NDEL1, RAB32,  ITPR3,  SDC1,  TMEM158,  FLNC, DAP, 
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CLIC3, S100A2, BCAT1, SLC2A3, IL4R, XYLT2, HERPUD1, ZNF331
C44 
LRRC59,  YWHAH,  KDELR2,  SLIT2,  MCM7,  FAM114A1,  UGDH,  CCND1,  EIF6,  PSIP1,  TULP3,  SLC20A1, 
IGFBP3,  XBP1,  MYBL1,  CSRP2,  VEGFC,  MCM6,  SMC4,  DSP,  PTPRK,  RHOA,  HNRNPAB,  ARF4,  MORC4, 
MAD1L1, CHSY1, RAC1, EXT1, KCNK2, BARD1, DNMT1, EZH2, TMEM214, MCM3, RBBP8, U2AF1, CREB3L2, 
FAM111A,  TRIB2,  HIST1H4C,  ACTR3,  UPP1,  SERTAD2,  ARCN1,  CBR3,  BUB3,  STX4,  ZDHHC13,  DEK, 
FAM57A, DONSON,  SMURF2,  IVNS1ABP,  SEC31A, GMPPA,  IQGAP1, CHIC2, PMM2,  TSPAN5, KIAA1462, 
COPG,  TULP4, CTPS, GOLGA5,  SLC39A7, GLS,  FZD6,  PPP4R1, CBFB, NR3C1,  YWHAQ, HSPA5, ARFGAP3, 
TES, KCTD5, TFDP1, H3F3B, ADAM12, LRRC42, PWP1, STAG1, CTCF, ARL4C, FZD7, OAT, RPS6KC1, PTGES3, 
TOP2B,  GOLGA3,  RBM15,  CRIM1,  PLS3,  SACS,  SWAP70,  PCNA,  CKLF,  LASP1,  ADSS,  MTMR6,  COPB2, 
ALDH18A1,  NRIP3,  ARF1,  MFSD1,  UTP18,  SLBP,  ILF2,  CEP170,  FKBP14,  FNDC3B,  NPM1,  PPP1R12A, 
CSGALNACT2, NUP85, DDX46, SEC16A, HOMER1, SNRPA1, FIP1L1, RPS6KA3, TOPBP1, MAP4K5, ACTR2, 
WAPAL, NACC2, DOCK4, MEX3C, OSBPL8, NSUN5, RNF138 
C5 
MOSC2,  PDE3B,  ITIH1,  SPARCL1,  PDE8B,  SPON1,  PLA2G2A,  ME1,  TF, MKNK2, OSBPL11,  ITIH5,  ISOC1, 
AZGP1,  ECHDC1,  ATP5S,  TSPAN3, NRCAM,  PFKFB1,  ACYP2,  PEX11A,  ELOVL6,  SYN2,  RDH5,  C6,  TRD@, 
SLC7A6,  PDZD2,  PCBD1,  SCARB1,  SNX10,  FAR2,  SLC19A3, OAS1,  PHLDA3,  KCNB1,  SLC16A7,  KIAA0040, 
ACSS3, MVD, HPGD, RNF125, PNPLA3, ARG2, ADRBK2, ACSL4, C13orf15, EIF4EBP2, CASP1, MRAS, CDR1, 
PDK4, ABCG1, ANKRD46, STX12, PFKFB3, ABCD2, AP3B2, ATF3, LACTB2, AGT, STMN2, ACOX1, SCAMP5, 
MID1IP1, ABCA1, SC5DL, LAIR1, RAMP2, CASP7, FNDC4, GAB2, SLC25A10, S100B, GBAS, CIDEA, ADRB2, 
PDK2, BANK1, CA5B, RRN3, WFDC1, MPDZ, ARHGEF2, UQCC, CHPT1, SLC47A1, AMBRA1, SOX9, CASQ2, 
CADM3, MECR, STARD8 
C51 
PRPS1, SMTN, KRT19, MALL, NP, FEN1, MICAL2, CCDC99, DTL, CAP2, SYNJ2, YIF1A, ADCY7, ETV5, PDGFC, 
GINS2,  LPXN, BAALC, MCM2, AMIGO2, USP1, PLAUR, EXOSC9, GAP43, CDCA4, NETO2, KIF23, OSBPL3, 
PRKCA,  RASA1,  RAGE,  NUP205,  NEK7,  CDC45L,  CTNNAL1,  POLA1,  SEC24D,  AHNAK2,  LDB2,  ATXN1, 
HNRNPD, MACF1, LANCL2, YARS, HJURP, SLC17A9, POLE2, RFC3, CD97, MET, FHOD3, MCM10, NMNAT2, 
DOCK10, BTG3, GINS1,  SH2B3, MYO1B,  ENO2, MAFF,  EML1,  TARS, RAD51AP1,  KCNN4, DCK, MARCKS, 
EXO1,  SHB,  COG7,  MRPL17,  KRT14,  SFRS2,  CDC6,  SH2D4A,  MAPKAPK3,  DOK1,  PRSS3,  PELO,  CHMP6, 
SEC24A, PRRC1, UBR7, YIPF5, MGC4294, GAR1, HELLS, SLC4A2, ACBD3, PRIM1, MSH2, ANXA1, PYROXD1, 
FBXO5 
C53  NUP93,  WSB2,  GALE,  ABHD2,  TACC2,  PSMD14,  PTS,  C16orf61,  ARL1,  KIF5B,  EXOSC8,  POLD3,  PARP2, 
SFRS3, SFRS1, SEC23A, SNRPD1, UCHL3, NUP107, DYNLL1, SAC3D1, NIF3L1, AKTIP, PALLD, GLOD4, EEF1E1
C54  TUBB2C,  MARS,  CIB1,  ARPC5L,  SLC1A4,  LONP1,  TMEM106C,  CKAP2,  TUBG1,  BANF1,  EHD4,  SLC31A1, EBNA1BP2, ODZ4,  EPRS,  TRA2B, GRAMD3, H2AFV, NRAS, MLH1,  CCDC90A, UBE2M,  C11orf51,  CSRP1, 
TDP1, TAGLN, RPA1, VANGL1, OLFML2A, HPRT1, SPRY2, THAP10 
C6 
PDHA1,  BRP44L,  DBI,  NSDHL,  DUSP4,  GYG2,  UCP2,  C10orf116,  DLAT,  HADH,  CD36,  PCK1,  CDKN2C, 
C7orf68, HSD17B12, STBD1, ACO2, AGPAT2,  IDI1, HIST2H2BE, TM7SF2, MGST3, ACAT2, ACY1, ADIPOR2, 
PPP2R5A,  ATP5G3,  KCNIP2,  SLC25A1,  PCCB,  PDHB,  SLC7A10,  CAMK1,  DHCR7,  CS,  PPP1R1A,  MDH1, 
AK3L2, LIPE, HMGCR, BRP44, PYGL, PTGER4, LSS, COX5B, RTN3, SUCLG1, AIFM1, NQO2, ALAS1, HMGCS1, 
CCDC56, HSD17B10, BCKDHB, LETM1, COL4A1, HEBP2, UCRC, GRPEL1, UQCRFS1, NFU1, UVRAG, GYPC, 
ACACA, ATP5B,  COQ9,  IMMT,  CYP51A1, GGCT,  ECHS1,  FAM82A2,  ETFDH, ACADVL, WDR77, ALDH1B1, 
COX7B,  FDFT1,  SMCR7L,  NMB,  BCAP31,  FDPS,  SREBF1,  PGRMC1,  VIPR1,  MRPL46,  ACAD8,  ZNF117, 
NDUFA3, TIMM8B, GLRX5, NDUFC2, NPR1, BBOX1, HISPPD2A, PLCXD1, SPTBN1, BAI2, ATP5J, C17orf42, 
COL4A2, MRPS16, HIBCH, C3, SLC25A44, FMO1, RHOB, WBP2, CD46, ACTG2 
C8  KANK1, MEST, LRIG1, VCAM1, CAV2, ATP9A, ACTA2, APEX2, SC4MOL, PLA2G4A, PJA1, ICT1, TJP2, FYCO1, 
ANP32A, SDC2, OPTN, ANAPC13, PNO1, BLCAP, ARHGAP29, MOSPD2, TSC22D1, DET1, RANBP6, SEH1L 
Table A5.2. Genes in each component of the adipogenesis model. 
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#  Genes  
C1 
RASL11B, CD24, LRRC15, COL11A1, SCRG1, OMD, ASPN, MFAP4, ATP1B1, PPAP2A, APOD, 
MMP7, PLEKHA5, IGF1, LRRC17, LUM, SDC1, CHN1, TCF4, DNAJC12, GJA1, STEAP1, SSPN, 
TSPAN13, SLC5A3, PMS1, NDUFB5, RIN2, PIGH, BMI1, TRMT61B, SMAD1, ZMAT3 
C11 RAB31, MAFB, FOXO1, JHDM1D, IFNGR1, MT1F, DDX3Y, RSL24D1, BDH2, SCD5, BCAT1 
C12 
MIF, STEAP3, SERPINA3, VKORC1, SERPING1, P4HA1, CA9, TNFRSF21, COL7A1, TRIB3, 
PSAP, CCNB1IP1, ACSL1, SNED1, OS9, GLTSCR2, C11orf10, SPAG4, TWIST1, CCNI, 
HIST1H2BK, GBE1, SLC3A2, DNAJC1, EEF1A2, EIF4B, NARF, AARS, PLOD1, OBFC1, TYRO3, 
OPN3, NNMT, ZNF274, PTGFR, MT1E, POLR1D, DYNLT3, TAF1D, PLTP, ZCCHC6, RASSF1, 
LRP1, SYNPO, ITGB3BP, H1F0, EIF1B, IFRD1, LMBRD1, OXSM, ANKMY2, FAH, SH3YL1, 
PLD3, TMEM135, CLK4 
C13 
ALDH6A1, TXNIP, SRPX, ITGA10, COPS8, FAM46A, PTER, STON1, PIK3R1, AACS, CHST1, 
JUN, SATB1, EIF4EBP1, TGDS, SLC46A3, BEND5, CDO1, DCP2, PHF17, ISLR, ARL4A, CUTC, 
NRBF2, CNIH4 
C14 SAT1, PGK1, UGP2, MT1X, BNIP3, PMAIP1, ABCA1, MT1M, FOXN3, OXR1, GNL3, HSPA13 
C19 
NFIL3, MXI1, TSC22D3, RGS2, IL1R1, GADD45B, C7orf68, TMEM204, PNRC1, BCL6, G0S2, 
NOL3, SESN1, PMP22, PPP1R3C, GAS1, SORBS2, SLC25A36, COL6A3, FBXO42, CCDC28A, 
ANKZF1, PER1, POLR2H, ARL4C, ZNF292, INSIG2, FKBP5, HERPUD1, C10orf26, LARP6, 
ZNF331, PDLIM4, PGF, TBC1D1, SMARCA2, TNS3, NID2, CD9, AGPAT5, PRKAB2, AK3L2, 
HIP1, RBM7, TMEM87A, TBC1D16, PIK3CA 
C2 
COL8A2, FMOD, ANGPTL2, TPST1, S100P, SOX9, TRPS1, SLC29A1, PID1, DYNC1I1, GPX7, 
SPARC, SOBP, VGLL4, IVNS1ABP, PAPSS2, COL1A1, EPS8L2, PDGFRL, GPC4, COL16A1, 
ITM2B, CCPG1, EDNRA, STXBP6, A2M, PLA2G4A, ARHGEF6, PLOD2, GPR153, LSP1, 
FAM102A, STK38L, IFT20, MTHFD2, PMEPA1, BIRC2, RP6-213H19.1, GOLM1, STIM1, 
CTNNB1 
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C21 
FOXO3, GFPT2, ANGPTL4, VEGFA, F3, KLF9, SLC39A14, AKAP13, SOCS2, DIXDC1, FOXF2, 
MARCKSL1, OSBPL9, MAP3K2 
C24 
COL4A2, IGFBP3, CD44, COL4A1, TMSB10, ARID5B, MAFF, TFPI2, CTSL1, LGALS3BP, 
BAALC, KIAA0802, PTPRG, SLC1A1, IFITM2, CAPG, WASF3, MAP4K4, AKR1B1, IER3, 
ARHGAP22, TAGLN2, CDK5RAP2, ST13, OSMR, PCYOX1 
C25 
STOM, LTBP2, IGFBP6, TGFBR3, CHI3L1, C5orf23, S100A6, CRISPLD2, FLNB, CTSA, DHRS3, 
MLPH, JMJD6, NPR3, PFKP, RRAGC, CALHM2, PTX3, MGAT4B, NPC2, S100A10, SCML1, 
CSTB, QSOX1, PECI, TRIP10, CDH13, GNS, TKT, ATP2B1, AHNAK2, YAP1, TSPAN5, F2R, 
SOAT1 
C3 
BGN, COL3A1, SERPINF1, DPT, COL10A1, COMP, HTRA1, MFAP2, ECH1, IGFBP5, CTSK, 
PTGDS, LPAR1, NDUFA4L2, SSR4, RNF144A, SRPX2, TMEM208, MMP13, PCOLCE2, PPP1CB, 
IMPA2, IGF2, BHLHE41, CSTA, SPON2, KLF11, DYRK4, DNM1, BET1, GOLGA9P, IRX5 
C31 
MYOF, GNG12, RAB3B, TPM1, FHL2, PPAP2B, NQO1, MEST, EFEMP1, CAP1, AXL, PENK, 
COTL1, GLIPR1, ACTN1, TRAM2, KIAA1199, PHLDA2, TRIOBP, NRP1, GAS6, PTRF, BST1, 
TAGLN, ANXA2, DAB2, MFAP5, ERLIN1, EIF6, VCL, UBE2C, ANXA11, ATP2B4, KRT7, 
LASP1, SSH1, SLIT2, CORO1C, SYNJ2, IPO5, ALCAM, G6PD, KRT19, MTHFD1, MYL9, 
S100A11, CAPNS1, CFL1, STC2, FHL1, SDC4, CALM3, LAMC1, ATP13A3, PLEKHB2, 
M6PRBP1, UGDH, PFN1, APPL2, MET, CUTA, ENG, ENTPD6, NTM, ATP6V1B2, TLN1, 
POLR2E, CKS2, DNAJB6, RACGAP1, ATP6V1H, ARNTL2, LYPD1, DRAP1, CTNNAL1, C2CD2, 
CLTA, ASXL2, SPAG5, TRIP6, PKM2, STMN1, INPP5A, FLNA, ASAP1, ERLIN2, PDLIM2, 
CYP51A1 
C32 
PEA15, CITED2, ADAMTS1, APLP2, UGCG, IFI30, AP2S1, IGFBP4, MVP, RPS6KA2, PLA2G16, 
RRAS2, TXNRD1, FZD2, FAM62A, ZDHHC7, DHCR24, SH3BGRL3, CBR3, TGFBR2, PDLIM5, 
BDKRB1, SMAGP, INSIG1, SNRPA, PGD, ZYX, LPP, PAFAH1B3, ETHE1, ABL1, ISG15, 
EFHD2, RIT1, SLC25A1, ADAMTS5, RRM1, HRAS, RAB8A 
C33 
CAV1, TM4SF1, SQRDL, SERPINE2, FOXD1, DSP, LGALS1, MCM7, SRGN, TFRC, MCFD2, 
TPM2, ARPC1A, NT5E, AUTS2, C16orf45, ANXA6, TJP2, BNC2, GPX1, ACAT1, HMGA2, 
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WNT5A, C7orf10, SLBP, WNT5B, YWHAE, FZD6, GRAMD3, AHR, KIAA1462, SACS, TNFAIP8, 
MEIS2, SWAP70, SF3A3, IER5, TPST2, PNMA1 
C34 
TUBA1B, PRPS1, PSMD1, SAE1, THBS1, LIMA1, HEG1, ENDOD1, GALNT10, ACTA2, 
PSMD14, HSP90AA1, ACTB, SPCS3, MAPRE1, ZWINT, PDHB, EXT2, THY1, MAP2K3, HSPH1, 
PSMD11, TMEM50A, IDE, H2AFV, ACTR3, GMFB, AIFM1, SFRS2, YWHAB, SFRS1, ACTR2, 
ANGPT1, ANXA7, CRY1, NEDD4, COLEC12, LSM4, SLC20A1, HNRNPA2B1, CMTM6, 
DNAJA1, ANXA1, UXS1, MYL12A, ACTN4, TFDP1, EBNA1BP2, HSPA4, LIPA, WSB2, OSTM1, 
TULP4, PKD2, AMD1, ARHGAP17, TMEM47, LRRC8D, ZWILCH, HIF1A, UQCRFS1, NPTN, 
LHFP, TRIM37, MAP7D1, CLIC4, VRK1, TTPAL, OXCT1, SCP2, NDUFS1, SEH1L, PRKDC, 
EIF5A, BANF1, FAM3C, HARS, SLC9A6, SF3B4, ZNF706, VCAM1, UBP1, TOP2B, CHCHD3, 
ERBB2IP, GALNT7, LAP3 
C35 
CAP2, STAT1, DDAH1, EFNB2, GREM1, DLGAP5, PRC1, CSRP1, ATP6V0D1, EHD1, TPX2, 
PBK, RRM2, ROR1, LOXL1, POLR2L, BIRC5, CALD1, PRKCDBP, KIF4A, NEK7, BEX1, 
DNMT1, MELK, DDX39, NAPA, DNM1L, TXN, COPS7A, TK1, PTPLA, CDCA3, HJURP, GRB2, 
PHACTR2, DOCK5, TP53I3, ATP10D, ATP6V0E2 
C36 
CCNB2, KIF20A, TMEM106C, TPD52L1, CYP1B1, TCTA, GYG1, DPP3, PSMC3, NSF, TTK, 
RND3, NUTF2, RBMS3, EDIL3 
C37 
FSTL1, CENPF, CCNB1, TOP2A, ASPM, TYMS, CDKN3, NUSAP1, CDC2, FOXM1, OLFML3, 
BUB1B, C20orf3, CETN2 
C39 
RGS4, FGF2, CCL2, AMOTL2, FGF5, FST, HAS2, NRG1, HOXA9, CCNA2, CBX5, FAM111A, 
CENPE, KCTD20, CCDC99, SH2D4A, DKK1, IL7R, BARD1, RASA1, SMURF2, TUFT1, 
DEPDC1, MPP5, DOK5, NGF, CNN2, FAM13B, PPM2C, CDC25B, HOXC6 
C4 
COL5A1, COL5A2, PRELP, AOC2, SPP1, CLEC11A, CSGALNACT1, SCD, CKB, IRF7, PLCD1, 
WIPF1, GLT25D2, CLTCL1, PCOLCE, ALDH2, RABAC1, WIPI1, CLU, FKBP11, CST3, CTSD, 
ROBO1, LTBP1, BMP1, FKBP10, SLC22A17, GTPBP2, S100A13, SLC2A10 
C40 
ARHGAP29, CXCL12, TNFRSF11B, KCNK2, WDR1, RAGE, SH3BP4, MGLL, VEGFC, TACC3, 
199 
 
CCND1, AURKA, MARCKS, GINS2, TUBB2C, SMAD3, LANCL2, ARSJ, BDNF, SOCS5, EXT1, 
PRR16, C1GALT1, DRAM, FDFT1, DTL, TRIP13, MLF1IP, C6orf145, LPXN, TBC1D2, PODXL, 
ADH5, VGLL3, MCM2, CKAP2, NRAS 
C42 LDB2, SYNC, FZD7, FAM69A, STK17A, TUBB2A, GREM2, BCAR3, GCLM, CAV2, SPIN1 
C43 
TUBB6, TUBG1, RFTN1, ARPC5, NAV3, FEN1, IL6, ATIC, PRDX3, NACC2, TUBA1C, DYNLL1, 
EBP, PUS7, USP14, C21orf59, ACAT2, NUP107, SNTB2, NARG1, SSB, HDHD1A 
C56 
MEF2C, C1QTNF3, MXRA5, ACAN, PTH1R, RBP4, IBSP, PCK2, CXCR7, THBS3, PPFIBP2, 
DRD4, MATN2, COL9A2, S100A1, GTF3C1, FAM129A, SRI, EYA2, LEPRE1, MIA, CHAC1, 
PDGFD, ECM2, KRT16, TRPV4, WNT11, REEP1, SEMA3B, STX18, PPA1, EFHD1, HOMER2, 
WFDC1, UGCGL2, NES, SC65, OLFML2B, KDELC1, ENTPD3, LRRC8E, ADAM22, CHAD, 
SLC38A3, RNFT1, MT1G 
C57 
C4orf31, C13orf15, EHD3, GPC1, SLC7A5, CHST3, SDC2, LITAF, CMAH, KRT14, RAMP1, 
PHGDH, SLC31A1, CSPG4, CYB5R1, PAMR1, F13A1, C11orf75, MATN4 
C58 
C4orf31, C13orf15, EHD3, GPC1, SLC7A5, CHST3, SDC2, LITAF, CMAH, KRT14, KRT16, 
TRPV4, WNT11, REEP1, RAMP1, PHGDH, SEMA3B, STX18, PPA1, EFHD1, HOMER2, WFDC1, 
UGCGL2, SLC31A1, CSPG4, NES, CYB5R1, SC65, PAMR1, OLFML2B, F13A1, KDELC1, 
ENTPD3, C11orf75, LRRC8E, ADAM22, CHAD, SLC38A3, MATN4, RNFT1, MT1G 
C7 SPARCL1, CHI3L2, EIF3E, EIF4A2, TNFAIP6, CCL20, RPL11, SMC6, PLAT, TMEM100, IL8 
C9 
NBL1, DCN, CPE, CRLF1, TGFB3, LAMA2, CSRP2, BMP2, HCFC1R1, HIST1H2AC, CGRRF1, 
PNMAL1, EFNA1 
Table A5.3. Genes in each component of the chondrogenesis model. 
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